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1. Introduction 
Over the last 50 years, mortality rates caused by cardiovascular diseases (CVD) 
dropped by 60 % and thereby faster than any other cause. These outstanding 
ameliorations in CVD outcomes were mainly due to improvements in the prevention and 
treatment of CVD.1 But still, in the year 2012, 17.5 million deaths were associated with 
CVD, making it the number one cause of death in the world, representing 31 % of all 
global deaths. Of these fatalities, approximately 7.4 million (42 % of all CVD related 
deaths) were due to coronary heart disease and 6.7 million (38 % of all CVD related 
deaths) were due to stroke.1 CVD include a group of conditions which are mainly related 
to the heart and vasculature, such as stroke, abdominal aortic aneurysms or coronary 
artery diseases (CAD). The underlying cause of these disorders is predominantly 
atherosclerosis. There are a plethora of different risk factors involved in the onset of 
CVD which can include genetic predispositions and natural aging, but also smoking, 
obesity, hypertension, diabetes mellitus, and hyperlipidemia.2 Until today, 
atherosclerosis has not been considered curable. This is due to a lack of appropriate 
early diagnosis or successful disease modifying treatments, which aim to either prevent 
atherosclerotic lesion progression or reduce already existing lesion size. Therefore, 
understanding key mechanisms in play and the investigation of the pathogenesis of 
atherosclerosis is crucial to develop and establish more effective therapeutic 
approaches and novel therapies. Hypertension and hyperlipidemia are well known risk 
factors for atherosclerosis, but today it is also appreciated that atherosclerosis is a 
chronic inflammatory disease of the arterial wall, driven and modulated by immune 
responses.3 Whereas the role of monocytes/macrophages to the progression of 
atherosclerosis is well established, the role of other mononuclear cells, namely T cells 
and dendritic cells (DCs) still needs to be further elucidated. 
The following introduction describes the role of the immune system during 
atherosclerosis. It points out the implications different immune cells - primarily DCs and 
T cells – have during the onset of this disease. Furthermore, it will give a brief overview 
of the immune system and additionally on the origin of leukocytes and elucidates their 
potential roles during atherogenesis. 
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1.1. The immune system 
The main duty of the immune system is to preserve the integrity of an individual by 
providing protection against attacks from “outside” (e.g. bacteria, viruses, parasites) and 
from within such as degenerated cells or modified agents like lipids.4 To fulfill this 
responsibility effectively the immune system must carry out four main tasks: First, the 
immunological recognition, where the presence of an infection must be detected. 
Second, it has to be contained and third, if possible eliminated. As important the 
elimination of an infection is, an overwhelming immunological response can lead to 
tissue damage and has to be avoided. Therefore, the immune response must be kept 
under control, and has to be regulated. The fourth task is generating an immunological 
memory which protects the individual against reappearing pathogens and allows an 
immediate and stronger response against any subsequent exposure to it.5 An immune 
response can be mediated via two differently organized immunological effector systems. 
First the innate (unspecific) immunity and second the adaptive (specific) immunity. 
1.1.1 The innate immune system 
The innate immune response serves as the first defense against pathogens. It is formed 
by a variety of cells and molecules (Figure 1) which are able to mount an immediate 
innate immune response as soon as microorganisms breach physical and chemical 
defense barriers such as skin and mucosal epithelia (lining airways or gut). Important 
components of the innate immune system are phagocytic cells (macrophages and 
granulocytes), that continuously patrol the body searching for dangerous non-self-
components (pathogen–associated molecular patterns (PAMPS) which they can detect 
with their germ line encoded pattern recognition receptors (PRR), such as Toll-like 
receptors (TLRs).6 Stimulated cells then engulf the pathogen and degrade it 
intracellularly. Together with the complement system, these cells play a pivotal role in 
fighting extracellular pathogens. Other components of the innate immune system, like 
natural killer cells (NK-cells) and interferons (IFN), are key mediators in fighting 
intracellular pathogens like viruses.7 Often, the innate immune response does not 
succeed in resolving the infection. Therefore, triggering of an acquired/adaptive immune 
response becomes necessary. 
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1.1.2. The adaptive immune system  
Next to the innate immune system, the acquired or adaptive immune system is the 
second immunological effector system and further characterized through its antigen 
specificity. An adaptive immune response starts when antigen presenting cells (APC), 
carrying an antigen they picked up at sites of infection, travel to secondary lymphoid 
organs. DCs (see Chapter Dendritic cells) are highly specialized APCs and, like 
macrophages and granulocytes, DCs engulf pathogens and process them. However, the 
main role of DCs is not the clearance of an infection. Their principal duty lies in 
presenting antigens through the Major Histocompatibility Complex (MHC) to cells of the 
adaptive immunity, placing them at the border of innate and adaptive immunity. APCs 
can carry two types of MHC peptide-binding proteins: MHC class I and MHC class II. 
While intracellular antigens bind to MHC class I and are recognized by cluster of 
differentiation (CD) 8+ T cells, extracellular antigens are presented by MHC class II to 
CD4+ T cells. Besides DCs, other cells, namely activated macrophages and B cells can 
act as APCs and present antigens via MHC molecules. Nevertheless, among APCs DCs 
are the most specialized cells, expressing the highest amounts of MHC molecules. 
Another feature of APCs, next to the expression of MHC molecules, is the expression of 
costimulatory molecules (e. g. B7 molecules). These molecules provide the co-
stimulatory signal, which is characterized by being antigen nonspecific. Co-stimulatory 
signals are provided for instance through interactions of CD28 (on T cells) and 
CD80/CD86 (B7 molecules on APCs).5  
Through antigen presentation, DCs can activate specific antigen-recognition receptors 
on the surface of lymphocytes. Lymphocytes include natural killer cells, T cells (see 
Chapter  
T cells and B cells. They are the main type of cell found in lymph, which led to the term 
"lymphocyte".5 The antigen-recognition receptors on the surface of lymphocytes are 
termed either B cell receptor (BCR) on B cells or T cell receptor (TCR) on T cells, 
respectively. The BCR and the TCR are not germ line encoded (as PRR on cells of the 
innate immunity), but are rather created by somatic V(D)J gene rearrangement.8 For 
instance, the T-cell receptor α and β chains each consist of a variable (V) amino-
terminal region and a constant (C) region. The TCRα locus contains V and J gene 
segments (Vα and Jα). The TCRβ locus contains D gene segments in addition to Vβ and 
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Jβ gene segments. The T cell receptor gene rearrangement occurs during T-cell 
development through somatic recombination, to form complete V-domain exons and 
takes place in the thymus.5 The processes underlying gene rearrangement in B and T 
cells are similar. Regarding the α chain, a functional V-region exon is generated, when a 
Vα gene segment rearranges to a Jα gene segment. Transcription and splicing of the 
VJα exon to Cα generates the messenger ribonucleic acid (mRNA) that is translated to 
yield the T-cell receptor α-chain protein.5 The variable domain of the β chain is encoded 
in three gene segments denominated, Vβ, Dβ, and Jβ. Rearrangement of these 
segments results in a functional VDJβ V-region exon. This VDJβ V-region exon is further 
transcribed and spliced to join to Cβ. The resulting mRNA is translated to yield the T-cell 
receptor β chain. After their biosynthesis the α and β chains will pair to yield the α:β T-
cell receptor heterodimer.5 This process of somatic V(D)J gene rearrangement allows for 
an essentially unlimited adaptive immune recognition through antigen receptors, 
enabling specific immune responses to almost any pathogen. Activated pathogen 
specific lymphocytes proliferate and are recruited to the site of inflammation to fight the 
intruder. Activated B cells for example induce a humoral immune response through the 
production of antibodies, whereas active T cells secrete a specific set of cytokines that 
are part of a cell-mediated immune response.9,10 After first contact and successful 
elimination of an invader some of the antigen-specific lymphocytes are retained and 
create a memory cell repertoire, that leads to faster and enhanced response to 
subsequent encounters with the same pathogen.11 
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Figure 1. Cells of the innate and adaptive immune system. The innate immune system acts as the first 
line of defense during an inflammation. It consists of various cell types such as natural killer cells, 
macrophages, dendritic cells and granulocytes. Granulocytes can be subdivided into basophils, 
eosinophils and neutrophils. Humoral components of the innate immunity include the complement system 
and antimicrobial peptides. The innate immune system is build up by B cells and T cells. B cells produce 
antibodies and T cells can be further grouped into CD4
+
 T helper cells and CD8
+
 cytotoxic T cells. γδ T 
cells and natural killer cells bridge between innate and adaptive immunity (copied from Dranoff et al.).
12 
 
1.2. Cells of the immune system 
Leukocytes or white blood cells make up the cellular compartment of both the innate and 
the adaptive immune response. Leukocytes originate in the bone marrow from 
hematopoietic stem cells (HSC). HSCs can give rise or differentiate into common 
myeloid (CMP) and lymphoid progenitor cells (CLP). On the one side, macrophages, 
granulocytes, DCs and megakaryocytes originate all from CMPs and form together the 
branch of the innate immune system. On the other side, CLPs develop into B cells and T 
cells, which build up adaptive immunity. DCs can be generated either from CMPs or 
CLPs underscoring their significant role at the border of innate and adaptive immunity 
(Figure 2).13,14 
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Figure 2. Leukopoiesis. Leukocytes develop from hematopoietic stem cells (HSCs) and multipotent 
progenitor cells (MPPs). The figure shows how progenitor cells give rise to the different hematopoietic cell 
lineages. Conventional DCs (cDC) arise from the common DC progenitor (CDP). Monocytes originate 
from a common myeloid progenitor (CMP). Lymphoid cells such as T and B cells originate from the 
common lymphoid progenitor (CLP). GMP granulocyte and macrophage progenitor; MCP mast cell 
progenitor; MDP macrophage and DC progenitor; MEP megakaryocyte and erythroid progenitor; NK 
natural killer; pDC, plasmacytoid DC. (Adapted from Gabrilovich et al.)
15
 
 
1.2.1 Dendritic cells 
Dendritic cells (from the greek work déndron, “tree”) where first described in 1973 by 
Ralph Steinman and Zenvil A. Cohn. Both depicted DCs as large cells with branch-like 
projections, retractile and contorted in shape, giving them a stellate morphology (Figure 
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3 ).16 Soon after Steinman and Cohn´s discovery, a multitude of studies exposed cells 
with similar phenotypic characteristics in most non-lymphoid tissues. 
 
 
Figure 3. Conventional and plasmacytoid dendritic cells. A) Morphology of an immature-DC (left) and 
a CD40L activated mature DC (right) examined by scanning electron microscopy. (Adapted from Baron et 
al.).
17
 B) Morphology of pDCs Examined by scanning electron microscopy. Resting pDCs have a spherical 
shape (left), whereas CD40L-activated pDCs have a dendritic cell–like morphology (right). Original 
magnifications, ×3,000 (adapted from Colonna et al.).
18
 
 
DCs are a heterogeneous population of cells, which play a pivotal role at the border 
between the innate and adaptive immunity. As mentioned above DCs can originate in 
the bone marrow either from common myeloid progenitors (CMPs) or from common 
lymphoid progenitor (CLPs) and are the most potent APCs. Subsequently, CMPs 
develop into monocyte/macrophages and DC precursors (MDPs) and further into the 
monocyte precursor (cMOP) or the common DC precursor (CDP).19 cMOP differentiates 
into monocytes20 which migrate into tissues where, under certain conditions, they are 
able to give rise to DCs. In tissues CDPs are able to differentiate under steady state into 
DCs (Figure 4).21 
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Figure 4. Classic model of DC development. DCs and monocytes develop from bi-potential MDPs 
residing in the bone marrow. MDPs further differentiate into monocytes and CDPs. CDPs can develop 
either into DCs, which fully develop in the bone marrow, or into pre-DCs, which migrate through the blood 
to tissues. In the tissues pre-DCs differentiate into CD11b
−
 (including CD8α
+
 cDCs in lymphoid tissue and 
migratory CD103
+
 cDCs in non-lymphoid tissue) and CD11b
+
 cDCs. Monocytes develop in the bone 
marrow and reach peripheral tissues via the bloodstream. There they further differentiate into monocyte-
derived DCs (mo-DCs) or macrophages (MØs) (mo-MØs) in response to environmental cues (copied from 
Schraml et al.).
22
 
 
Their ability to phagocyte pathogens and present their antigens by MHC, as well as their 
capacity to migrate from sites of inflammation to lymphoid tissues, is vital for igniting 
protective pro-inflammatory, as well as tolerogenic immune responses.23 In lymphoid 
tissues (e.g. lymph nodes (LN)) the now-mature DCs are able to activate T cells carrying 
a T cell receptor being specific for the foreign-peptide–MHC complexes on the DC 
surface. Therefore, DCs are described as sentinels of the immune system, as they 
survey the peripheral tissues and instruct the adaptive immune system in response to 
peripheral cues.24 
Besides their role of sampling the environment for antigens and migrating to peripheral 
lymphoid organs, DCs are important mediators attracting T lymphocytes to sites of 
antigen accumulation and exposure. Through the secretion of different constitutive and 
inducible chemokines DCs are able to attract T cells to sites where they are needed. 
Important chemokines attracting naive T cells into the T cell zone of lymphoid tissues, 
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are the DC-derived CC chemokine 1 (DC-CK1) (CCL18)25 and EBV-ligand chemokine 
(ELC) (CCL19).26 Inflammatory chemokines such as macrophage inflammatory protein 
(MIP)-1α (CCL3),27 and macrophage-derived chemokine (MDC) (CCL22)28 mainly recruit 
activated cells to sites of inflammation. 
DCs can be subdivided into three distinct groups: plasmacytoid DCs (pDCs), 
conventional DCs (cDCs) and monocyte derived DCs (moDCs).29 pDCs are a special 
subset of DCs which differentiate (dependent on the transcription factor E2-2) 
completely in the bone marrow and reside in lymphoid organs under steady state 
conditions.30 Their main function lies in the production of high amounts of type I 
interferons (mainly IFN-α) upon activation of TLR7/9 signaling, after viral infections. 
pDCs can act as APCs, but are less efficient in antigen presentation than other DC 
subsets.31 In mice, pDCs are characterized by their expression of Siglec-H, B220, Ly6C 
and CCR9. In humans, they are characterized as Human Leukocyte Antigen – antigen D 
Related positive (HLA-DR+), interleukin-3 receptor positive (CD123+) and blood dendritic 
cell antigen 2 protein positive (BDCA-2+) (Figure 3).32 
Differentiation into cDCs is regulated by the transcription factor inhibitor of DNA binding 
2 (Id2).33 There are two main populations of cDCs with distinct functions: CD11b+ and 
CD11b-cDCs. CD11c- DCs can be further divided into CD8a+ DCs residing in lymphoid 
organs and into CD103+ DCs located in non-lymphoid organs. These two subsets of 
CD11b-cDCs, depending on the transcription factors BATF3 (Basic leucine zipper 
transcriptional factor ATF-like 3)34 and IRF-8 (Interferon regulatory factor 8)35 
respectively, are the most efficient cross-presenting (naive cytotoxic CD8+ T cell 
stimulation) DCs, characterized by high expression of MHC-I.36 In contrast, CD11b+ DCs 
are characterized by the expression of CD11c, CD11b and CD172a and require the 
transcription factors IRF4 and RbpJ (Recombining binding protein suppressor of 
hairless) for their differentiation and reside in lymphoid organs. CD11b+ DCs are 
specialized in presenting antigens via MHC-II to CD4+ T helper cells.37 
moDCs are nearly absent during steady state conditions but can originate, as their name 
suggests, from Ly6Chigh monocytes during inflammation, cancer and, infections.38 They 
are described by the expression of MHCII, CD11b, CD11c, F4/80, Ly6C, CD206, 
CD115, LAMP2 (lysosomal-associated membrane protein 2), CD64, Zbtb46 (Zinc finger 
and BTB domain-containing protein 46) and, FcεR. The later allowing to distinguish 
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them from cDCs. In humans, moDCs are characterized by expression of HLA-DR, 
CD11c, BDCA1, CD1a, FcεRI, CD206, CD172a, CD14 and CD11b and ZBTB46.38,39 
1.2.2 T cells 
Development of T cells begins in the bone marrow, from where pluripotent progenitors 
migrate towards the thymus, a primary lymphoid organ, and go through a rigorous 
differentiation protocol.40 Till today, it is agreed on that the thymus is responsible for the 
differentiation of various distinct T cell population. These include γδ T cells, αβT cells 
(including CD4+ and CD8+ T cells, as well as their regulatory counterparts) and Natural 
Killer T cells (NKT cells, as well as intraepithelial lymphocytes (IEL). The following 
chapters will be focusing on the development and the function of αβ T cells and their 
different subpopulations.40 
After entering the thymus, early T cell progenitors (ETP) undergo extensive proliferation, 
which is initiated through thymic stromal cells, producing interleukin (IL)-7.41 This 
proliferative state is denominated as the double negative (DN) stage 2 (Figure 5). At the 
DN2 T cell progenitors are yet not fully committed to the T cell lineage.42 Next the T cells 
enter the DN3 stage, stop proliferating and undergo TCR gene rearrangements (see 
chapter 1.1.2.). Furthermore, they express antigen receptors consisting of only one 
chain (either the TCRβ chain or the TCRγ and TCRδ chain).43 Only cells carrying 
appropriate pre-TCRs will survive. Cells not carrying appropriate pre-TCRs will enter 
apoptosis, due to lack of signal. Continuing the maturation, T cells carrying a 
successfully rearranged TCRβ chain undergo β-selection inducing the expression of 
CD4 and CD8, transforming them into double positive cells (DP).42 In the DP stage, the 
T cells will undergo αTCR gene rearrangements (see chapter 1.1.2) and express the full 
αβTCR, which will be the basis for a specific selection program. Immature cells 
recognizing self-peptide-MHC molecules with their specific TCR in the thymus, but 
exhibit a weak affinity will further differentiate. This process is denominated positive 
selection.44 If the αβTCR of the DP interacts appropriately with MHC-I/peptide 
complexes it differentiates into CD8+ single positive (SP) αβ T cells. If the αβTCR of the 
DP interacts appropriately with MHC-II/peptide complexes it differentiates into CD4+ SP 
αβ T cells.45 If the TCR binds with to high affinity, the cell will undergo apoptosis 
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(negative selection). T cells with rearranged TCRγ and TCRδ chains will be selected as 
γδ T cells.44 
At the end of the thymic selection process, the SP progenitor is no longer responsive to 
apoptosis. In this last stage, the SP progenitor is able to proliferate after stimulation 
through the TCR. The mature and naïve T cell that is able to proliferate, emigrates from 
the thymus.46 
 
Figure 5. Cross-section through an adult thymic lobule showing the migration path of T cell 
precursors during development. First, T cell precursors enter the thymus through blood vessels near 
the cortico–medullary junction. These early T-cell precursors (ETP) migrate, and differentiate from double 
negative (DN) to double positive (DP) to single positive (SP) stages, through the distinct 
microenvironments of the thymus. ETPs can continue their expansion with minimal differentiation in the 
cortico–medullary junction region or differentiate into DN2 cells that begin migrating from the site of entry 
to the outer rim of the cortex. -selection occurs during the accumulation of the DN3 T cells in the 
subcapsular zone. If the αβTCR of the DP interacts appropriately with MHC-I/peptide complexes it 
differentiates into CD8
+
 single positive (SP) αβ T cells. If the αβTCR of the DP interacts appropriately with 
MHC-II/peptide complexes it differentiates into CD4
+
 SP αβ T cells. In this last stage, the SP progenitor is 
able to proliferate after stimulation through the TCR. The mature and naïve T cell that is able to proliferate, 
emigrates from the thymus. Broken arrows depict alternative developmental pathways which are still 
possible for ETPs and for different subsets of DN2 cells which are likely to correspond to DN2a and DN2b 
cells before they complete their commitment to the T-cell-lineage. CCR9, CC-chemokine receptor 9; ISP, 
immature single positive; LMPP, lymphoid primed multipotent progenitor; NK, natural killer; TCR, T-cell 
receptor (copied from Rothenberg et al.).
40
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Mature naïve T cells express antigen receptors and co-stimulatory molecules necessary 
for the antigen recognition. However, these naïve cells are not capable of carrying out 
effector mechanisms allowing them to combat pathogens. For this purpose, naïve T cells 
need to be activated and differentiate into T effector cells. This process will occur in 
secondary lymphoid organs.47 For homing towards LN, most naïve T cells express 
CCR7 as well as CXCR4 and enter the LN through high endothelial venules (HEV). The 
chemokine CCL21 is produced by HEV and presented on their luminal endothelium.48,49 
CCL19 and CXCL12 (the ligand for CXCR4) are produced by fibroblastic reticular cells 
(FRC) and transcytosed across the HEV and presented on their luminal endothelium, as 
already described for CCL21.50 Similar to the DC, the T cell follows the CCL21/19 
gradient in the subcapsular sinus of the LN to migrate into the T cell area of the LN, 
where it scans DCs for foreign antigens.47 
The activation and differentiation of T cells can be divided into three stages: First, 
antigen recognition and co-stimulation resulting in cytokine secretion. Second, the clonal 
expansion, describing the process where a T cell clone recognizes its specific antigen 
and starts proliferating. Third and last, T cells differentiate either into CD4+ or CD8+ T 
effector cells or memory T cells.4 CD8+ cytotoxic T cells are mainly responsible for 
eliminating infected or damaged cells via interaction of MHCI. Almost all cells (exception 
of non-nucleated cells) express MHCI on the surface. When infected, these cells 
degrade foreign peptides and present antigens via MHCI, which in turn, can be detected 
by CD8+ T cells. When activated CD8+ T cells start proliferating and releasing cytotoxins 
such as perforins and granzymes which induce apoptosis of the APC.51 
CD4+ T cells, also known as T helper cells, assist in shaping the activity of 
macrophages, B cells and dendritic cells. Through secretion of certain cytokines and 
through upregulation of CD40 ligand on the surface of T cells they induce the activation 
of macrophages, B cells and, DCs. Thus, leading to improved phagocytosis, increased 
expression of co-stimulatory factors on the APC surface, and, in the case of B cells, to 
an augmented antibody production.4 Mature CD4+ T cells can differentiate into several 
subpopulations of effector cells, of which the most studied and prominent candidates are 
T helper type 1 (TH1), TH2, TH17 and regulatory T cells (Tregs). The differentiation of 
naïve T cells into these effector subsets occurs after few days of direct contact with 
APCs.52 Innumerous factors are involved during this differentiation process. These 
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include the affinity of the antigen, the type of signaling induced by the TCR, the set of 
co-receptors involved, the underlying cytokine milieu present, as well as the set of signal 
transducer and activator of transcription (STAT) factors expressed in the T cell. The 
following chapters will focus on these T helper cell subsets.4 
 
 
Figure 6. CD4+ T cell subsets. Depicted are the five best described CD4
+
 T helper (TH) cell subsets, 
their immunomodulatory mediators, cell specific surface markers and transcription factors and a 
corresponding cytokine milieu controlling the individual TH-subset differentiation. Adapted after 
http://www.lonza.com/products-services/bio-research/primary-cells/hematopoietic-cells/hematopoietic-
knowledge-center/cd4-t-cell-subsets.aspx 
 
1.2.2.1. TH1 cells 
TH1 cells are characterized by the secretion of IFN-γ, IL-2, TNF-α and Lymphotoxin. All 
of these enhance pro-inflammatory cell mediated immune responses by maximizing 
killing efficacy of macrophages and proliferation of cytotoxic CD8+ T cells. This increase 
in killing efficacy is for example initiated by stimulating antibody production, mainly 
opsonizing isotypes of immunoglobulin G (IgG) by B cells.51 Naïve T cells differentiate 
into TH1 cells when they are surrounded by an inflammatory cytokine milieu composed 
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of IL-12, and Type I Interferons (IFN-α and IFN-β) and INF-γ, among others (Figure 6). 
This inflammatory cytokine milieu (IL-12; Type I interferons, IFN-y) is primarily being 
secreted by macrophages and DCs after activation through extracellular pathogens, 
such as bacteria.53 IFN-γ stimulation of naive T cells leads to activation of the Janus kinase 
(JAK) 1 + 2 pathway that further (downstream) activates the transcription factor STAT1. STAT1 
activation induces the expression of the transcription factor T-box expressed in T cells (Tbet) 
(Figure 6). This transcription factor is responsible for remodeling the IFN-γ gene locus and 
therefore the expression and secretion of IFN-γ. Furthermore, Tbet maintains expression and 
stabilization of the IL-12 receptor on the surface of the TH1 cell.
54
 
1.2.2.2. TH2 cells 
The predominant role of TH2 cells is their interaction with B cells. Through this 
interaction TH2 cells promote the stimulation of the humoral immune system.
52 Cytokines 
involved during this process are IL-4, IL-5, IL-6, IL-10 and IL-13 (Figure 6). With these 
tools TH2 cells promote protection against helminthic infections but are also involved in 
several allergic diseases.55 The TH2 signature cytokine IL-4 is also known as B cell 
stimulating factor. IL-4 is crucial for the induction of IgE synthesis by activated B 
lymphocytes and influences class switching to IgG1 as well.56 IL-4 itself is a key cytokine 
during polarization of TH2 cells and through binding to the IL-4 receptor on the surface of 
naïve T cells, IL-4 activates STAT6 signaling. STAT6 signaling on the other hand leads 
to the expression of the transcription factors c-Maf (musculoaponeurotic fibrosarcoma 
oncogene homologue) and GATA binding protein 3 (GATA3) (Figure 6). c-Maf induces 
high expression of IL-4, whereas GATA3 antagonizes TH1 differentiation by inhibiting the 
expression of IL-2 receptor β-chain and of STAT4.53 
1.2.2.3. TH17 cells 
With the proposition of the dichotomy of TH1 and TH2 cells, which was proposed by 
Mossman and Coffman in 1989,57 that divided CD4+ T helper cells in IFN-γ producing 
TH1 cells and IL-4 producing TH2 cells it was thought to explain the tendency of T cells to 
act either in a cellular or a humoral immune response.57 However, it was predicted that 
there must be other subsets involved that would explain STAT3-dependent CD4+ T cells 
during autoimmune diseases and infections.  
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In studies performed in a mouse model of experimental autoimmune encephalopathy 
(EAE), which at that point was thought to be dependent of TH1 cells, it was shown that 
development of EAE failed in mice deficient of p40.58,59 The subunit p40 forms together 
with the subunit p35 IL-12. As mentioned in chapter 1.2.2.1., IL-12 induces TH1 cell 
differentiation. Nevertheless, mice deficient in the subunit of p35 still developed EAE.60 
Later it was found that p40 not only forms heteromers with p35, but is also able to form 
heteromers with p19, creating IL-23. Further studies in mice lacking p19 failed to 
develop EAE, phenocopying p40 deficiency and indicating the crucial role of IL-23 in the 
onset of EAE.61 Furthermore, it was shown that IL-23 induces the secretion of IL-17 from 
another TH subset, denominated TH17 cells.
62 
IL-23 is not the sole factor driving TH17differentiation; it is rather a mixture of cytokines, 
including TGF-β and IL-6, promoting TH17cells (Figure 6).
63-65 IL-6 plays a pivotal role in 
activating STAT3. Through this activation, expression of several genes regulating TH17 
induction is induced. These include Rorc (encodes the transcription factor RAR-related 
orphan receptor gamma (RorγT)), Il17 and Il23r (Figure 6).66-68 STAT3 also inhibits TGF-
β-induced expression of Forkhead-Box-Protein P3 (Foxp3), thus suppressing the 
generation of regulatory T cells.69 IL-6 also induces the expression of IL-1R, a receptor 
for the pro-inflammatory cytokine IL-1β.70 IL-1β induces the phosphorylation of the 
mechanistic Target of Rapamycin (mTOR) (a protein kinase that regulates cell growth, 
cell proliferation, cell motility, cell survival, protein synthesis, autophagy, and 
transcription) in TH17 cells and increases proliferation of TH17 cells during 
inflammation.71 TGF-β plays a more complex role and functions either as an obligate 
TH17 inducing factor or indirectly suppresses alternate cell fates by repressing Tbet and 
GATA3.69 
RoryT+ TH17 cells are divided into two groups: Host protective cells expressing IL-17 and 
IL-10 and inflammatory cells characterized by IL-17, IL-22, IFN-γ and GM-CSF 
(Granulocyte-macrophage colony-stimulating factor) expression.72 TGF-β and IL-6-
induced TH17 cells promote (via IL-10 secretion) a host protective phenotype, related to 
mucosal defense against microorganisms and barrier tissue integrity. IL-23 activated 
TH17 cells on the other hand promote chronic tissue inflammation during infections and 
autoimmunity.69 
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1.2.2.4. Regulatory T cells 
Regulatory T cells (Tregs) are also known as suppressor T cells and are a 
subpopulation of CD4+ T cells. Their main responsibilities are the modulation and 
regulation of the immune system by ensuring the balance between immune activation 
and tolerance towards self-antigens.73 In mice, Tregs are characterized as 
CD3+CD4+CD25+ and the transcription factor Foxp3+.74 At least in mice Foxp3 is 
associated with the suppressive functions of Tregs. In humans, the expression of Foxp3 
can be transient.74 There are two distinct subtypes of Tregs. Those generated in the 
thymus and denominated natural Tregs (nTregs)73 and those induced in the periphery 
(iTregs).75 Tregs generated in the thymus develop similar to naïve T cells (described in 
chapter 1.2.2.). The affinity of interaction with self-peptide MHC complex plays a pivotal 
role in determining the fate of the developing T cell. T cells that encounter very strong 
signals will undergo apoptosis. A weak signal will induce survival programs and the cell 
will become an effector cell. In the case of an intermediate signal strength, the T cell will 
develop into a regulatory T cell.76 
Next to the strength of the TCR stimulus, other factors contribute to the development of 
nTregs. These include cytokines such as IL-2, IL-15 and TGF-β, who all increase the 
expression of Foxp3.74 Induced regulatory T cells (iTregs) develop from mature CD4+ T 
cells outside of the thymus. This requires stimulation in an anti-inflammatory milieu. The 
cytokines TGF-β and IL-10 as well as DCs play a pivotal role in this process.77,78 
Moreover, Tregs are classified into three distinct groups, characterized by their secretion 
profile. TH3 cells are the predominant producers of TGF-β
79, whereas Tr1 cells are the 
main producers of IL-1080 and Tr35 cells are known to secrete high amounts of IL-35.81 
Tregs can modulate the immune response through a plethora of mechanisms. One 
mechanism is the inhibition of immune responses via secretion of cytokines such as 
TGF-β, IL-10 and IL-35. IL-10 for instance inhibits the expression of pro inflammatory 
cytokines such as IL-12. This leads to a reduced TH1 response.
82 Another important role 
of IL-10 is its induction of phagocytic activity in phagocytic cells. Consequently, cellular 
debris at inflamed sites get removed faster and more efficient.82 
IL-35 is an immunosuppressive cytokine known to inhibit proliferation of CD4+ T helper 
cells and promotes the differentiation of naïve T cells into inducible Tr35 cells (iTr35). 
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These iTr35 cells are highly suppressive and produce again high amounts of IL-35.83 IL-
35 was further shown to be involved in the conversion of B cells into B regulatory cells.84 
The role of TGF-β in promoting anti-inflammatory immune responses is rather complex. 
Briefly, TGF-β is capable of regulating several immune cells. For instance, it is involved 
in suppressing effector T cell differentiation and driving differentiation of naïve T cells 
into Tregs (depending on the cytokine milieu also into TH17 cells).
85 TGF-β has also 
been implicated in inhibiting the activity of macrophages, DCs and NK cells.86 
Besides secretion of anti-inflammatory cytokines, Tregs can mediate their suppressive 
effects via cytolysis of pro-inflammatory cells through secretion of granzyme and 
perforin.87 Tregs are also able to inhibit proliferative responses via consumption of IL-
2.88 Furthermore, cyclic adenosine monophosphate (cAMP) (an important secondary 
messenger used in many intracellular signal transduction pathways) mediated metabolic 
inhibition89 and immunomodulation mediated via the A2 adenosine receptor,90 are 
inhibitory mechanisms used by Tregs. Tregs are also capable to interact with DCs, 
through cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4)-CD80/86 interactions, 
and modulate their maturation and function.91 
Tregs are found broadly across most lymphoid and non-lymphoid tissues during 
homeostatic conditions.92 In humans, expression of chemokine receptors on Tregs 
change with age. In neonatal cord blood Tregs are naïve and express CCR7 and 
CXCR4 (LN homing receptors), as conventional naïve T cells do, or they express the 
gut-homing receptor CCR9.93,94 In a three year old child Tregs appear to be divided into 
two groups that resemble a memory phenotype. They are characterized as CCR7+ L-
selectin+ Tregs resembling central memory T (TCM) cells or, CCR7- Tregs that resemble 
effector memory T (TEM) cells. This memory like Tregs downregulate CCR9 and instead 
express skin-, lung-, or inflammation-homing chemokine receptors such as CXCR3, 
CCR2, CCR4, CCR5, CCR6 and CCR8.93,94 All of the latter are part of the chemokine-
chemokine receptor system which will be described in the next section. 
1.3. The chemokine – chemokine receptor system 
Chemokines belong to a superfamily of secreted chemotactic cytokines that are best 
known to control migration of immune cells. Chemokines are small molecules with a 
molecular weight of around 8-10 kDa. Today the chemokine system consists of around 
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50 endogenous chemokines and 20 G protein-coupled seven-transmembrane signaling 
receptors (see also Figure 7).95 The chemokine system is involved in many physiological 
and pathological processes, such as embryogenesis, immune system development and 
function, inflammation, tumorigenesis and cancer metastasis.96 
 
 
Figure 7. Chemokine superfamily. Overview of the most important chemokine receptors  and their 
cognate chemokine ligands. (Courtesy of Yvonne Döring) 
 
Chemokines have a highly conserved secondary structure and built up by their unique 
tetracysteine motif. Through this motif, the chemokine superfamily can be subdivided 
into four distinct groups. The majority of chemokines belongs to the CC group where the 
N-terminal cysteine’s are next to each other. The CXC group is characterized by an 
amino acid that separates the first two cysteine’s from each other. The CX3C group has 
only one member, Fraktaline (CX3CL1), and is characterized by three amino acids, 
Introduction 
______________________________________________________________________ 
19 
which separate the N-terminal cysteins. Chemokines belonging to the C group possess 
only two out of the four cysteines present in other chemokines.97,98 
 
Figure 8. Chemokine subclasses. Chemokines are divided into four families according to the number 
and spatial organization of conserved cysteine residues in their N-terminus. Disulfide bridges are shown 
as black lines. The transmembrane domain of CX3CL1 is depicted by lipids (in gray) (copied from de 
Munnik et al.).
99
 
 
The chemokine receptors are named according to the group of chemokines they bind 
(CC, CXC, XC, and CX3C). These G protein-coupled seven-transmembrane receptors 
signal through coupled heterotrimeric G proteins. In general, receptor binding induces a 
signal transduction cascade that leads to activation of protein kinases and increase in 
intracellular Ca2+.100 
 
Figure 9. G protein-coupled receptors (GPCRs) and their signaling. A) Depicted are the three 
extracellular loops (ECL1-3) and the N-terminus in the extracellular (EC) region and the three intracellular 
loops (ICL1-3) and the C-terminus in the intracellular (IC) region. The seven transmembrane (TM) helices 
contain a number of proline-dependent kinks that divide the GPCR into the ligand binding module and the 
module that binds downstream effectors such as G proteins. The C-terminus of many GPCRs is folded 
into an eighth helix that runs parallel to the plasma membrane and is often anchored to the membrane via 
a palmitoylation site.
99,101
 (B) G protein-dependent signaling: Gα proteins are divided into Gαs, Gαi, Gαq, 
and Gα12/13 protein families that regulate different effector proteins such as AC and PLC. Effector proteins 
produce second messengers (e.g., cAMP) that subsequently activate transcription factors such as CRE, 
NFAT and SRF. Abbreviations: AC, adenylyl cyclase; ATP, adenosine triphosphate; cAMP, cyclic 
Introduction 
______________________________________________________________________ 
20 
adenosine monophosphate; CRE, cAMP-responsive element; DAG, diacylglycerol; GEF, guanine 
nucleotide exchange factor; IP3, inositol 1,4,5-triphosphate; NFAT, nuclear factor of activated T-cells; PIP2, 
phosphatidylinositol-4,5-bisphosphate; PKA, protein kinase A; PKC, protein kinase C; PLCβ, 
phospholipase Cβ; RhoA, Ras homolog gene family A; ROCK, RhoA kinase; SRF, serum response factor 
8copied from de Munnik et al.).
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The main function of the chemokine system lies in the control of migratory patterns and 
positioning of immune cells.102 The majority of chemokines carries an overall net positive 
charge at neutral pH. This allows for interactions of varying affinity with different 
negatively charged extracellular structures like glycosaminoglycans (GAG) which are 
present for example on the surface of endothelial cells. This deposition allows the 
generation of a steeply decaying chemokine gradient, providing stable directional 
cues.103,104 The chemokine gradient plays a pivotal role during the leukocyte 
extravasation to sites of inflammation. When endothelial cells get activated through 
cytokines released during inflammation of the underlying tissue, they initially start 
expressing P- and later E-selectins.105 Circulating leukocytes recognize these selectins 
(P-selectin on endothelial cells binds for example PSGL-1 (P-selectin glycoprotein ligand 
1) on leukocytes) with moderate affinity. This causes the slow down and rolling of 
leukocytes on the endothelial surface. Rolling leukocytes, which encounter a chemokine 
gradient and recognize it with a specific receptor get then activated and start expressing 
integrins (lymphocyte function associated antigen-1 (LFA-1) and Very Late Antigen-4 
(VLA-4)) which mediate the arrest of rolling leukocytes on the endothelial surface and 
the transmigration into the tissue and to sites of inflammation.106,107 
As mentioned above chemokines are not just relevant during the migration of immune 
cells to the site of inflammation, but are also involved in guiding cells during 
homeostasis. During homeostatic conditions, DCs for example use a Ccr7-dependent 
process to migrate via the efferent lymphatics into the draining LN, similar to that 
described for T cells.108 Ccl21 is produced by lymphatic vessels in peripheral tissues and 
promotes migration of Ccr7+ cells. The migration through lymphatic vessels does not 
seem to be integrin-dependent, in contrast to the migration under high shear rates in the 
bloodstream.109 As soon as Ccr7+ DCs arrive in the lymphatics, Ccl21 and Ccl19 appear 
and play an additive role in DC migration into the subcapsular sinus of the draining LN. 
The DC follows a gradient of Ccl21 and Ccl19, produced by fibroblastic reticular cells 
(FRC) in the subcapsular sinus. This gradient promotes the positioning of DCs in the T 
cell area of the LN.110 
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1.3.1 Ccl17 – Ccr4 
Ccl17 was first discovered by Imai and Yoshida in 1996 and characterized as a CC 
chemokine constitutively expressed in the thymus and highly selective for T cells.111 In a 
follow up study the group was able to identify the chemokine receptor 4 (Ccr4) as 
receptor for Ccl17.112 Other studies point towards Ccr8 as a receptor for Ccl17113,114 but 
have to be considered with caution, as they have been questioned by others and still 
await confirmation.115,116 Furthermore, Ccl17 is expressed by thymic DC, LN DC and 
CD11c+ DC in the lung of mice.117 
Ccl17 is known to play a role in the recruitment and migration of different T cell subsets 
including TH1, TH2 and Tregs. In addition murine Ccl17 expressing DCs induce both, the 
production of the TH1 cytokine IFN-γ and the TH2 and Treg cytokine IL-10 in an antigen 
specific manner in T cells in vitro.118 Recent work of our group revealed that the DC-
derived chemokine Ccl17 promotes atherogenesis by controlling regulatory T cell (Treg) 
homeostasis, restraining their expansion, while its deficiency decreased plaque burden 
by facilitating Treg maintenance and survival. Despite a partial function of Ccr4 in acute 
inflammatory Treg recruitment and maintenance of Tregs, we did not observe a 
comparable reduction in lesion formation and infiltration in chimeric mice carrying Ccr4-/- 
bone marrow.119 Similar findings were obtained in a model of atopic dermatitis, where 
the inflammatory burden was reduced in mice lacking Ccl17 but not Ccr4120, giving rise 
to the conclusion that Ccl17 is required for sensitizing Ccr7- and Cxcr4-dependent DC 
migration to the LN and subsequent T cell priming. Accordingly, Ccr7-/-Ldlr-/- mice exhibit 
less plaque formation attributed to a critical involvement of Ccr7 in recirculation of T cells 
between lymphoid organs and sites of inflammation.121 Furthermore, and consistent with 
data obtained in our lab, Heisseke et al. were able to demonstrate that lack of Ccl17 
protects from intestinal inflammation due to a reduced inflammatory cytokine milieu of 
DC origin, which facilitates Treg expansion. Again, Ccl17 seemed to promote 
inflammation independently of Ccr4-mediated T cell recruitment, suggesting an 
autocrine mechanism stimulated by the Ccl17-Ccr4 axis in DCs, involving other 
cytokines.122 In contrast, others have shown that expression of Ccr4 on Treg is crucial to 
secure Treg recruitment to sites of inflammation123,124 and facilitates Treg-dependent 
graft survival.125 
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1.3.2 Ccl5 and its receptors 
Ccl5 or RANTES (Regulated upon Activation, Normal T cell Expressed, and Secreted) 
was first identified in the 1980s as a CC-chemokine expressed by T cells.126 It was 
described to recruit T cells, eosinophils and macrophages to sites of inflammation.127 Its 
expression is regulated by Kruppel-like factor 13.128 It is not only expressed by T cells, 
but also by macrophages, platelets, synovial fibroblasts, tubular epithelium and certain 
types of tumor cells. Further studies also revealed an upregulation of Ccl5 in activated 
vascular smooth muscle cells (VSMC).129-131 Ccl5 is involved in a variety of diseases 
including atherosclerosis, asthma, Acquired Immune Deficiency Syndrome (AIDS), graft 
versus host disease and autoimmune diseases such as arthritis and diabetes.  
Further, Ccl5 has been shown to bind to the receptors Ccr1, Ccr3 and Ccr5. Through 
binding to Ccr1 and Ccr5, Ccl5 induces leukocyte arrest and transmigration.132 In a 
mouse model of atherosclerosis Braunersreuther and co-workers could show in 2007 
that, Ccr5 deficiency but not Ccr1 deficiency protected from atherosclerotic lesion 
development, due to a reduction in monocyte recruitment.133 However, while various 
groups could confirm the data of Ccr5 deficiency, including ours, data regarding Ccr1 
deficiency has to be considered with caution. Söhnlein and Drechsler et al. did not find 
an increase of lesion size in the absence of Ccr1. The authors show that Ccr1 deficiency 
reduced atherosclerotic lesion formation at least in early stage lesions.134 Hence, further 
studies are required to clearly address the role of Ccr1 during atherosclerotic lesion 
formation. 
1.3.3 Chemokine heterodimerization 
Chemokines are small secreted proteins that are best known for their specialized roles 
in cell trafficking and cell positioning and increasing evidence supports an emerging role 
of chemokines in modulating immune mechanisms beyond cell trafficking and 
positioning. They not just appear in a monomeric form but are also able to form dimers 
and even higher order oligomers, based on two modes to support interfaces.135 On the 
one side, CC chemokines are able to form dimeric structures via interaction of the 
flexible N-termini. This leads to the formation of a two-stranded anti-paralleled β-sheet. 
On the other side, CXC chemokines form homodimers through antiparallel extension of 
preformed β-strands.135 CC-dimers are also able to form higher order oligomers, 
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consisting of up to 50 units and more. Through this the chemokine CCL3 (Macrophage 
inflammatory protein 1 alpha (MIP1-α)) for instance, is able to form rod-like structures.136 
This multimeric structures would allow the creation of soluble gradients (compared with 
stable gradients bound to GAGs) if dimers and monomers would be released from the 
multimeric structure in a constant rate.137 Chemokines are not just able to form 
homodimeric structures, but taking into account the structural similarities of this group, 
allows them to form unique heterodimers. These heterodimeric structures modify and 
fine-tune the overall signaling response of their receptors and with this open up a further 
dimension of biological versatility. 
Molecular dynamic simulation (MDS) for selected chemokine homo- and heterodimer 
pairs suggest that CC-Chemokines preferably form pairs with other CC-chemokines and 
that CXC chemokines interact preferably with CXC-chemokines.138 But it was also 
shown that CC-CXC heterodimerization occurs. A prominent member of the CC-CXC 
heteromers was identified by nuclear magnetic resonance (NMR) analysis and consists 
of CCL5 and CXCL4. In the case of CCL5-CXCL4 heterodimerization, our group was 
able to demonstrate that disruption of the CCL5-CXCL4 heterodimer reduced monocyte 
recruitment, thereby ameliorating the disease outcome after induced lung injury as well 
as atherosclerosis in mouse models.138 Inflammation and in particular chronic 
inflammation is characterized by marked vascular changes, including vasodilation, 
increased permeability and increased blood flow, which are induced by the actions of 
various inflammatory mediators. During inflammatory processes blood cells including T 
cells and DCs migrate to sites of inflammation where they play an important role in the 
maintenance of inflammation. To reach the site of inflammation but also for cell-cell 
communications chemokines and chemokine receptors have emerged major players. In 
the following section atherosclerosis as a chronic inflammation of the arterial wall and 
the role of T cells and DCs (and their secreted chemokines) in the pathophysiology of 
this disease will be further described. 
1.4. Atherosclerosis 
Atherosclerosis is a disease affecting mid-sized to large arteries. Atherosclerotic lesion 
formation takes place at sites of disturbed flow. In these areas endothelial dysfunction 
and sub-endothelial lipoprotein retention will occur, which will lastly lead to a non-
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resolving inflammatory response. As a consequence, intimal destruction, thrombosis and 
end-organ ischemia may occur.139 
The term ‘Atherosclerosis’ is derived from the two Greek words “athera” (gruel) and 
“sclerosis” (induration) and was first introduced by Johann Friedrich Lobstein in 1829. 
Atherosclerotic lesions are described by multiple atheromatous plaques within the 
arteries. Atheromatous plaques are nodular accumulations of a soft, yellowish material 
at the center of large plaques, composed of macrophages nearest the lumen of the 
artery.140,141 
In the later mid-19th century, researchers such as Carl von Rokitansky and Rudolph 
Virchow proposed two opposing views on the pathology of atherosclerosis. Rokitansky 
postulated that a trauma, caused by mechanical stress, would initially injure the vessel 
wall. This initial injury then would lead to endothelial dysfunction. Virchow on the other 
hand emphasized on the critical role of the immune system during atherosclerotic lesion 
development. He recognized atherosclerotic lesions as an irritation at the vessel wall, 
that preceded the fatty metamorphosis and compared that to swelling, cloudiness and 
general enlargement, as seen in other inflamed parts of the body.142 In the early 20th 
century Nikolai N. Anitschkow described the “cholesterinesterphagozyten” which derived 
from macrophages.140 These cells are known today as foam cells. This discovery 
elucidated the leading role of cholesterol in atherosclerotic lesion development. In the 
1970s Russell Ross established the “response to injury” hypothesis complementing 
Rokitansky’s hypothesis which he had postulated more than 100 years earlier. Russell 
brought together the importance of hyperlipidemia and inflammation and suggested that 
vascular accumulation of lipids triggers an inflammatory response.143-145 This hypothesis 
was further strengthened in the 1990s, when Daniel Steinberg and others proposed  
altered lipoprotein compositions and modified low density lipoprotein (LDL) (mainly 
oxidized LDL) as disease triggers being taken up by macrophages which would 
eventually turn into foam cells.146 
But, even to date – despite the intensive research in this field, the concordant 
acceptance of hyperlipidemia as the main risk factor and growing evidence that 
atherogenesis is strongly regulated by immunological mechanisms – the initial reason 
unbalancing the system remains vague.139 
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1.4.1 Pathomechanisms of atherosclerosis 
The normal artery is build up by three layers. The tunica intima is lined by a monolayer 
of endothelial cells, which is in contact with the blood stream. The tunica media contains 
smooth muscle cells (SMCs) embedded in a complex extracellular matrix and the 
adventitia contains mast cells, nerve endings and micro vessels147 (Figure10A). The 
main underlying cause for atherosclerotic lesion formation is endothelial dysfunction.148 
Endothelial dysfunction is caused by pro-inflammatory conditions putatively arising 
during long-term hyperlipidemic exposure.149 The activated endothelium upregulates 
adhesion molecules e.g., Selectin’s and Integrin’s, which will trigger the leukocyte 
adhesion cascade leading to infiltration of leukocytes into the intimal space. This 
infiltration will cause asymmetrical thickening of the intima.150 (Figure10B) 
Hyperlipidemia together with other risk factors allows for ongoing leukocyte infiltration 
leading to plaque growth and chronic inflammation.151 This inflammation will not be 
resolved, resulting in an increase of apoptotic cells and an accumulation of apoptotic 
bodies and cholesterol crystals. This will ultimately form a mature plaque, also known as 
atheroma.152,153 Atheromas consist of a necrotic core (containing lipids), surrounded by 
foam cells and other immune cells overall covered by a cap of smooth muscle cells and 
collagen rich matrix (Figure 10C).154,155 Furthermore, the secretion of pro-inflammatory 
cytokines and proteases limits collagen formation causing thinning of the fibrous cap. 
Weakening of the fibrous cap makes the plaque more vulnerable to rupture. Rupture of 
the fibrous cap results in thrombus formation possibly causing acute ischemia, 
manifesting as myocardial infarction or stroke (Figure10D).156,157 
Figure 10. shown on page 26. The normal muscular artery and changes that occur during 
atherosclerotic lesion progression as well as thrombus formation after plaque rupture. A) The 
normal artery is build up by three layers. The tunica intima is lined by a monolayer of endothelial cells 
which is in direct contact with the blood stream. The tunica media contains vascular SMCs embedded in a 
complex extracellular matrix. The third layer, called adventitia contains mast cells, nerve endings and 
microvessels. B) Atherosclerotic lesion development begins with endothelial dysfunction and subsequent 
adhesion of blood leukocytes to the activated endothelial monolayer, transmigration of the bound 
leukocytes into the intima, maturation of monocytes into macrophages taking up lipids thereby 
transforming into foam cells. C) As the lesion progresses SMCs migrate from the media into the intima, 
resident intimal SMCs and media-derived SMCs start proliferating, and increase the synthesis of 
extracellular matrix macromolecules. Plaque macrophages and SMCs may undergo apoptosis in 
progressing lesions. Extracellular lipids derived from dead and dying cells can accumulate in the central 
region of a plaque, often denoted the lipid or necrotic core. Advancing plaques also contain cholesterol 
crystals and microvessels. D) Thrombosis, often complicates a physical disruption of the atherosclerotic 
plaque. Shown is a fracture of the plaque's fibrous cap, which has enabled blood coagulation components 
to come into contact with tissue factors in the plaque's interior, triggering the thrombus that extends into 
the vessel lumen, where it can impede blood flow (copied from Libby et al.).
158
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1.4.2 Dendritic cells in atherosclerosis 
DCs are known to be present in the atherosclerotic lesion, as well as in the adventitia. In 
mice, an intimal network of CD11c+ MHCII+ DCs has been described at sites prone to 
develop atherosclerotic lesion. This network of DCs consist of fms like tyrosine kinase 3 
(Flt3)/Flt3L-dependent CD103+ and CD11b+CD172a+ conventional DCs. A large portion 
of DCs found in atherosclerotic lesions is monocyte-derived and express CD11b. 
Further, these cells depend on macrophage colony-stimulating-factor (M-CSF) or 
express CD64.159-161 Upon stimulation DCs mature and upregulate co-stimulatory 
molecules such as CD80 (B7-1) and CD86 (B7-2) as well as MHC-II, which are required 
for an appropriate stimulation of T cells (see chapter 1.1.2). DCs in atherosclerotic lesion 
mainly express the costimulatory molecules CD80 and CD86 indicating their activated 
state. Ldlr-/-mice deficient for both CD80 and CD86 showed reduced early and to some 
extent advanced atherosclerotic lesions. Furthermore, these mice showed decreased 
levels of MHCII+, as well as CD3+ cells in atherosclerotic lesions. Splenic T cells isolated 
from these Ldlr-/-Cd80-/-Cd86-/- mice showed reduced production of IFN-γ in response to 
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stimulation with heat shock protein 60. These results suggest that absence of co-
stimulatory molecules inhibits priming of an adequate TH1 response.
162  
Although DCs can be found in marginal parts of the plaque core, they mostly localize in 
the plaque shoulder and regions prone to rupture.163,164 Rohm et al. performed an 
immunohistochemical analysis of human carotid specimens, comparing stable and 
unstable plaques. The group found in unstable plaques an 1.6 fold increase in both 
fascin+ mDCs and S100+ DCs and a 5.9-fold increase of mature CD83+ mDCs.164 
Furthermore, Weyand, et al. demonstrated that 53% of endarterectomy samples 
contained CD123+ pDCs and CD11c+ DC-sign+fascin+ mDCs.165 But pDC numbers are 
very low compared to cDC numbers.166,167 Furthermore, DCs are present in the 
adventitia and in tertiary lymphoid organs (TLOs) that form in the adventitia of aged 
Apoe-/- mice.168 In humans, the presence of TLOs in atherosclerotic regions remains 
controversial but a recent study performed by Akhavanpoor et al.  demonstrates that 
adventitial cellular accumulations show characteristics of highly organized TLOs.169 As 
mentioned coronary artery disease (CAD) patients show increased numbers of DCs in 
the atherosclerotic vascular wall. However, interestingly Yilmaz et al. were able to show 
that CAD patients have decreased levels of circulating pDCs and mDCs and total DCs in 
the blood.170,171  
DCs are able to modulate atherosclerotic lesion development in many different ways 
(Figure 11). For instance, DCs invade the vascular wall stimulated by oxLDL, TNF-α and 
hypoxia, which are commonly found in atherosclerotic lesions.172,173 Other atherogenic 
factors such as, oxLDL174, advanced glycation end products (AGE),175 nicotine,176 
insulin177 and angiotensin II178 lead to further maturation of DCs. Furthermore, during 
hyperlipidemic conditions, vascular DCs are known to accumulate lipids, adopting a 
foam cell-like appearance.179 Moreover, it was shown that DCs play an important role in 
cholesterol homeostasis. In DC depletion studies, using the CD11c-DTR Apoe-/- mouse 
model, loss of DCs induced higher cholesterol levels in plasma of these mice. These 
effects were not observed in CD11b-DTR Apoe-/- mice with a depletion of 
monocytes/macrophages, neutrophils, and CD11b+ DCs indicating that CD11c+ DCs 
mostly control cholesterol metabolism.179,180 One of the major roles DCs play in the 
immune system is antigen presentation and priming of T cells. DCs may interact with T 
cells in the plaque or in the adventitia. However, it is also possible that they emigrate 
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from the vessel wall towards lymphoid organs and prime T cells there.181 Studies have 
shown the importance of DC-T cell interactions in the context of atherosclerosis. For 
example, a study performed in Ldlr-/- mice deficient for the invariant chain of MHCII 
showed protection against atherosclerosis. This was due to a reduction in activated T 
cells in the plaque.182 Furthermore, it was shown that different DC subtypes could 
control regulatory T cell responses. For instance, the Ccl17 expressing 
CD11b+CD11c+MHCII+ DC subset restrains regulatory T cells, thereby aggravating 
atherosclerosis.119 Importantly, patients with CAD show an increased level of serum 
Ccl17183 and reduced numbers of peripheral Treg numbers.184 Using Flt3-deficient mice 
it was shown that CD103+ cDC numbers where reduced in aortas, that diminished 
systemic and local regulatory T cell numbers and worsened atherosclerotic burden. This 
study indicates, that the Flt3-dependent CD103+CD11c+MHCII+ cDC subset promotes 
regulatory T cells and acts anti-atherogenic.159 pDCs are also able to interfere in 
atherosclerotic lesion development, but results obtained in different studies came to 
different conclusions. For instance, in a study using Ldlr-/- deficient mice treated with 
pDC depleting antibodies (PDCA1 neutralizing antibody) in a carotid artery cuff model, 
mice developed more atherosclerotic lesions.185 Moreover, in an Apoe-/- mouse model 
reduced atherosclerotic lesions where observed.166,167 More recently, Sage et al. were 
able to demonstrate that by using CD11c-restricted deletion of the transcription factor 
Tcf4/E2-2 (required for pDC development and maintenance), pDC deficiency reduced 
atherosclerotic lesion formation in Ldlr−/− chimeras186. This phenotype was confirmed in 
chimeras lacking the pIII and IV promoters of MHC-II transactivator (CIITA) in pDCs, 
leading to MHC-II-restricted antigen presentation defects in pDCs.187 Together these 
findings point towards a pro-atherogenic role for pDCs in experimental atherosclerosis. 
However, a study performed by Yun et al. suggested that pDCs might act tolerogenic 
and protective in experimental atherosclerosis, decreasing plaque progression via 
induction of Tregs.188 The authors generated atherosclerotic chimeric mice by 
transplanting bone marrow from BDCA2-DTR mice into Ldlr−/− mice. In these mice, the 
simian diphtheria toxin receptor (DTR) is expressed under the transcriptional control of 
the human pDC gene promoter BDCA-2.189 This model allows pDCs to be successfully 
and selectively depleted 24 h after diphtheria toxin (DT) treatment. Atherosclerotic 
plaque formation significantly increased in the sinus of pDC-depleted animals.188 
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Interestingly, the authors found that mouse and human aortic pDCs expressed the 
tolerogenic enzyme indoleamine 2,3-dioxygenase (IDO)-1, suggesting an 
activated/matured pDC phenotype. Moreover, they showed an interesting correlation 
between aortic pDCs and Treg numbers with disease progression and proposed a direct 
functional link between the presence of Indolamin-2,3-Dioxygenase (IDO-1)+ pDCs and 
Treg generation in the diseased vessel.188 However, in a study performed by Mandl et 
al. the authors used Apoe−/− BDCA2-DTR mice to further investigate the role of pDCs in 
atherosclerosis.190 In this study, DT administration to induce pDC depletion for 4 weeks 
during high-fat diet (HFD) did not affect lesion formation in the aortic sinus. Importantly 
and surprisingly, a detailed analysis of depletion efficiency demonstrated complete pDC 
depletion for 1 week only. After 4 weeks of continuous DT administration, pDCs failed to 
express Diphtheria toxin receptor (DTR) anymore and therefore, could not be 
depleted.190 It is possible that crossing of BDCA2-DTR mice to Apoe−/− mice may have 
led to altered pDC depletion. However, the results presented by Mandl et al. 
demonstrate that long-term experiments with BDCA2-DTR mice have to be evaluated 
carefully. 
 
Figure 11. Dendritic cells (DCs) in atherosclerosis. CD11c
+
 DCs can be found in atherosclerotic 
lesions, and exert different pro-atherogenic and protective functions in disease development. DCs can 
engulf lipids to adopt a foam cell-like appearance that may constitute the earliest stages of plaque 
formation. In addition, DCs regulate cholesterol homeostasis and decrease serum very low–density 
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lipoprotein (VLDL) and low-density lipoprotein (LDL) levels by yet unknown mechanisms. Plasmacytoid 
DCs (pDCs) promote atherosclerosis by a MHCII-dependent activation of TH1 cell responses and 
secretion of interferon (IFN) α; a subset of CCL17-expressing CD11b
+
 DCs restrains Treg responses and 
drives atherosclerosis; CD103
+
 classical DCs promote Treg responses and protect from atherosclerosis. 
(Courtesy of Yvonne Döring) 
 
1.4.3 T cells in atherosclerosis 
T cells are an abundantly present leukocyte population in atherosclerotic plaques. 
Considering their plasticity though, deciphering the role of various T cell subsets in the 
development of atherosclerosis is not an easy task. Focusing on CD3+CD4+ T helper 
cells the most abundant subsets present in atherosclerotic plaques is the TH1 cell.
191,192 
Differentiation into TH1 subsets requires the transcription factor Tbet and a cytokine 
milieu containing IL-12 and IL-18 as well as IFN-y (all mainly produced by macrophages; 
see chapter 1.2.2.1).193 Studies performed in Ifn-γR-/-Apoe-/- mice showed a 60% 
reduction in lesion size compared to Apoe-/- control mice.194 Furthermore, studies in 
which Apoe-/- mice where either lacking IL-12195,196 or IL-18197,198 showed reduced 
atherosclerosis compared with control animals, which was accompanied by reduced 
IFN-γ levels. Consistent with these studies, mice deficient for the transcription factor 
Tbet showed also reduction of atherosclerotic lesion size by 30%. These results were 
accompanied by an increase in TH2 cytokine production (IL-4, IL-5 and IL-10) and an 
increase in IgM natural antibodies.199 
Since Tbet deficiency increased TH2 cytokine production and TH2 cells are thought to 
oppose differentiation of TH1 cells it was assumed that TH2 cells ought to be athero-
protective. However, studies revealed that defining the role of TH2 cells during 
atherosclerotic lesion development might be more challenging than for TH1 cells. For 
instance, the TH2 signature cytokine IL-4 leads to upregulation of CD36 (scavenger 
receptor class B member 3, important for scavenging oxLDL)200,201 and class A 
scavenger receptor (important for scavenging oxLDL and collagens) on 
macrophages,202 as well as upregulation of vascular cell adhesion molecule 1 (VCAM-
1)203,204 and matrix metalloproteinase (MMP) 1,205 which would all indicate an 
atherogenic phenotype. On the other hand, studies performed on Il4-/-Apoe-/- mice have 
shown no difference in plaque burden. Regarding one other TH2 signature cytokine, IL-5, 
it could be shown that bone marrow transplantation studies, where Ldlr-/- mice were 
reconstituted with Il5-/- bone marrow had increased plaque size compared to control 
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mice. This was due to reduced amounts of plasma natural IgMs. Natural IgMs act as 
blocking antibodies against modified lipoproteins such as oxLDL.206 
The role of TH17 cells in atherosclerosis is still controversial. As mentioned before, TH17 
cells are induced in the presence of IL-6 and TGF-β and are known to secret IL-17 and 
IL-22. In general IL-17 signaling leads to the production of TNF, IL-1β,207,208 IFN-γ209 as 
well as G-CSF (Granulocyte-colony stimulating factor).210 All together these are pro-
inflammatory mediators that would suggest that TH17 cells play an atherogenic role. 
Animal models of atherosclerosis show conflicting results. For instance, studies 
performed in Apoe-/- mice using a rat-anti mouse IL-17A antibody show 50% reduction in 
aortic root lesions. Interestingly, this study did not show any evidence of reduced IL-17A 
signaling, which could explain a reduction in atherosclerotic lesion formation.207,211 In 
another experiment performed by Cheng et al., the authors used a mouse-anti mouse 
IL-17A. In this study, the authors did not observe any changes in atherosclerotic lesion 
size, although they found reduced levels of IL-17A.211 Results obtained from knock out 
studies showed also conflicting results depending on the mouse model used to study 
atherosclerotic lesion development. Il17a-/-Ldlr-/- mice displayed no difference in 
atherosclerotic lesion size compared to their controls,209 whereas Il17a-/-Apoe-/- mice 
showed a reduction of 35 % compared to the control group.212 Regarding human 
studies, patient data revealed a possible atherogenic role of TH17 cells since patients 
with unstable angina have increased levels of IL-17A as well as IL-6 and IL-23.213,214 
Thus, the role of TH17 cells and its signature cytokine IL-17 in the development of 
atherosclerosis has to be further elucidated. 
Tregs are known as immune suppressor cells and are a subpopulation of CD4+ T helper 
cells. They are characterized as CD3+CD4+CD25+ and Foxp3+. Tregs are able to 
negatively regulate pro-inflammatory immune effects through a variety of mechanisms, 
e.g. via secretion of their signature cytokines IL-10, IL-35 and TGF-β (Figure 12). 
Antibody depletion of TGF-β (targeting TGFβ-1, -2 and -3) promotes atherosclerotic 
lesion formation through increased numbers in pro-inflammatory cells. For instance, the 
lesion cross-sectional area occupied by MOMA-2+ macrophages increased in anti-TGF-
β-treated mice when compared to control mice. Furthermore, reduction of collagen 
content in the plaque was observed in the anti–TGF-β–treated mice when compared to 
the control group. 215,216 IL-10 is known to have a protective role in atherogenesis. IL-10-
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deficiency in mice results in three fold increased atherosclerotic lesions, accompanied 
by a 2.5 fold increase in CD3+ T-cell infiltration, strong IFN-γ expression, and decreased 
collagen content. Furthermore, in vivo, transfer of murine IL-10 achieved 60% reduction 
in lesion size.217,218,219 The Treg cytokine IL-35 is known to suppress T effector cell 
mechanisms and induces the secretion of IL-10 thereby acting protective during 
atherogenesis220. In vitro studies also revealed that Tregs are able to inhibit foam cell 
formation and skewed macrophages into an M2-like, anti-inflammatory phenotype.221,222 
Furthermore, Tregs are known to suppress B cell responses (Figure 12).223 B cell 
depletion in Apoe−/− mice using anti-CD20 neutralizing antibodies reduced 
atherosclerosis lesion formation. Furthermore, adoptive transfer of conventional B2 B 
cells but not B1 B cells to an Apoe−/−Rag-2−/− deficient (lymphocyte deficient) mouse that 
was fed a high-fat diet increased atherosclerosis by 72%.224 In this study levels of IgG, 
IgM and total Ig´s did not differ. The increased size of atherosclerotic lesions in mice 
which received adoptively transferred B2 B cells was attributed to elevated levels of 
TNF-α in these mice. Though, the inhibition of B cells by Tregs might be one mechanism 
underlying the protective effect of Tregs during atherosclerosis.225 Tregs show anti-
inflammatory effects on endothelial cells leading to a decrease in expression of 
adhesion molecules and recovery of endothelial function (Figure 12).226 Other studies 
also revealed beneficial effects of Tregs regarding foam cell formation, showing that 
Tregs reduced macrophage and lipid content in atherosclerotic plaques and increased 
smooth muscle cell numbers. These findings were accompanied by higher levels of 
collagen as well as reduced expression of pro-inflammatory cytokines and MMPs in the 
lesion.227 Interestingly, Tregs are of very low abundance in atherosclerotic plaques (1-5 
% of all T cells) compared to other chronically inflamed tissues (approx. 25% of all T 
cells in eczema or psoriasis).228,229 A study performed on a prospective cohort consisting 
of a random sample of participants (n=700), aged 68 to 73 years, in Sweden showed 
low numbers of circulating regulatory T cells correlated with development of myocardial 
infarction and for coronary events in general.230 
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Figure 12. Mechanisms of Treg cell-mediated suppression and the implicative pathways. The 
mechanisms by which Tregs mediate their suppression can be classified into two major categories: cell-
contact-independent mechanisms (production of inhibitory cytokines, deprivation of IL-2 and ATP/ADP) and 
cell-contact-dependent mechanisms (induction of cytolysis, modulation of APCs). CTLA-4, cytotoxic T 
lymphocyte-associated antigen-4; DC, dendritic cell; ITAM, immunoreceptor tyrosine-based activation motif; 
LAG3, lymphocyte activation gene 3; MHC, major histocompatibility complex; TGF, transforming growth 
factor; TREG cell, regulatory T cell (copied from Meng et al.).225 
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2. Materials and methods 
2.1. Materials 
2.1.1 General equipment 
Table 1: General equipment 
equipment source 
autoclave Systec 2540EL (Systec, Wettenberg, Germany) 
balance Analytical Plus, (Ohaus, Pine Brook, NJ, USA) 
centrifuges Eppendorf 5427R (Eppendorf, Hamburg, 
Germany), 
Heraeus Laborfuge 400 and Heraeus Multifuge 
3 S-R (Heraeus, Osterode,Germany) 
Eppendorf 5920R (Eppendorf, Hamburg, 
Germany) 
flow cytometers FACSCantoII, FACSAria (BD Biosciences, San 
Jose, CA, USA) 
fluorescence plate reader SpectraFluor Plus (Tecan, Crailsheim, 
Germany) 
laminar flow hood Herasafe (Heraeus, Osterode, Germany) 
microscopes Olympus IX71 and BX51 (Olympus Optical, 
Hamburg, Germany), Leica DMLB (Leica, 
Wetzlar, Germany) 
pH-meter InoLab level 1 (WTW, Weilheim, Germany) 
spectrometer NanoDrop (Peqlab, Erlangen, Germany) 
Irradiator Faxitron (Tucson, USA) 
Incubator Thermo Fisher Scientific (Waltham, USA) 
BIAcore GE - BIAcore, AB (Uppsala, Sweden) 
Luminex ™ xMAP Luminex Corp. (Austin, USA) 
2.1.2 Consumables 
  
Table 2: Consumables 
consumables source 
96well plates flat, round 
bottom 
Corning, New York, USA 
cannulas 23G, 27G BD, Franklin Lakes, USA 
cell strainer BD, Franklin Lakes, USA 
disposable scalpel Feather Safety Razor Co., Osaka, Japan 
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FACS-tubes BD, Franklin Lakes, USA 
microscope slides Thermo Scientific, Braunschweig, Germany 
microtubes EDTA, with clot 
activator for sera 
Sarstedt, Nümbrecht, Germany 
glassware Schott, Mainz, Germany 
reaction cups 1,5ml, 2,0ml Eppendorf, Hamburg, Germany 
reaction tubes 15ml, 50ml Sarstedt, Nümbrecht, Germany 
serological pipettes 5ml, 10ml, 
25ml 
Sarstedt, Nümbrecht, Germany 
sterile filter-tips Starlab, Ahrensburg, Germany 
syringes 2ml, 5ml, 10ml, 20ml BD, Franklin Lakes, USA 
syringes 1ml Braun, Melsungen, Germany 
2.1.3 Buffers, chemicals, media, solutions 
If not mentioned otherwise, protocols were adapted from standard protocols (ref 159). 
Solutions were prepared with Millipore water (Milli-Q Plus ultrapure purification, Millipore, 
MA). If not stated otherwise, chemical reagents were obtained either from Fulka (Buchs, 
Switzerland), Sigma-Aldrich (Deisenhofen, Germany) or Roth (Karlsruhe, Germany). 
Table 3: Buffers chemicals, media and solutions 
Buffer/Solution/Medium Composition 
FACS staining buffer 2% mouse serum; 2% rabbit serum (both Sigma-Aldrich, 
St. Louis, USA); 2% human serum (Innovative 
Research, Novi, USA); 2% bovine serum albumin (BSA) 
(Serva, Heidelberg, Germany); dissolved in PBS 
Hank´s complete HBSS (Thermo Fisher Scientific (Gibco) Waltham, 
USA), 0,3mM diNaEDTA, 0,1% BSA 
Lysis buffer 150mM NH4Cl; 10mM KHCO3; 0,1mM diNaEDTA, pH 
7,4 
Phosphate buffered 
saline (PBS) 
w/o Ca2+ and Mg2+, sterile (Thermo Fisher Scientific 
(Gibco) Waltham, USA), pH 7,4 
RPMI Medium RPMI1640 (Thermo Fisher Scientific (Gibco) Waltham, 
USA); 10% fetal calf serum (FCS) (Thermo Fisher 
Scientific (Gibco) Waltham, USA) 
Paraformaldehyde 4% Paraformaldehyde, 5% Sucrose, 0,02M EDTA, pH 
7,4 
ELISA Stop 2N sulfuric acid 
ELISA Wash 10 mM phosphate buffer pH 7.4, 150 mM NaCl, 0.05% 
Tween 20 
MACS Buffer phosphate-buffered saline (PBS), 2% fetal calf serum 
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(FCS) (Thermo Fisher Scientific (Gibco) Waltham, 
USA), 1 mM EDTA 
DEMEM Medium DEMEM (Thermo Fisher Scientific (Gibco) Waltham, 
USA); 10% fetal calf serum (FCS) (Thermo Fisher 
Scientific (Gibco) Waltham, USA) 
2.1.4 Peptides, antagonists and antibodies 
Peptides, antagonists and antibodies used for different experimental setups are listed 
below in tables 4-8. Antagonists were all obtained from Tocris bioscience (Bristol, United 
Kingdom). If not stated otherwise, all antibodies used (table 5) were reactive to mouse. 
Table 4: Peptides 
Peptide Manufacturer 
rmCcl17 (TARC) BioLegend, San Diego, USA 
rmTgf-ß BioLegend, San Diego, USA 
rmCcl3 Peprotech, Hamburg, Germany 
rmCcl1 Peprotech, Hamburg, Germany 
rmCcl18 Peprotech, Hamburg, Germany 
rmCcl20 Peprotech, Hamburg, Germany 
CCR8 (Human) Proteoliposome Abnova, Taipei City, Taiwan 
 
Table 5: Antagonists 
Antagonist Type Specific against 
C021 
Dihydrochloride 
Small molecule Chemokine (C- C motif) receptor 4 
DAPTA Peptide Chemokine (C-C motif) receptor 5 
J113863 Small molecule Chemokine (C-C motif) receptor 1 
 
Table 6: Primary antibodies 
Antibody Specificity Conjugate Application Manufacturer 
Anti-Mac-2 Mouse/Human 
Mac-2 (Galectin-
3) 
unconjugated IHC Cedarlane, 
Burlington, 
Canada 
Anti-Actin, 
α-Smooth 
Muscle 
Mouse Actin, 
α-Smooth Muscle 
FITC IHC Sigma-Aldrich, 
St. Louis, US 
Anti-FoxP3 mouse Foxp3 unconjugated IHC Abcam, 
Cambridge, UK 
Anti-Ccl3 mouse Ccl3/Mip- unconjugated IHC Abcam, 
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1a Cambridge, UK 
Anti- Ccl5 mouse 
Ccl5/RANTES 
unconjugated IHC BioTechne, 
Minneapolis, 
US 
Anti-Ccl17 mouse 
Ccl17/TARC 
unconjugated IHC R&D System, 
Minneapolis, 
US 
Anti-Ccl1 mouse Ccl1 unconjugated IHC Biorbyt, 
Cambridge, UK 
Anti-Ccl3 mouse Ccl3 unconjugated IHC R&D Systems, 
Minneapolis, 
US 
Anti-Ccr8 mouse Ccr8 unconjugated IHC GeneTex, 
Irvine, USA 
Anti-Ccr5 mouse Ccr5 unconjugated IHC Santa Cruz 
Biotechnology, 
Dallas, USA 
Anti-Ccr4 mouse Ccr4 unconjugated IHC Thermo Fisher 
Scientific 
Waltham, USA 
IHC: Immunohistochemistry 
Table 7: Primary antibodies 
Antibody Specificity Conjugate 
Applicatio
n 
Manufacturer 
Anti-CD25 Regulatory T cells APC FC 
Thermo Fisher 
Scientific 
(eBioscience) 
Waltham, USA 
Anti-CD115 
Monocytes, 
Macrophages 
PE FC 
Thermo Fisher 
Scientific 
(eBioscience) 
Waltham, USA 
Anti-CD11b 
Neutrophils, 
Monocytes, Macro-
phages 
PerCP, 
PE-Cy7 
FC 
Thermo Fisher 
Scientific 
(eBioscience) 
Waltham, USA 
Anti-CD11c Dendritic cells PE-Cy7 FC 
Thermo Fisher 
Scientific 
(eBioscience) 
Waltham, USA 
Anti-B220 
B-cells, Plasmacytoid 
DCs 
PerCP, 
PE-Cy7 
FC 
Thermo Fisher 
Scientific 
(eBioscience) 
Waltham, USA 
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Anti-CD3 T-cells FITC FC 
Thermo Fisher 
Scientific 
(eBioscience) 
Waltham, USA 
Anti-CD45 All Leukocytes APC-Cy7 FC 
Thermo Fisher 
Scientific 
(eBioscience) 
Waltham, USA 
Anti-CD4 T helper cells V500 FC 
BD Biosciences, 
Franklin Lakes, 
USA 
Anti-CD8 Cytotoxic T cells eF450 FC 
Thermo Fisher 
Scientific 
(eBioscience) 
Waltham, USA 
Anti-FoxP3 Regulatory T cells PE FC 
Thermo Fisher 
Scientific 
(eBioscience) 
Waltham, USA 
Anti-MHC-II 
Dendritic Cells, 
Macrophages, B cells 
V500 FC 
BD Biosciences, 
Franklin Lakes, 
USA 
Anti-PDCA-
1 
Plasmacytoid DCs PE FC 
BD Biosciences, 
Franklin Lakes, 
USA 
Anti-F4/80 Macrophages PE FC 
Thermo Fisher 
Scientific 
(eBioscience) 
Waltham, USA Anti-Gr-1 
(Ly6C and 
Ly6G) 
Neutrophils and one 
subset of mouse 
Monocytes 
APC FC 
Thermo Fisher 
Scientific 
(eBioscience) 
Waltham, USA 
Anti-
SiglecH 
Plasmacytoid DCs eF450 FC 
Thermo Fisher 
Scientific 
(eBioscience) 
Waltham, USA 
Anti-CD301 M2 Macrophages APC FC 
Biorad, Hercules, 
USA 
FC: Flow Cytometry 
Table 8: Secondary antibodies 
Antibody Specificity Conjugate Applicatio
n 
Manufacture
r 
Anti- Rabbit 
IgG 
Rabbit  FITC IHC Dianova, 
Hamburg 
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Anti- Rat IgG Rat  Cy3 IHC Sigma-
Aldrich, St. 
Louis, US 
IHC: Immunohistochemistry 
2.1.5 Reagent kits and miscellaneous 
 
Table 9: Reagent kits and miscellaneous 
Kit Purpose Manufacturer 
Cytokine & Chemokine 26-
Plex Mouse ProcartaPlex™ 
Panel 1 
assessing multiple 
protein biomarkers in a 
single sample 
Thermo Fisher Scientific 
(eBioscience) Waltham, 
USA) 
Ccl3 Mouse Uncoated ELISA 
Kit with Plates 
accurate and precise 
measurement of mouse 
Ccl3 protein levels 
Thermo Fisher Scientific 
(eBioscience) Waltham, 
USA 
Mouse Ccl17 Quantikine 
ELISA Kit 
accurate and precise 
measurement of mouse 
Ccl3 protein levels 
R&D Systems, 
Minneapolis, US 
CD11c MicroBeads 
UltraPure, mouse 
isolation of mouse DCs 
from single-cell sus-
pensions from lymphoid 
tissues 
Miltenyi Biotec GmbH, 
Bergisch Gladbach, 
Germany 
CD4+CD62L+ T Cell Isolation 
Kit II, mouse 
isolation of mouse 
CD4+CD62L+ T helper 
cells from spleen and 
lymph nodes 
Miltenyi Biotec GmbH, 
Bergisch Gladbach, 
Germany 
CD4+ T Cell Isolation Kit, 
mouse 
isolation of mouse CD4+ 
T cells from spleen and 
lymph nodes 
Miltenyi Biotec GmbH, 
Bergisch Gladbach, 
Germany 
CD4+CD25+ Regulatory T 
Cell Isolation Kit, mouse 
solation of CD4+CD25+ 
regulatory T cells (Treg) 
from single-cell 
suspensions of mouse 
spleen and lymph nodes 
Miltenyi Biotec GmbH, 
Bergisch Gladbach, 
Germany 
Monocyte Isolation Kit 
mouse 
isolation of monocytes 
from single-cell 
suspensions of mouse 
spleens 
Miltenyi Biotec GmbH, 
Bergisch Gladbach, 
Germany 
Duolink® In Situ Red 
Goat/Rabbit  
Detection and 
quantification of protein 
interactions and their 
Sigma-Aldrich, St. 
Louis, US 
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modifications 
Foxp3 / Transcription Factor 
Staining Buffer Set 
staining with antibodies 
to transcription factors 
and nuclear proteins 
Thermo Fisher Scientific 
(eBioscience) Waltham, 
USA) 
CountBright™ Absolute 
Counting Beads, for flow 
cytometry 
Calculation of absolute 
cell numbers in flow 
cytometry 
Thermo Fisher Scientific 
(life technologies) 
Waltham, USA) 
2.1.6 Mice 
Wild-type (wt) C57BL/6 and Apolipoprotein E-deficient (Apoe-/-) mice were obtained from 
the local animal breeding facility (Zentrale Versuchstierhaltung Innenstadt (ZVH), 
Klinikum der Universität München) or purchased at Charles River, England or Janvier, 
Belgium. Mice deficient for different chemokine receptors and ligands were all received 
from the in-house animal facility of the Clinic of the University of Munich. All strains used 
are summarized in table 10 and were backcrossed for at least ten generations in their 
stated genetic background. All mouse strains deficient for a chemokine receptor or 
ligand are furthermore deficient for Apolipoprotein E. 
Table 10: Mouse strains 
Gene Name Abbreviation Background Mutation Origin 
Wildtype Bl6 wt C57/Bl6 None Jackson 
Laboratories (Bar 
Harbor, USA) 
Apolipo-
protein E 
Apoe C57/Bl6 Targeted 
mutation 
(Knock-out) 
Jackson 
Laboratories (Bar 
Harbor, USA) 
Chemokine 
(C-C motif) 
receptor 1 
Ccr1 C57/Bl6 Targeted 
mutation 
(Knock-out) 
Gao et al.  
J Exp Med. 1997 
PMID: 9166425   
Chemokine 
(C-C motif) 
receptor 4 
Ccr4 C57/Bl6 Targeted 
mutation 
(Knock-out) 
Chvatchko et al.  
J Exp Med. 2000 
PMID: 10811868 
Chemokine 
(C-C motif) 
receptor 5 
Ccr5 C57/Bl6 Targeted 
mutation 
(Knock-out) 
Kuziel et al. 
Atherosclerosis. 
2003 
PMID: 12618265 
Chemokine 
(C-C) ligand 
Ccl17 C57/Bl6 Targeted 
mutation 
Lieberam, Förstner 
Eur J Immunol. 1999 
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17 (GFP 
reporter 
Knock-in) 
PMID: 12615900 
Chemokine 
(C-C) ligand 
3 
Ccl3 C57/Bl6 Targeted 
mutation 
(Knock-out) 
Cook et al.  
Science. 1995 
PMID: 7667639 
Chemokine 
(C-C) ligand 
5 
Ccl5 C57/Bl6 Targeted 
mutation 
(Knock-out) 
    Makino et al.  
Clin Immunol. 2002 
PMID: 11890717 
2.2. Methods 
2.2.1. In vivo experiments 
2.2.1.1. Mouse models 
Ccr4-/- mice were kindly provided by PD Dr. med. David Anz (Ludwig-Maximilians- 
Universität, München, Germany), whereas the Ccl17e/e mice were generously provided 
by I. Förstner (Universität Bonn, Germany). Ccl3-/- mice were purchased from the 
Jackson Laboratories (Bar Harbor, USA). Ccr1-/- mice and Ccr5-/- mice were bread in 
house. Ccr4-/-, Ccr1-/-, Ccr5-/-, Ccl17e/e and Ccl3-/- mice were crossed with Apoe-/- mice, 
purchased from the Jackson Laboratories (all C57BL/6J background). Apoe-/-, Apoe-/-
Ccr4-/-, Apoe-/-Ccl17e/e, Apoe-/-Ccl3-/- were fed normal chow.  
2.2.1.2.  Mouse models of atherosclerosis 
For atherosclerosis studies, mice were fed an atherogenic high-fat diet (HFD) containing 
21% fat and 0.15-0.2% cholesterol (Altromin 132010, Sniff TD88137), starting at 8-10 
weeks of age for 12 weeks, after which they were sacrificed. Experiments were 
approved by local authorities and complied with German animal protection law. Every 
effort was made to minimize suffering. Hearts, aortic arches, aortas, blood, bone 
marrow, lymph nodes (axillar, mesenteric, inguinal and para-aortic), and spleens were 
harvested. Hearts, aortic arches and aortas were fixed in 4 % PFA for further histological 
and immunohistological analysis of atherosclerotic lesion size and composition. 
2.2.1.3. Bone marrow transplantation 
Bone marrow cells (3×106/mouse) from C57BL/6 Apoe-/- mice or from Apoe-/- Ccr4-/- 
mice were flushed from femur and tibia cavities and subsequently administered to 
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C57BL/6 Apoe-/- recipient mice by lateral tail vein injection one day after a lethal dose of 
whole-body irradiation (2x 6.5 Gy). After four weeks of recovery, the mice were placed 
on HFD for up to 12 weeks as mentioned under 2.2.2.  
2.2.1.4. Cell culture 
Cell culture was performed under sterile conditions in a laminar flow hood. Cells were 
maintained in a CO2-incubator at 37°C and a humidified 5% CO2 atmosphere. Cells 
were cultured in growth medium (RPMI 1640) supplemented with 10% (v/v) fetal calf 
serum (FCS), 2 mM L-glutamine and penicillin (100 U/mL)/streptomycin (100 μg/mL) 
(Thermo Fisher Scientific (Gibco) Waltham, USA) to avoid contamination with bacteria. 
FCS was incubated at 56°C for 30 min to inactivate the complement system and stored 
at -20°C until use. All media and solutions used for cell culture were from Gibco if not 
stated otherwise and purchased sterile or sterilized through a 0.2 μm filter. Cultured cells 
were regularly tested to be mycoplasma free by the VenorGeM Mycoplasma detection 
kit (Minerva Biolabs, Berlin, Germany). 
2.2.1.5. Preparation of primary cell suspensions 
For flow cytometric analysis of lymph nodes (axillary, inguinal, para-aortic, and 
mesenteric) or spleen organs were pressed through a 70-μM cell strainer. Cells isolated 
from spleen were lysed with red blood cell lysis buffer for 5 min. Bone marrow (BM) 
cells were extracted from the tibia and femur with Hank’s complete solution using a 1 ml 
syringe and 23-gauge needle. The single cell suspension was centrifuged and the pellet 
resuspended in about 1 ml RBC lysis buffer for 5 min. Whole blood obtained from the 
retro-orbital plexus of mice was EDTA-buffered and subjected to red-cell lysis for 15 min 
in 5 ml RBC lysis buffer, followed by 2 wash steps in Hank’s complete solution. Cells 
were then used for further analysis 
2.2.1.6. Isolation of CD4+ T cells 
CD4+T cells were isolated from secondary lymphoid organs via depletion of non-CD4+T 
cells. For this purpose, the CD4+T cell Isolation Kit (containing a cocktail of biotin-
conjugated Abs against CD8a, CD45R, CD11b, CD49b and Ter-119, as well as 
magnetic anti-biotin MicroBeads) and a separation column (all Miltenyi Biotec) were 
used according to the recommended protocol, allowing a negative selection of CD4+T 
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cells. Briefly, the freshly isolated secondary lymphoid organ cells were mixed with the 
cocktail of biotin-conjugated antibodies (Abs) and incubated for 10 min at 4°C. After 
washing with MACSbuffer, the cells were mixed with magnetic anti-biotin microbeads, 
incubated for 15 min at 4°C, washed and loaded onto the separation column. The 
magnetically labeled cells were retained in a separation column placed in a magnetic 
field, whereas cells were recovered in the eluate and cultured in cell culture medium for 
further analysis.  
2.2.1.7. Isolation of CD4+CD25+ regulatory T cells 
The isolation is performed in a two-step procedure. At first, non-CD4+ are indirectly 
magnetically labeled with a cocktail of biotin-conjugated antibodies against CD8, CD11b, 
CD45R, CD49b, Ter-119 and Anti-Biotin MicroBeads as mentioned under 2.2.1.6. The 
labeled cells are subsequently depleted over a separation column. The flow-through 
fraction contains pre-enriched CD4+ T cells which in a second step, can be labeled with 
CD25 MicroBeads (all Miltenyi Biotec) for subsequent positive selection of CD4+CD25+ 
regulatory T cells (Tregs).  
2.2.1.8. Isolation of CD4+CD62L+ naive T cells 
Mouse naive CD4+ T cells are isolated by depletion of memory CD4+ T cells and non-
CD4+ T cells. Single-cell suspensions of mouse spleen or lymph nodes are indirectly 
magnetically labeled with a cocktail of biotinylated monoclonal antibodies, and anti-biotin 
MicroBeads, as secondary labeling reagent as mentioned under 2.2.1.6. Subsequently, 
CD4+CD62L+ T cells are positively selected from the enriched CD4+ T helper cell fraction 
with CD62L (L-selectin) MicroBeads (all Miltenyi Biotec).  
2.2.1.9. Isolation of CD11c+ dendritic cells 
For the isolation of CD11c+ DCs cells from spleens and LN of wt mice cell suspensions 
were incubated with CD11c MicroBeads (Miltenyi) for 15 min at 4°C, washed and loaded 
onto the separation column. The CD11c+ DCs retained in the separation column and 
could be eluted after the column was removed from the magnetic field.              
Furthermore, eGFP+Ccl17e/+ and eGFP+Ccl17e/e DCs were sorted using a BD FACSAria 
(BD). For this purpose single-cell suspensions of mouse (either Apoe-/-Ccl17e/e or Apoe-/-
Materials and methods 
______________________________________________________________________ 
45 
Ccl17e/+) lymph nodes were stained with Antibodies against CD45, CD11c, MHCII and 
eGFP.  
2.2.1.10. Isolation of monocytes 
Using the Monocyte Isolation Kit mouse (all Miltenyi Biotec), monocytes are isolated by 
depletion of non-target cells. Non-target cells are indirectly magnetically labeled with a 
cocktail of biotin-conjugated monoclonal antibodies, as primary labeling reagent, and 
anti-biotin monoclonal antibodies conjugated to MicroBeads as secondary labeling 
reagent. The unwanted cells are depleted by retaining them within a separation Column 
in a magnetic field, while the unlabeled monocytes pass through the column. 
2.2.1.11. Isolation of neutrophils 
Neutrophils are isolated by depletion of non-target cells using the Miltenyi Neutrophil 
isolation kit. Non-target cells are indirectly magnetically labeled with a cocktail of biotin-
conjugated monoclonal antibodies, as primary labeling reagent, and anti-biotin 
monoclonal antibodies conjugated to MicroBeads as secondary labeling reagent. The 
unwanted cells are depleted by retaining them within a separation Column in a magnetic 
field, while the unlabeled monocytes pass through the column. 
2.2.2. Protein assays 
2.2.2.1. Analysis of atherosclerotic lesion using histology  
For analysis of mouse atherosclerotic lesions, the aortic root and the thoraco-abdominal 
aorta were stained for lipid depositions with Oil-Red-O. In brief, hearts with aortic root 
were fixed with 4% paraformaldehyde and embedded in Tissue-Tek O.C.T. compound 
(Sakura) for cryo-sectioning. Atherosclerotic lesions were quantified in 4 µm transverse 
plane sections and averages were calculated from 3 sections. The thoraco-abdominal 
aorta was fixed with 4% paraformaldehyde and opened longitudinally, mounted on glass 
slides and en face-stained with Oil-Red-O. The aortich arch was stained using 
Haematoxylin-Eosin (HE) staining. Aortic arches with main branch points 
(brachiocephalic artery left subclavian artery and left common carotid artery) were fixed 
with 4% paraformaldehyde and embedded in paraffin. Lesion size was quantified after 
HE-staining of 4 coronal plane sections.  
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2.2.2.2. Analysis of the cellular composition of atherosclerotic lesion 
using immunohistochemistry 
For analysis of the cellular composition or inflammation of atherosclerotic lesions, aortic 
root sections were stained with an antibody to Mac2 (AbD Serotec) and SMA (Dako). 
Nuclei were counter-stained by 4',6-Diamidino-2-phenylindol (DAPI). After incubation 
with a secondary FITC- or Cy3-conjugated antibody (Life Technologies), sections were 
analyzed using a Leica DMLB fluorescence microscope and charge-coupled device 
(CCD) camera. Blinded image analysis was performed using Diskus, Leica Qwin 
Imaging (Leica Lt.) or Image J software. For each mouse and staining, 3 root sections 
were analyzed and data were averaged. 
2.2.2.3. Laboratory parameters and flow cytometry 
Leukocyte counts in blood were determined using a Celltac Automated Hematology 
Analyzer (Nihon Kohden) or counting beads (Invitrogen) during flow cytometry analysis. 
Differential white blood cell counts were performed by flow cytometric analysis. For flow 
cytometry analysis primary cell suspensions from lymph nodes, spleen, bone marrows 
and whole blood were made as described under 2.2.1.5 Leukocyte subsets were 
analyzed using the following combination of surface markers: neutrophils 
(CD45+CD11b+CD115-Gr1high), monocytes (CD45+CD11b+CD115+), classical monocytes 
(GR1high monocytes), non-classical monocytes (GR1low monocytes), conventional 
dendritic cells (CD45+CD11c+MHCII+) plasmacytoid dendritic cells (CD45+B220+SigH+), 
B-cells (CD45+B220+), T-cells (CD45+CD3+), cytotoxic T cells (CD45+CD3+CD8+), T 
helper cells (CD45+CD3+CD4+). Regulatory T cells (Tregs) were classified as 
CD45+CD3+CD4+CD25+Foxp3+, whereas Foxp3 was stained using the Foxp3/ 
Transcription Factor Staining Buffer Set (eBioscience). Cell populations and marker 
expression were analyzed using a FACSCanto-II, FACSDiva software (BD Biosciences) 
and the FlowJo analysis program (Treestar). Cholesterol and triglyceride levels in mouse 
plasma or serum were measured using enzymatic assays (Roche). 
2.2.2.4. Enzyme-Linked Immunosorbent Assay (ELISA) 
The enzyme-linked immunosorbent assay (ELISA) is an easy method to detect and 
quantify an antigen (e.g. proteins such as cytokines or chemokines) within nearly every 
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type of biological fluid e.g. serum, cell culture supernatant or lavage. All Kits used during 
this thesis were based on the principle of a sandwich ELISA. 
The mechanism of a sandwich ELISA is based on a purified Ab specific for the antigen 
of interest (capture antibody) which is pre-coated onto a microplate. Samples and 
standards are added onto and bind the plate bound capture antibody. After several 
washing steps the detection antibody is added, and also binds to the antigen. After 
further washing steps an enzyme-linked secondary antibody is added which binds the 
detecting antibody. After adding a specific substrate the enzyme reaction leads to a blue 
product that turns yellow when the 2 N sulfuric acid stop solution is added. The intensity 
of the color measured is in proportion to the amount of antigen bound in the initial step. 
The sample values are then read of a standard curve. Mouse plasma and cell culture 
supernatants were analyzed using the “Ccl3 Mouse Uncoated ELISA Kit with Plates” 
(Thermo Fisher Scientific (eBioscience) Waltham, USA). 
2.2.2.5. ProcartaPlex Bead assays 
ProcartaPlex Bead assays enable assessing multiple targets in a single biological 
sample (cell/tissue culture supernatants, serum, and plasma). The ProcartaPlex assays 
use the Luminex™ xMAP technology for multi-analyte detection of secreted proteins 
including cytokines, chemokines, growth factors and other proteins. 
Cell culture supernatants and mouse plasma were analyzed for various cytokines using 
the “Cytokine & Chemokine 26-Plex Mouse ProcartaPlex™ Panel 1” (Thermo Fisher 
Scientific (eBioscience) Waltham, USA), sample preparation and analysis was 
performed according to the manufacturer’s protocol. The kit allows the simultaneous 
detection and quantification of soluble murine IFN gamma; IL-12p70; IL-13; IL-1 beta; IL-
2; IL-4; IL-5; IL-6; TNF alpha; GM-CSF; IL-18; IL-10; IL-17A; IL-22; IL-23; IL-27; IL-9; 
GRO alpha; IP-10; MCP-1; MCP-3; MIP-1 alpha; MIP-1 beta; MIP-2; RANTES; Eotaxin. 
The bead-based assay follows the principles of a sandwich immunoassay. Fluorescent 
magnetic beads are coupled with antibodies specific to the analytes to be detected. 
Beads are differentiated by their sizes and distinct spectral signature (color-coded) by 
flow cytometry using the Luminex™ xMAP. 
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2.2.2.6. Surface plasmon resonance (SPR) 
SPR was performed on a BIAcore X100 instrument (GE Healthcare Europe GmbH, 
Freiburg, Germany) using neutravidin-modified C1 sensor chips.231 Biotinylated 
chemokine CCL17 was immobilized on flow cells to 0.3-1.3x103 response units (RU). 
Screening of chemokine receptor  binding with CCR8 proteoliposomes was performed 
starting at a concentration of 100 nM in HBS-EP+ buffer at 90 µl/min after 20 s. 
Apparent affinities were calculated from on and off rates after fitting of the curves 
obtained from increasing analyte concentrations using a 1:1 Langmuir interaction model 
(BIAevaluation software, GE Healthcare).  
2.2.2.7. Proximity ligation assay  
Proximity ligation was carried out using the Duolink In Situ Red Kit Goat/Rabbit on PFA 
fixated mouse dendritic cells cultured on collagen-coated cover slips which were pre-
incubated with mouse Ccl1 and Ccl17 (BioLegend) alone using primary polyclonal 
antibodies to mouse Ccl17 (R&D, AF529), mouse Ccl1 (Acris, AP20618PU-N), mouse 
Ccr1 (Biorbyt), mouse Ccr4 (Thermo Scientific) and mouse Ccr8 (Abcam) according to 
the manufacturer’s instructions. Imaging was performed using fluorescence microscopy 
(Leica DM4000, Germany) after which deconvolution algorithms for wide field 
microscopy were applied to improve overall image quality (Huygens professional 16.10; 
SVI, the Netherlands). The number of Duolink detected interactions was determined in 
the processed images using the Leica LAS 4.2 analyses software. In order to more 
accurately resolve the interactions detected with Duolink, representative dendritic cell 
samples of each condition were also visualized with a Leica SP8 3X microscope 
(Germany) using a combination of 3D confocal microscopy (DAPI) and 3D STED 
nanoscopy (Duolink Red). Image processing and deconvolution of the resultant 3D 
datasets was performed using the Leica LAS X and Huygens professional software 
packages. 
2.2.3. Functional assays 
2.2.3.1. Transmigration assays 
Transmigration assays were performed using Transwell-96 Permeable Support plates 
(Corning) with a 3.0 µm pore size. Murine rCcl17 (BioLegend) was added to bottom 
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chambers at a concentration of 100 ng/mL in RPMI-1640 medium containing 0.5% BSA. 
Naïve CD4+ spleen and LN T cells were obtained by immunomagnetic isolation (Miltenyi 
Biotec) (refer to 2.2.1.6.) and activated via plate bound α-CD3 (10 µg/ml, 50 µl per well, 
4 °C overnight) and soluble α-CD28 (1 µg/ml) (both eBioscience). Activated CD4+ T cells 
(2x105) were allowed to migrate for 2 h from the top chamber. Ccr4 receptor antagonist 
C021 Dihydrochloride (Tocris) was added at a concentration of 0,5 µM to top chambers. 
The number of cells migrated was analyzed by flow cytometry (FACSCanto II, BD 
Biosciences) and FlowJo v.10 software (Tree Star Inc.). The chemotactic index was 
calculated as the ratio of chemokine-stimulated to unstimulated migration. 
2.2.3.2. T effector polarization assays 
Naive CD62L+CD4+ spleen and LN cells were obtained by immunomagnetic isolation 
(Miltenyi Biotec) (refer to 2.2.1.8). CD4+T cells (1 × 105) were cultured in 96-well tissue 
round bottom culture plates in the presence of 3 μg/ml anti-CD3e, α-CD28 (1 µg/ml ) 
and supplemented with TGF-β (5 ng/ml) in the presence or absence of Ccl3 (100 ng/mL) 
for 3 days. The number of regulatory T cells was analyzed by flow cytometry 
(FACSCanto II, BD Biosciences) and FlowJo v.10 software (Tree Star Inc.). 
2.2.3.3.  Co culture experiments 
Isolated wt, EGFP+ Ccl17e/e, Ccr4-/- , Apoe-/-, Apoe-/-Ccl3-/-, EGFP+ Apoe-/-Ccl17e/+ and 
EGFP+ Apoe-/-Ccl17e/e DCs (refer to 2.1.1.9.) (5 ×104) were co cultured for 3 days in 96-
well tissue flat bottom culture plates with naïve CD4+ LN T cells (1 × 105) obtained by 
immunomagnetic isolation (Miltenyi Biotec  refer to 2.1.1.8) from different genetic 
backgrounds (wt, Apoe-/-Ccr4-/-, Apoe-/-Ccr1-/-, Apoe-/-Ccr5-/-). The number of regulatory T 
cells was analyzed by flow cytometry (FACSCanto II, BD Biosciences) and FlowJo v.10 
software (Tree Star Inc.).  
2.2.3.4. Cyclic AMP signaling 
The GloSensor cAMP (cyclic adenosine monophosphate) assay (Promega) provides a 
sensitive format for the interrogation of overexpressed or endogenous GPCRs that 
signal via changes in the intracellular concentration of cAMP. The assay uses 
genetically encoded biosensor variants with cAMP binding domains fused to mutant 
forms of Photinus pyralis luciferase. Upon binding to cAMP, conformational changes 
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occur that promote large increases in light output. The magnitude of the luminescence 
increase is directly proportional to the amount of analyte or protease activity present. 
Levels of cAMP were measured in confluent HEK293 transfected with either Ccr4 or 
Ccr8, after stimulation with chemokines over up to 30 min. After incubation with luciferin-
EF (2.5 mM) at RT for 2 h, cells were stimulated with PBS control, Ccl17 (100 ng/ml), 
Ccl1 (100 ng/ml) or Ccl18 (100 ng/ml) and luminescence indicating the reduction of 
cAMP was recorded.  
2.2.4. Statistical analysis 
Data are expressed as mean ± standard error of the mean (SEM) unless otherwise 
specified. If D'Agostino & Pearson omnibus and/or Shapiro-Wilk normality test indicated 
Gaussian distribution, an unpaired t-test for side-by-side comparisons or one-way 
ANOVA with Newman-Keuls post-test for multiple comparisons were performed. 
Otherwise, Mann-Whitney-tests for side-by-side comparison and Kruskal-Wallis-test for 
multiple comparisons were performed using GraphPad Prism for Windows (GraphPad 
Software, San Diego, USA). For animal studies, a power analysis was performed using 
BiAS software (version 11.02). We assumed a detectable biological difference of at least 
50% among up to four groups with a standard deviation < 15%, an α of 0.05, and a 
resultant power of 0.8. The number of biological replicates for each data point is 
included in the figure legends.  
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3. Results 
As described before, recent work performed in our group revealed that the DC-derived 
chemokine Ccl17 promotes atherogenesis by controlling regulatory T cell (Treg) 
homeostasis, restraining their expansion, while its deficiency decreased plaque burden 
by facilitating Treg maintenance and survival. During this study, we did not observe a 
comparable reduction in lesion formation and infiltration in chimeric mice carrying Ccr4-/- 
bone marrow.119 Using a reporter mouse model, which allows tracking of Ccl17-
expressing cells, as well as mice deficient for various chemokine receptors including 
Ccr4-, Ccr5-, and Ccr1-deficient mice, we investigated the role of Ccl17 during the onset 
of atherosclerotic lesion formation and its involvement in restraining Treg homeostasis.  
The following section will explain and display the experimental results, which were 
obtained throughout this thesis. 
The first part will detail on differences observed between Ccl17- deficient mice and Ccr4-
deficient mice, as seen in atherosclerotic plaque development and describe experiments 
and subsequent conclusions drawn, to further unravel the role of Ccl17 and Ccl17-
producing DCs during the onset of atherosclerosis (Figure 13).  
The second part illustrates the experimental setup chosen to gain insight in how Ccl17 
promotes lesion development and through which alternative receptors Ccl17 might be 
able to signal. Furthermore, this part will highlight pro-inflammatory mediators which are 
key players in mediating Ccl17-dependent promotion of atherosclerosis and restrain of 
regulatory T cell homeostasis (Figure 13). 
The third part will briefly introduce the concept of chemokine heterodimerization, using 
Ccl5-Ccl17 heterodimer as an example. Further, this section will explore possible 
actions of this heterodimeric structure on T cell and DC function, possible receptor 
interactions and the potential role heterodimeric structures, in particular Ccl5-Ccl17, 
have on atherosclerotic lesion development (Figure 13).  
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Figure 13. Experimental setup. Part I. Comparison between Ccl17 and Ccr4 deficiency. Evaluation of 
atherosclerotic lesion size and composition (12 weeks HFD), lipid levels and serum cytokine titers, 
followed by subsequent monitoring of Treg numbers in blood, spleen, and lymph nodes. Part II. How 
does Ccl17 affect Treg maintenance and homeostasis? Evaluation of direct autocrine Ccl17 
stimulation on Tregs. Analysing effects of Ccl17 and Ccl17-producing DCs, as well as Ccr4 involvement, 
on T cell migration and Treg polarization/differentiation (I). Evaluation of autocrine Ccl17 stimulation on 
DCs and subsequent release of secondary mediators by DCs (II) and involvement of alternative Ccl17 
recpetors (III). Analysis of the role of a possible secondary mediator on Treg polarization/differentiation 
(IV) Part III. Ccl5-Ccl17 heterodimers. Analysis of Ccl5-Ccl17 heterodimers and their role on T cell 
migration and arrest, as well as their chemokine receptor binding behavior.  
 
3.1. Discrepancy between Ccl17 deficiency and Ccr4 deficiency  
3.1.1. Deficiency of Ccl17 reduces atherosclerosis in Apoe-/- mice by 
restraining Tregs 
To investigate the role of the Thymus- and activation-regulated chemokine (TARC) or 
Ccl17 during the onset of atherosclerosis we used Apoe-/-Ccl17e/e mice and fed them a 
high fat diet (HFD) for 12 weeks. We analyzed atherosclerotic lesion formation in the 
aortic root, the aortic arch and in the thoraco-abdominal aorta (Figure 14A). A significant 
reduction in atherosclerotic lesion formation was observed in Apoe-/-Ccl17e/e mice in 
comparison to Apoe-/- control mice, as visible after Oil-red-O staining in the aortic root 
and the en face prepared thoracoabdominal aorta (Figure 14B and D), as well as after 
HE staining in the aortic arch (Figure 14C). Body weight, cholesterol and triglyceride 
plasma levels did not reveal any differences comparing Apoe-/- and Apoe-/-Ccl17e/e mice 
(Figure 14E-G).  
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Figure 14. Deficiency of Ccl17 reduces atherosclerosis. (A) Experimental scheme depicting the type of 
animals used, duration of diet feeding and endpoint analysis performed. B-D) Atherosclerotic lesions were 
quantified in Apoe
-/-
 and Apoe
-/-
Ccl17
e/e
 mice after 12 weeks of HFD. (B) Representative images (left) and 
quantification (right) of Oil-red-O+ area in aortic root sections are shown. (C) Representative images (left) 
and quantification of lesion size in HE-stained aortic arches are depicted. (D) Representative images (left) 
and quantification of Oil-red-O+ area in en face prepared thoracoabdominal aortas are shown. (E-G) 
Bodyweight (E), plasma cholesterol levels (F), and plasma triglyceride levels (G) of Apoe
-/-
 and Apoe
-/-
Ccl17
e/e
 mice after 12 weeks of HFD are depicted. (A-G) Data represent mean±SEM with *P < 0.05; **P < 
0.005 as analyzed by Student’s t-test with Welsh correction (n=10-11 per group). 
Quantitative immunostaining revealed that the reduction in atherosclerotic lesion size 
observed in Apoe-/-Ccl17e/e mice, was accompanied by a significant decrease in the 
absolute numbers of Dapi+ cells and MAC2+ macrophages, whereas the relative content 
of macrophages was unaltered, when compared to Apoe-/- control mice (Figure 15 
A,B,D). Furthermore, the relative content in SMA+ smooth muscle cells was significantly 
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increased in Apoe-/-Ccl17e/e mice, whereas the total counts of SMA+ smooth muscle cells 
showed a tendency towards higher counts (Figure 15A+C). This data indicates a shift 
towards a more stable plaque phenotype in Apoe-/-Ccl17e/e mice. 
 
Figure 15. Deficiency of Ccl17 influences plaque composition. Atherosclerotic lesion composition was 
analyzed using immunohistochemistry. (A) Representative images of macrophage (red) and smooth 
muscle cell (green) staining, in the aortic root of Apoe
-/-
(upper picture) and Apoe
-/-
Ccl17
e/e
 mice (lower 
picture) after 12 weeks of HFD are shown; cell nuclei are counterstained by DAPI (blue); scale bars: 200 
μm. (B-D) The relative (left) and absolute quantification (right) of MAC-2
+
 macrophages (B) and SMA
+
 
smooth muscle cells (C) and the absolute number of DAPI
+
 cells (D) per plaque area are depicted. (B-D) 
Data represent mean±SEM, Student t test with Welch correction. (n=10-11) *P < 0.05.  
To determine the differences in plaque size and plaque composition between Apoe-/- 
versus Apoe-/-Ccl17e/e, we performed Fluorescence-activated Cell Sorting (FACS) 
analysis of blood, as well as of single cell suspensions of bone marrow, spleen and 
para-aortic-, axillar-, inguinal- and mesenteric lymph nodes. Analyzing the distribution of 
different CD45+ leukocyte populations as described in chapter 2.2.2.3. in the above 
mentioned organs, we only observed higher frequencies and an expansion of 
CD4+CD25+Foxp3+ Tregs in Apoe-/-Ccl17e/e mice when compared to Apoe-/- control mice 
(Figure 16A-G and Supplemental table 1-4). CD45+CD3+CD4+CD25+Foxp3+ Tregs were Figure 2
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significantly increased in spleen, para-aortic-, axillary-, inguinal- and mesenteric lymph 
nodes of Apoe-/-Ccl17e/e mice when compared to Apoe-/- control mice but where not 
altered in the circulation of these mice. 
 
Figure 16. Ccl17 deficiency affects regulatory T cell populations. (A) Representative dot plots of Flow 
cytometric analysis of CD3
+
CD4
+
CD25
+
Foxp3
+
 Tregs in para-aortic LNs of Apoe
-/-
 and Apoe
-/-
Ccl17
e/e
 
mice after 12 weeks of HFD; numbers in dot plots are percentage of CD4
+
 events. (B-G) Flow cytometric 
analysis of CD3
+
CD4
+
CD25
+
Foxp3
+
 Tregs (B) in Blood (C) Spleen (D) para-aortic LNs (E) axillar LNs (F) 
inguinal LNs and (G) mesenteric LNs of Apoe
-/-
 and Apoe
-/-
Ccl17
e/e
 mice after 12 weeks of HFD employing 
indicated surface and intracellular markers. Data (B-G) represent mean±SEM, Student t test with Welch 
correction. (n=10-11) *P < 0.05; **P < 0.005; **P < 0.001. 
 
3.1.2. Deficiency of Ccr4 does not reduce atherosclerosis in Apoe-/- mice 
and has no effect on regulatory T cell populations 
To clarify the mechanisms of Ccl17 action, namely a potential involvement of its bona 
fide receptor Ccr4, during the progression of atherosclerosis, we used Apoe-/-Ccr4-/- mice 
and fed them a HFD for 12 weeks. We analyzed atherosclerotic lesion formation in the 
aortic root, the aortic arch and in the thoraco-abdominal aorta (Figure 17A). No changes 
in atherosclerotic lesion formation were observed in Apoe-/-Ccr4-/- mice in comparison to 
Apoe-/- control mice, as visible after Oil-red-O staining in the aortic root and the en face 
prepared thoraco-abdominal aorta (Figure 17B and D), as well as after HE staining in 
the aortic arch (Figure 17C). Body weight, cholesterol and triglyceride plasma levels did 
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also not differ between Ccr4-deficient and control animals (Figure 17E-G).  
 
Figure 17. Deficiency of Ccr4 does not reduce atherosclerosis. (A) Experimental scheme depicting 
the type of animals used, duration of diet feeding and endpoint analysis performed. (B-D) Atherosclerotic 
lesions were quantified in Apoe
-/-
 and Apoe
-/-
Ccr4
-/-
 mice after 12 weeks of HFD. (B) Representative 
images (left) and quantification (right) of Oil-red-O
+
 area in aortic root sections are shown. (C) 
Representative images (left) and quantification of lesion size in HE-stained aortic arches are depicted. (D) 
Representative images (left) and quantification of Oil-red-O
+
 area in en face prepared thoraco-abdominal 
aortas are shown. (E-G): Bodyweight (E), plasma cholesterol levels (F), and plasma triglyceride levels (G) 
of Apoe
-/-
 and Apoe
-/-
Ccr4
-/-
 mice after 12 weeks of HFD are depicted. (A-G) Data represent mean±SEM 
with *P < 0.05; **P < 0.005 as analyzed by Student’s t-test with Welsh correction (n=16-20). 
 
Quantitative immunostaining could not show any differences in absolute numbers of 
Dapi+ cells nor MAC2+ macrophages per plaque when comparing Apoe-/-Ccr4-/- mice to 
Apoe-/- control mice. Interestingly, there was a decrease in SMA+ smooth muscle cell 
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frequency in lesions of Apoe-/-Ccr4-/- mice compared to Apoe-/- control mice (Figure 18A-
D).  
 
Figure 18. Deficiency of Ccr4 does not influence plaque composition. Atherosclerotic lesion 
composition was analyzed using immunohistochemistry. (A) Representative images of macrophage (red) 
and smooth muscle cell (green) staining, in the aortic root of Apoe
-/-
(upper picture) and Apoe
-/-
Ccr4
-/-
 mice 
(lower picture) after 12 weeks of HFD are shown; cell nuclei are counterstained by DAPI (blue); scale 
bars: 200 μm. (B-D) The relative (left) and absolute quantification (right) of MAC-2
+
 macrophages (B) and 
SMA
+
 smooth muscle cells (C) and the absolute number of DAPI
+
 cells (D) per plaque area are depicted. 
(B-D) Data represent mean±SEM, Student t test with Welch correction. (n=10-11) *P < 0.05. (n=9-10). 
 
To unravel why Ccr4 deficiency does not phenocopy the results obtained in Ccl17-
deficient animals and to explain the different outcomes in atherosclerotic lesion sizes 
between Apoe-/-Ccl17e/e and Apoe-/-Ccr4-/- we again performed flow cytometric analysis 
of blood, as well as of single cell suspensions from bone marrow, spleen and para-
aortic-, axillar-, inguinal- and mesenteric lymph nodes. Analyzing the distribution of 
different CD45+ leukocyte populations, as mentioned in 2.2.2.3 in the above mentioned 
organs we observed a significant decrease of neutrophils (CD45+Gr1+CD115-) in the 
bone marrow of Apoe-/-Ccr4-/- mice when compared to Apoe-/- control mice 
(Supplemental table 5-9). No differences in the CD4+CD25+Foxp3+ Treg population was 
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observed in blood, spleen, para-aortic-, axillar-, inguinal- and mesenteric lymph nodes of 
Apoe-/-Ccr4-/- mice in comparison to Apoe-/- control mice (Figure 19A-G). 
 
Figure 19. Ccr4 deficiency does not affect regulatory T cell populations. (A) Representative dot plots 
of Flow cytometric analysis of CD3
+
CD4
+
CD25
+
Foxp3
+
 Tregs in para-aortic LNs of Apoe
-/-
 and Apoe
-/-
Ccr4
-/-
 mice after 12 weeks of HFD; numbers in dot plots are percentage of CD4
+
 events. (B-G) Flow 
cytometric analysis of CD3
+
CD4
+
CD25
+
Foxp3
+
 Tregs (B) in Blood (C) Spleen (D) para-aortic LNs (E) 
axillar LNs (F) inguinal LNs and (G) mesenteric LNs of Apoe
-/-
 and Apoe
-/-
Ccr4
-/-
 mice after 12 weeks of 
HFD employing indicated surface and intracellular markers. Data (B-G) represent mean±SEM, Student t 
test with Welch correction. (n=16-20) *P < 0.05; **P < 0.005; **P < 0.001. 
 
3.1.3. Hematopoietic deficiency of Ccr4 increases atherosclerotic lesions in 
Apoe-/- mice through hypocholesteremia 
To further investigate a potential involvement of the Ccl17 receptor Ccr4 during the 
onset of atherosclerosis and to rule out possible side effects of a full body knock out, we 
wanted to concentrate on the role of hematopoietic Ccr4 expression during 
atherosclerotic lesion development. For this purpose, we performed a bone marrow 
transplantation of either Apoe-/-Ccr4-/- bone marrow into Apoe-/- mice (Apoe-/-Ccr4-/-
►Apoe-/-) or Apoe-/- control bone marrow into Apoe-/- animals (Apoe-/-►Apoe-/-). After 
one month of recovery, we fed them a HFD for 12 weeks. We quantified the extend of 
atherosclerotic lesion formation in the aortic root, the aortic arch and in the thoraco-
abdominal aorta (Figure 20A). No changes in atherosclerotic lesion size in the aortic root 
was observed in Apoe-/-Ccr4-/-►Apoe-/- mice in comparison to Apoe-/-►Apoe-/- control 
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mice, as visible after Oil-red-O staining in the aortic root (Figure 20B). When analyzing 
atherosclerotic lesions in the HE stained aortic arch as well as in the en face prepared 
and oil-red-O stained thoracoabdominal aorta we observed a significant increase in 
lesion size in the Apoe-/-Ccr4-/-►Apoe-/- animals when compared to the Apoe-/-►Apoe-/- 
control mice (Figure 20C and D). These findings were in line with higher levels of plasma 
cholesterol in the Apoe-/-Ccr4-/-►Apoe-/- mice in comparison to the Apoe-/-►Apoe-/- 
control mice (Figure 20G). Body weight and triglyceride plasma levels were not altered 
in both groups (Figure 20E and F). 
 
Figure 20. Hematopoietic deficiency of Ccr4 does not reduce atherosclerosis. (A) Experimental 
scheme depicting the type of animals used, the procedure performed for bone marrow transplantation as 
well as duration of diet feeding and endpoint analysis performed. (B-D) Atherosclerotic lesions were 
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quantified in Apoe
-/-
 ►Apoe
-/-
 or Apoe
-/-
Ccr4
-/-
 ►Apoe
-/- 
mice after 12 weeks of HFD. (B) Representative 
images (left) and quantification (right) of Oil-red-O
+
 area in aortic root sections are shown. (C) 
Representative images (left) and quantification of lesion size in HE-stained aortic arches are depicted. (D) 
Representative images (left) and quantification of Oil-red-O
+
 area in en face prepared thoracoabdominal 
aortas are shown. (E-G): Bodyweight (E), plasma triglyceride levels (F), and plasma cholesterol levels (G) 
of Apoe
-/-
 ►Apoe
-/-
 or Apoe
-/-
Ccr4
-/-
 ►Apoe
-/- 
mice after 12 weeks of HFD are depicted. (A-G) Data 
represent mean±SEM with *P < 0.05; **P < 0.005 as analyzed by Student’s t-test with Welsh correction 
(n=9-10 per group). 
 
Quantitative immunofluorescence staining’s of aortic root sections did not reveal any 
differences in absolute numbers of Dapi+ cells nor in the number of MAC2+ 
macrophages per plaque comparing Apoe-/-Ccr4-/-►Apoe-/- mice to Apoe-/-►Apoe-/- 
control mice. There were also no differences observed in the SMA+ smooth muscle cell 
content per plaque in Apoe-/-Ccr4-/-►Apoe-/-mice in comparison to Apoe-/-►Apoe-/- 
control animals (Figure 21A-D).  
 
Figure 21. Hematopoietic deficiency of Ccr4 does not influence plaque composition. Atherosclerotic 
lesion composition was analyzed using immunohistochemistry. (A) Representative images of macrophage 
(red) and smooth muscle cell (green) staining, in the aortic root of Apoe
-/-
►Apoe
-/-
 (upper picture) and 
Apoe
-/-
Ccr4
-/-
►Apoe
-/-
 mice (lower picture) after 12 weeks of HFD are shown; cell nuclei are 
counterstained by DAPI (blue); scale bars: 200 μm. (B-D): The relative (left) and absolute quantification 
(right) of MAC-2
+
 macrophages (B) and SMA
+
 smooth muscle cells (C) and the absolute number of DAPI
+
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61 
cells (D) per plaque area are depicted. (B-D) Data represent mean±SEM, Student t test with Welch 
correction. (n=9-10) *P < 0.05. 
  
FACS analysis of different leukocyte subsets (see methods chapter 2.2.2.3.) revealed a 
significant increase of CD45+Gr1+CD115- neutrophils and a reduction in classical 
monocytes (CD45+Gr1+CD115+) in the blood of Apoe-/-Ccr4-/-►Apoe-/- mice compared to 
Apoe-/-►Apoe-/- mice. Furthermore, we saw a significant increase of neutrophils and 
macrophages in the bone marrow of Apoe-/-Ccr4-/-►Apoe-/- mice when compared to 
Apoe-/-►Apoe-/- mice. The spleen of the Apoe-/-Ccr4-/-►Apoe-/- mice contained significant 
lower numbers of CD45+Gr1-CD115+ non-classical monocytes, T cells, cytotoxic T cells 
and T helper cells in comparison to Apoe-/-►Apoe-/- mice. The para-aortic LN of the 
Apoe-/-Ccr4-/-►Apoe-/- mice contained increased numbers of classical monocytes, non-
classical monocytes and CD45+CD11c+MHCII+ cDCs. (Supplemental table 9-12) No 
differences in the CD4+CD25+Foxp3+ Treg population was observed in blood, spleen, 
para-aortic-, axillar-, inguinal- and mesenteric lymph nodes of Apoe-/-Ccr4-/-►Apoe-/- 
comparing them with Apoe-/-►Apoe-/- control mice (Figure 22A-G). 
 
Figure 22. Hematopoietic Ccr4 deficiency does not affect regulatory T cell populations. (A) 
Representative dot plots of Flow cytometric analysis of CD3
+
CD4
+
CD25
+
Foxp3
+
 Tregs in para-aortic LNs 
of Apoe
-/-
►Apoe
-/-
 and Apoe
-/-
Ccr4
-/-
►Apoe
-/-
 mice after 12 weeks of HFD; numbers in dot plots are 
percentage of CD4
+
 events. (B-G) Flow cytometric analysis of CD3
+
CD4
+
CD25
+
Foxp3
+
 Tregs (B) in Blood 
(C) Spleen (D) para-aortic LNs (E) axillar LNs (F) inguinal LNs and (G) mesenteric LNs of Apoe
-/-
►Apoe
-/-
 
and Apoe
-/-
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markers. Data (B-G) represent mean±SEM, Student t test with Welch correction. (n=9-10) *P < 0.05; **P < 
0.005; **P < 0.001. 
  
3.1.4. Ccl17 induces T cell migration via Ccr4 but does not affect Tregs 
directly 
Ccl17 is known to be a chemoattractant for T cells. To confirm that this chemoattraction 
is mediated via Ccr4 we performed in vitro transwell assays (see methods 2.2.3.1.). 
CD4+ T cells were isolated from spleen and LNs of wt mice and were allowed to 
transmigrate towards recombinant murine (rm) Ccl17 in the presence or absence of the 
Ccr4 inhibitor C 021 dihydrochloride, which was placed in the lower chamber of 
transwell-migration plates. Transmigrated cells were monitored using flow cytometry. We 
observed that CD4+ cells did migrate towards rmCcl17 and that this migration was 
impaired in the presence of the Ccr4 inhibitor C 021 dihydrochloride (Figure 23). 
 
Figure 23. Ccl17 attracts CD4+ T cells via Ccr4. Transwell migration of CD4+ T cells towards 
recombinant murine Ccl17, in the presence or absence of the Ccr4 inhibitor C 021 dihydrochloride was 
quantified by FACS analysis (n=3-6). Data represents mean±SEM, Student t test with Welch correction. 
*P<0.05.  
 
To investigate if Ccl17 is directly involved in mechanisms of Treg expansion, we studied 
whether Ccl17 affects the polarization of naive T cells toward Tregs (see methods 
2.2.3.2.). In in vitro T cell polarization assays using TGF-β, addition of Ccl17 did not alter 
the frequencies of Foxp3+ Tregs among CD4+ T cells (Figure 24). Implying that Ccl17 
has no direct effect on restraining Treg polarization. 
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Figure 24. Ccl17 does not affect Treg polarization directly. Naïve CD4
+
 CD62L
+
 T cells were cultured 
under Treg polarization conditions using TGF-β in the presence or absence of recombinant murine Ccl17. 
Frequencies of CD4
+
CD25
+
Foxp3
+
 Tregs among CD4
+
 T cells were analyzed by flow cytometry (n=5). 
Data represents mean±SEM. 1-way analysis of variance (ANOVA) with, Kruskal-Wallis test with Dunn 
posttest were used. P values <0.05 were considered statistically significant.  
 
Since Ccl17 appears not to directly affect Treg maintenance, we thought that Ccl17 
producing DCs might limit Treg expansion and differentiation, through secretion of 
unknown mediators. To further study the mechanisms by which Ccl17 producing DCs 
affect Tregs and to elucidate a potential involvement of Ccr4, we performed co-culture 
experiments employing wt T cells and DCs isolated either from wt, Ccl17e/e or Ccr4-/- 
mice (see methods 2.2.3.3.). Notably, the frequency of CD4+Foxp3+ Tregs obtained in 
co-culture with wild-type DCs was significantly higher than that obtained in co-cultures 
with Ccr4-/- DCs or wt DCs (Figure 25). This implies that Ccr4 on DCs is not involved in 
mediating effects of Ccl17 on Treg maintenance, at least in vitro, but that the Ccl17 
producing DC might secrete an unknown mediator influencing Treg development. 
 
Figure 25. Ccl17-deficient DCs induce iTreg differentiation. DCs isolated via flow cytometric sorting 
from either wt, Ccl17
e/e 
or Ccr4
-/-
 mice were cultured together with wt naïve CD4
+
 CD62L
+
 T cells for three 
days. Frequencies of CD4
+
CD25
+
Foxp3
+
 Tregs among CD4
+
 T cells were analyzed by flow cytometry. 
Data represent three independent experiments depicted as mean±SEM. One-way analysis of variance 
(ANOVA) with Kruskal-Wallis test with Dunn posttest were used. P values <0.05 were considered 
statistically significant. *P<0.05.  
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3.1.5. Summary and hypothesis 
As mentioned in the results above Apoe-/-Ccl17e/e mice show reduced atherosclerotic 
lesion size after 12 weeks HFD accompanied by higher frequencies of 
CD3+CD4+Cd25+Foxp3+ Treg cells in spleen, para-aortic LN, axillar LN, inguinal LN and 
mesenteric LN, when compared to Apoe-/- control mice. Although, so far Ccr4 is the only 
known bona fide receptor for Ccl17, Apoe-/-Ccr4-/- mice do not phenocopy observations 
made in mice lacking Ccl17, instead Apoe-/-Ccr4-/- mice show no differences in 
atherosclerotic lesion size nor in Treg frequencies. Hematopoietic deficiency in Ccr4 
does also not phenocopy Ccl17 deficiency but rather increases lesion size after 12 
weeks HFD, when compared to Apoe-/- control mice. These results suggest an 
alternative mechanism through which Ccl17 engages its atherogenic functions. Further 
experiments concluded that recombinant murine Ccl17 induces migration of CD4+ T 
cells via Ccr4 but does not affect polarization of naïve CD62L+CD4+ T cells towards 
Tregs. Ccl17-deficient DCs do promote iTreg differentiation independent of Ccr4, since 
Ccr4-deficient DCs do not promote iTreg differentiation. These results suggest that, 
instead of acting directly upon Tregs, Ccl17 binds via an alternative receptor (not Ccr4), 
in an autocrine fashion to (specific) DCs and induces the release of a secondary 
mediator restraining Treg homeostasis (Figure 26). 
 
Figure 26. Summary and hypothesis. A) Apoe
-/-
Ccl17
e/e
 mice show reduced atherosclerotic lesion size 
after 12 weeks HFD accompanied by higher frequencies of CD3
+
CD4
+
Cd25
+
Foxp3
+
 Treg cells in spleen, 
para-aortic LN, axillar LN, inguinal LN and mesenteric LN, when compared to Apoe
-/-
 control mice. 
Although, Ccr4 is the only known bona fide receptor for Ccl17, Apoe
-/-
 Ccr4
-/-
 mice do not phenocopy 
Apoe-/- Apoe-/-
Ccl17e/e
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iTreg differentiation x iTreg differentiation √
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Ccl17 binds via an alternative receptor and in an autocrine fashion to (specific) DCs
and induces release of a secondary mediator restraining Treg homeostasis.
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Ccl17 deficiency, showing no differences in atherosclerotic lesion size or Treg frequencies. Hematopoietic 
deficiency in Ccr4 also does not phenocopy Ccl17 deficiency but rather increases lesion size after 12 
weeks HFD. B) Recombinant murine Ccl17 induces migration of CD4
+
 T cells dependent on Ccr4, but 
does not affect polarization of naïve CD62L
+
CD4
+
 T cells towards Tregs. Ccl17-deficient DCs do promote 
iTreg differentiation independent of Ccr4 since Ccr4-deficient DCs do not promote iTreg differentiation. 
 
3.2. Searching for a secondary mediator 
3.2.1. Ccl17-dependent secretion of Ccl3 and Cxcl10 by DCs 
Since previous results indicate that Ccl17 does not directly act upon Tregs, but rather 
binds an alternative receptor (not Ccr4) in an autocrine fashion on DCs, and this leads to 
the secretion of a secondary mediator, which is responsible for restraining Treg 
homeostasis, we thought to investigate the secretion profile of DCs upon Ccl17 
stimulation. For this purpose, CD11b+CD11c+MHCII+ DCs were cultured for 4h at 37°C 
in the presence or absence of Ccl17 and with or without the Ccr4 inhibitor C 021 
dihydrochloride. The supernatant of these cells was analyzed using a Luminex 
multiplex-bead-array measuring protein concentrations of 26 different cytokines and 
chemokines (see methods 2.2.2.5) (Figure 27). Out of the 26 cytokines and chemokines 
analyzed, only two showed differences after stimulation with Ccl17. Concentrations of 
the chemokines Ccl3 and Cxcl10 were significantly increased in supernatants of DCs 
which had been treated with rmCcl17 (Figure 27B-C). Using the Ccr4 inhibitor C 021 
dihydrochloride, we observed a reduction in Cxcl10 in the supernatants after stimulation 
with rmCcl17, when compared to the untreated control group (Figure 27C). The Ccr4 
inhibitor did not affect Ccl3 levels after Ccl17 stimulation (Figure 27B). Taken together 
these results indicate that, Ccl3 secretion by DCs after stimulation with Ccl17 is 
independent of Ccr4, whereas Cxcl10 secretion from DCs after Ccl17 stimulation 
depends on Ccr4. This makes Ccl3 a promising candidate for studying its effects on 
regulatory T cells.  
 
Results 
______________________________________________________________________ 
66 
 
Figure 27. Ccl17-dependent secretion of Ccl3 and Cxcl10. (A) Sorted CD11b
+
CD11c
+
MHCII
+
 DCs 
were cultured for 4h at 37°C in the presence or absence of rmCcl17 and with or without the Ccr4 inhibitor 
C 021 dihydrochloride. Subsequently the supernatant was subjected to a Luminex multiplex-bead-array 
measuring protein concentrations of 26 different cytokines and chemokines. (B) Ccl3 concentrations 
(pg/ml) and (C) Cxcl10 concentrations (pg/ml) in supernatants of stimulated DCs. Data (B+C) represent 
mean±SEM, Student t test with Welch correction (n=4-5). P values <0.05 were considered statistically 
significant. *P<0.05. 
 
Following the discovery that Ccl3 secretion by DCs is mediated by Ccl17 we analyzed 
Ccl3 concentrations using ELISA in plasma samples obtained either from Apoe-/- or 
Apoe-/-Ccl17e/e mice under steady state conditions and observed a reduction in Ccl3 
plasma levels in Ccl17-deficient mice compared to the wild type control (Figure 28A). 
These findings were also seen in Apoe-/- and Apoe-/-Ccl17e/e mice after 12 weeks HFD 
(Figure 28B). In line with our hypothesis that Ccl17 induces secretion of Ccl3 by DCs we 
could not observe any differences in Ccl3 plasma levels when comparing Apoe-/- 
►Apoe-/- and Apoe-/-►Apoe-/- Ccl17e/e mice (hematopoietic system is Ccl17 competent) 
after 12 weeks HFD (Figure 28C). Furthermore, and as expected we could not observe 
any differences in Ccl3 plasma levels when comparing Apoe-/- and Apoe-/-Ccr4-/- mice 
after 12 weeks HFD (Figure 28D). 
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Figure 28. Ccl3 plasma levels are reduced in Ccl17-deficient mice. (A-D) Ccl3 concentrations were 
measured using ELISA in plasma obtained either from (A) Apoe
-/- 
and Apoe
-/-
Ccl17
e/e
 mice under steady 
state conditions (n=10); (B) Apoe
-/-
 and Apoe
-/-
Ccl17
e/e
 mice after 12 weeks HFD (n=10-15); (C) Apoe
-/-
 
►Apoe
-/-
 and Apoe
-/-
►Apoe
-/-
 Ccl17
e/e
 mice after 12 weeks HFD (n=5); (D) in Apoe
-/-
 and Apoe
-/-
Ccr4
-/-
 
mice after 12 weeks HFD (n=27). Data (A-D) represent mean±SEM, Student t test with Welch correction. 
P values <0.05 were considered statistically significant. *P<0.05, **P<0.01, ***P<0.001. 
 
To elucidate the role of Ccl3 in Treg maintenance we performed flow cytometric analysis 
of blood, as well as of single cell suspensions of spleen and para-aortic-, axillar-, 
inguinal- and mesenteric lymph nodes, isolated from Ccl3-/- mice under steady state 
conditions. Analyzing the distribution of CD4+CD25+Foxp3+ Tregs in the above 
mentioned organs, we observed significant increases in the CD4+CD25+Foxp3+ Treg 
populations in the para-aortic-, axillar-, inguinal- and mesenteric lymph nodes of Ccl3-/- 
mice when compared to C57BL/6 control mice (Figure 29A-G). 
Figure 29. shown at page 68. Ccl3 deficiency affects regulatory T cell populations. (A) 
Representative dot plots of Flow cytometric analysis of CD3
+
CD4
+
CD25
+
Foxp3
+
 Tregs in para-aortic LNs 
of Ccl3
-/-
 and C57BL/6 mice under steady state conditions; numbers in dot plots are percentage of CD4
+
 
events. (B-G) Flow cytometric analysis of CD3
+
CD4
+
CD25
+
Foxp3
+
 Tregs (B) in Blood (C) Spleen (D) 
para-aortic LNs (E) axillar LNs (F) inguinal LNs and (G) mesenteric LNs of Ccl3
-/-
 and C57BL/6 mice 
employing indicated surface markers. Data (B-G) represents mean±SEM, Student t test with Welch 
correction (n=10). P values <0.05 were considered statistically significant. *P<0.05, **P<0.01, ***P<0.001. 
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To clarify whether DCs are the only cell type that secret Ccl3 after Ccl17 stimulation, or if 
other leukocyte populations are also able to release Ccl3 upon rmCcl17 treatment, we 
isolated CD11b+CD11c+MHCII+ DCs, CD3+ T cells and B220+ B cells through flow 
cytometric sorting. In addition, we used positive magnetic sorting to obtain CD115+ 
monocytes. Furthermore, we carried out negative magnetic sorting to obtain untouched 
neutrophils. These cells were cultured for 4h at 37°C in the presence or absence of 
rmCcl17. Subsequently Ccl3 concentrations in the supernatant were measured by 
ELISA. Notably, DCs were the only cell population secreting considerable amounts of 
Ccl3 after Ccl17 stimulation, while T cells, B cells, monocytes and neutrophils did not 
release significant amounts of Ccl3 after stimulation with rmCcl17 (Figure 30). 
 
Spleen
Bl6 Ccl3-/- Bl6 Ccl3-/-
F
o
x
P
3
CD25
paraaortic LN
C
D
4
+
C
D
2
5
+
F
o
x
p
3
+
 C
e
lls
(%
 o
f 
C
D
4
+
T
 c
e
lls
)
0
2
4
6
8
Blood
0
5
10
15
axiliar LN
C
D
4
+
C
D
2
5
+
F
o
x
p
3
+
 C
e
lls
(%
 o
f 
C
D
4
+
 T
 c
e
lls
)
0
5
10
15 **
Bl6 Ccl3-/-
0
5
10
15
*
Bl6 Ccl3-/-
0
5
10
15 *
Bl6 Ccl3-/-
inguinal LN
0
5
10
15
mesenteric LN
Bl6
12.6% 15.6%
Ccl3-/-
Bl6 Ccl3-/-
A B C
D E F G
C
c
l3
 [
p
g
/m
L
]
0
5
10
15
DC s T cells MonocytesB cells Neutrophils
rCcl17 - ++++ - - - - +
Results 
______________________________________________________________________ 
69 
Figure 30. DCs are the main producers of Ccl3 after Ccl17 stimulation. Sorted CD11b
+
CD11c
+
MHCII
+
 
DCs, CD3
+
 T cells, B220
+
 B cells and magnetically sorted CD115
+
 monocytes and untouched neutrophils 
were cultured for 4h at 37°C in the presence or absence of rmCcl17. Subsequently the supernatant was 
subjected to an ELISA measuring Ccl3 concentration (pg/ml). Data represents mean±SEM (n=3-6). 
 
To further dissect the mechanism by which Ccl3 restrains Tregs, we isolated naïve CD4+ 
CD62L+ T cells from spleens of Apoe-/-, Apoe-/-Ccr4-/-, Apoe-/-Ccr5-/-, or Apoe-/-Ccr1-/- 
mice. We cultured them under Treg polarizing conditions using TGF-β in the presence or 
absence of recombinant murine Ccl3 (see methods 2.2.3.2.). Frequencies of 
CD4+CD25+Foxp3+ Tregs among CD4+ T cells were analyzed by flow cytometry. We 
observed significant decreases in CD4+CD25+Foxp3+ Treg frequencies when treating 
cells isolated from Apoe-/-, Apoe-/-Ccr4-/-, Apoe-/-Ccr5-/- mice with Ccl3 compared to the 
non- treated control. Only cells isolated from Apoe-/-Ccr1-/- mice and treated with Ccl3 
displayed no differences in CD4+CD25+Foxp3+ Treg frequencies, indicating that Ccl3 
signals via Ccr1 to restrain Tregs (Figure 31A). Furthermore, we investigated if Ccl3 
might affect the polarization of T cells and direct them towards a more pro-inflammatory 
phenotype. For this purpose, we isolated again naïve CD4+CD62L+ T cells from spleens 
of Apoe-/-, Apoe-/-Ccr4-/-, Apoe-/-Ccr5-/-, or Apoe-/-Ccr1-/- mice and cultured them under 
Treg polarizing conditions using TGF-β in the presence or absence of rmCcl3. 
Frequencies of either CD4+Tbet+ TH1 cells (Figure 31B), CD4
+GATA3+ TH2 cells (Figure 
31C) or CD4+RorγT+ TH17 cells (Figure 31D), among CD4
+ T cells were analyzed by 
flow cytometry. We observed significant increases in TH1 cell frequencies and TH17 cell 
frequencies when treating cells with TGF-β in combination with Ccl3 compared to TGF-β 
treated cells alone. Only cells isolated from Apoe-/-Ccr1-/- mice did not reveal any 
differences in TH1 cells frequencies nor TH17 cells frequencies upon treatment with 
TGF-β in combination with Ccl3, indicating that Ccl3 signals via Ccr1 to induce TH1 and 
TH17 differentiation and demonstrating its strong pro-inflammatory properties. We were 
not able to observe any effects of Ccl3 towards differentiation into TH2 cells. 
Figure 31. shown on page 70. Ccl3 induces differentiation of naïve T cells into TH1 and TH17 cells. 
Naïve CD4
+
 CD62L
+
 T cells isolated either from spleens and LN of Apoe
-/-
, Apoe
-/-
Ccr4
-/-
, Apoe
-/-
Ccr5
-/-
, or 
Apoe
-/-
Ccr1
-/-
 mice were cultured under Treg polarization conditions using TGF-β in the presence or 
absence of rmCcl3 for 3 days. Frequencies of (A) CD4
+
CD25
+
Foxp3
+
 Tregs (n=6) (B) CD4
+
Tbet
+
 TH1 
cells (n=3) (C) CD4
+
GATA3
+
 TH2 cells (n=3) and D) CD4
+
RorγT
+
 TH17 cells (n=3), among CD4
+
 T cells 
were analyzed by flow cytometry. Displayed are percentages normalized to the non-Ccl3 treated control 
group. (A-D) Data represent mean±SEM. 1-way analysis of variance (ANOVA) with, Kruskal-Wallis test 
with Dunn posttest were used. P values <0.05 were considered statistically significant. *P<0.05. **P<0.01. 
***P<0.001. 
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To elucidate if Ccl17 producing DCs are responsible for the secretion of Ccl3 and the 
subsequent restrain of Tregs, we isolated CD11b+CD11c+MHCII+eGFP+ DCs from either 
Apoe-/-Ccl17e/w (Ccl17 competent) or Apoe-/-Ccl17e/e (Ccl17-deficient) mice. We cultured 
them together with naïve CD4+CD62L+ T cells isolated from either Apoe-/-, Apoe-/-Ccr4-/-, 
or Apoe-/-Ccr1-/- for three days (see methods 2.2.3.3.) (Figure 32). We analyzed the 
frequencies of CD4+CD25+Foxp3+ Tregs among CD4+ T cells and observed that when 
co-cultured with Apoe-/-Ccl17e/w DCs, Apoe-/- naïve CD4+CD62L+ T cells differentiated 
less into CD4+CD25+Foxp3+ Tregs. When Apoe-/- naïve CD4+CD62L+ T cells were co-
cultured with Apoe-/-Ccl17e/e DCs, we observed an increase in CD4+CD25+Foxp3+ Tregs. 
Similar results were obtained when Apoe-/-Ccl17e/w DCs or Apoe-/-Ccl17e/e DCs were co-
cultured with Apoe-/-Ccr4-/- naïve CD4+CD62L+ T cells respectively. Only when Apoe-/-
Ccr1-/- naïve CD4+CD62L+ T cells where co-cultured with Apoe-/-Ccl17e/w DCs we could 
not observe changes in Treg frequencies when comparing them to the ones co-cultured 
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with Apoe-/-Ccl17e/e. These results indicate that Ccl17 producing DCs secrete a 
secondary mediator that restrains Tregs via the chemokine receptor Ccr1. 
 
Figure 32. DC-T cell co-culture Treg differentiation. CD11b
+
CD11c
+
MHCII
+
eGFP
+
 DCs where isolated 
via flow cytometric sorting from either Apoe
-/-
Ccl17
e/w
 or Apoe
-/-
Ccl17
e/e
 mice and cultured together with 
naïve CD4
+
 CD62L
+
 T cells isolated from either Apoe
-/-
, Apoe
-/-
Ccr4
-/-
, or Apoe
-/-
Ccr1
-/-
 mice for three days. 
Frequencies of CD4
+
CD25
+
Foxp3
+
 Tregs among CD4
+
 T cells were analyzed by flow cytometry.  
 
3.2.2. Deficiency of Ccl3 reduces atherosclerosis in Apoe-/- mice by 
restraining Tregs and thereby phenocopies Ccl17 deficiency 
To investigate whether Ccl3 acts as a secondary mediator for Ccl17 and if Ccl3 
deficiency phenocopies Ccl17 deficiency during the onset of atherosclerosis, we used 
Apoe-/-, Apoe-/-Ccl3-/- and Apoe-/-Ccl17e/e mice and fed them a HFD for 12 weeks. We 
analyzed atherosclerotic lesion formation in the aortic root, the aortic arch and in the 
thoraco-abdominal aorta (Figure 33A). As expected we found a significant reduction in 
atherosclerotic lesion formation in Apoe-/-Ccl17e/e mice, as well as in Apoe-/-Ccl3-/- in 
comparison to Apoe-/- control mice, as visible after Oil-red-O staining in the aortic root 
and in the en face prepared thoraco-abdominal aorta (Figure 33B and D). These effects 
were also observed after HE staining in the aortic arch (Figure 33C). No alterations were 
seen in terms of body weight or cholesterol or triglyceride plasma levels (Figure 33E-G).  
Figure 33. shown on page 72. Deficiency of Ccl3 reduces atherosclerosis and phenocopies Ccl17 
deficiency. (A) Experimental scheme depicting the type of animals used, duration of diet feeding and 
endpoint analysis performed. (B-D) Atherosclerotic lesions were quantified in Apoe
-/- 
(n=23), Apoe
-/-
Ccl3
-/-
 
(n=13) and Apoe
-/-
Ccl17
e/e
 (n=10) mice after 12 weeks of HFD. (B) Representative images (left) and 
quantification (right) of Oil-red-O
+
 area in aortic root sections are shown. (C) Representative images (left) 
and quantification of lesion size in HE-stained aortic arches are depicted. (D) Representative images (left) 
and quantification of Oil-red-O
+
 area in en face prepared thoracoabdominal aortas are shown. E-H) 
Bodyweight (E), plasma cholesterol levels (F), plasma triglyceride levels (G), CCL3 Plasma levels (H) of 
Apoe
-/- 
(n=23), Apoe
-/-
Ccl3
-/-
 (n=13) and Apoe
-/-
Ccl17
e/e
 (n=10) mice after 12 weeks of HFD. Data (A-H) 
represent mean±SEM, One-way analysis of variance (ANOVA) with, Kruskal-Wallis test with Dunn 
posttest were used. P values <0.05 were considered statistically significant. *P<0.05. **P<0.01.  
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Quantitative immunostaining revealed that the reduction in atherosclerotic lesion size 
observed in Apoe-/-Ccl3-/- and Apoe-/-Ccl17e/e mice was due to different outcomes in 
plaque composition. While Apoe-/-Ccl3-/- mice showed a significant reduction in the 
relative and absolute amount of Mac2+ macrophages compared to Apoe-/- mice, Apoe-/-
Ccl17e/e mice did not show these effects (Figure 34A,B,D). Furthermore, the relative and 
absolute content in SMA+ smooth muscle cells was significantly increased in Apoe-/-
Ccl17e/e mice, whereas Apoe-/-Ccl3-/- mice displayed no differences in SMC content 
compared to control animals (Figure 34A, C). 
Apoe-/-
Apoe-/-Ccl3-/-
Apoe-/-Ccl17e/e
12 weeks HFD
Apoe-/-
Ccl17e/e
Apoe-/-
root
arch
root
a
o
rta
Apoe-/-
Ccl3-/-
Apoe-/-
Apoe-/-Ccl3-/-
Apoe-/-Ccl17e/e Apoe-/- Apoe-/-
Ccl3-/-
Apoe-/-
Ccl17e/e
Apoe-/- Apoe-/-
Ccl3-/-
Apoe-/-
Ccl17e/e
Apoe-/- Apoe-/-
Ccl3-/-
Apoe-/-
Ccl17e/e
0
1 0
2 0
3 0
Apoe-/- Apoe-/-
Ccl3-/-
Apoe-/-
Ccl17e/e
B
C D
A
E F G H
0
1
2
3
4
5
***
**
Apoe-/- Apoe-/-
Ccl3-/-
Apoe-/-
Ccl17e/e
0
1
2
3
4
5
* **
0
5
1 0
1 5
*
**
0
1 0
2 0
3 0
4 0
*
**
0
2 0 0
4 0 0
6 0 0
8 0 0
1 0 0 0
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
Apoe-/- Apoe-/-
Ccl3-/-
Apoe-/-
Ccl17e/e
Apoe-/- Apoe-/-
Ccl3-/-
Apoe-/-
Ccl17e/e
O
il-
re
d
 O
+
a
re
a
(%
 t
o
ta
l 
ro
o
t 
a
re
a
)
O
il-
re
d
 O
+
a
re
a
(%
 t
o
ta
l 
a
o
rt
ic
 a
re
a
)
H
E
+
s
ta
in
in
g
(%
 t
o
ta
l 
a
rc
h
 a
re
a
)
B
o
d
y
w
e
ig
h
t 
[g
]
C
h
o
le
s
te
ro
l 
[m
g
/d
L
]
T
ri
g
ly
c
e
ri
d
e
s
 [
m
g
/d
L
]
C
c
l3
 [
p
g
/m
l]
Results 
______________________________________________________________________ 
73 
 
Figure 34. Ccl3- and Ccl17-deficiency differentially impact on plaque composition. Atherosclerotic 
lesion composition was analyzed using immunohistochemistry. (A) Representative images of macrophage 
(red) and smooth muscle cell (green) staining, in the aortic root of Apoe
-/- 
(n=23; upper picture), Apoe
-/-
Ccl3
-/-
 (n=13; middle picture) and Apoe
-/-
Ccl17
e/e
 (n=10; lower picture) mice after 12 weeks of HFD, are 
shown; cell nuclei are counterstained by DAPI (blue); scale bars: 200 μm. (B-D) The relative (left) and 
absolute quantification (right) of MAC-2
+
 macrophages (B) and SMA
+
 smooth muscle cells (C) and the 
absolute number of DAPI
+
 cells (D) per plaque area was analyzed by quantitative immunofluorescence. 
Data (B-D) represent mean±SEM, One-way analysis of variance (ANOVA) with, Kruskal-Wallis test with 
Dunn posttest were used. P values <0.05 were considered statistically significant. *P<0.05. **P<0.01. 
***P<0.001. 
In order to explain the differences in plaque size and plaque composition between Apoe-
/- versus Apoe-/-Ccl3-/- and Apoe-/-Ccl17e/e, we performed flow cytometric analysis of 
blood, as well as of single cell suspensions of bone marrow, spleen and para-aortic-, 
axillar-, inguinal- and mesenteric lymph nodes. Analyzing the distribution of CD45+ 
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74 
leukocyte subsets mentioned in chapter (see methods 2.2.2.3.), we only observed 
higher frequencies and an expansion of CD4+CD25+Foxp3+ Tregs in Apoe-/-Ccl3-/- and 
Apoe-/-Ccl17e/e mice when compared to Apoe-/- control mice. These results indicate that 
Ccl3 deficiency induces similar effects already revealed in mice lacking Ccl17 (Figure 35 
and Supplemental table 13-16). CD4+CD25+Foxp3+ Tregs were significantly increased in 
spleen, para-aortic-, axillar-, inguinal- and mesenteric lymph nodes of Apoe-/-Ccl3-/- and 
Apoe-/-Ccl17e/e mice when compared to Apoe-/- control mice but where not altered in the 
circulation of these animals (Figure 35). 
 
Figure 35. Ccl3 and Ccl17 deficiency affects regulatory T cell populations. (A) Representative dot 
plots of Flow cytometric analysis of CD3
+
CD4
+
CD25
+
Foxp3
+
 Tregs in para-aortic LNs of Apoe
-/- 
(n=23), 
Apoe
-/-
Ccl3
-/-
 (n=13) and Apoe
-/-
Ccl17
e/e
 (n=10) mice after 12 weeks of HFD; numbers in dot plots are 
percentage of CD4
+
 events. (B-G) Flow cytometric analysis of CD3
+
CD4
+
CD25
+
Foxp3
+
 Tregs (B) in Blood 
(C) Spleen (D) para-aortic LNs (E) axillar LNs (F) inguinal LNs and (G) mesenteric LNs of Apoe
-/- 
(n=23), 
Apoe
-/-
Ccl3
-/-
 (n=13) and Apoe
-/-
Ccl17
e/e
 (n=10) mice after 12 weeks of HFD employing indicated surface 
markers. Data (B-G) represent mean±SEM, One-way analysis of variance (ANOVA) with, Kruskal-Wallis 
test with Dunn posttest were used. P values <0.05 were considered statistically significant. *P<0.05. 
**P<0.01. ***P<0.001. 
 
3.2.3. Recombinant Ccl3 reverses effects of Ccl17 deficiency 
To investigate if treatment with rmCcl3 could reverse the atheroprotective effects of 
Ccl17 deficiency, we employed Apoe-/-Ccl17e/e mice and fed a HFD for 4 weeks, while 
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75 
injecting 20 µg rmCcl3 intraperitoneally three times a week. As a control, Apoe-/-Ccl17e/e 
and Apoe-/- mice received shots of PBS three times per week, during a 4 week HFD 
(Figure 36A). We observed, as expected, a reduction in atherosclerotic lesion size in the 
Apoe-/-Ccl17e/e mice that were treated with PBS when compared with Apoe-/- control 
mice. Analyzing the Apoe-/-Ccl17e/e treated with rmCcl3 we observed plaque sizes that 
were comparable in size to that of the Apoe-/- control mice receiving PBS (Figure 
36B+C). Moreover, CD4+CD25+Foxp3+ Tregs significantly increased in para-aortic 
lymph nodes of Apoe-/-Ccl17e/e animals treated with rmCcl3 in comparison to the control 
group. Treg numbers in Apoe-/-Ccl17e/e mice treated with rmCcl3 were comparable to 
that of the Apoe-/- control mice receiving PBS (Figure 36D+E). 
 
Figure 36. Recombinant Ccl3 reverses effects of Ccl17 deficiency. (A) Experimental scheme 
depicting the type of animals used, treatment carried out, duration of diet feeding and endpoint analysis 
performed. (B+C) Atherosclerotic lesions were quantified in Apoe
-/-
, Apoe
-/-
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76 
Apoe
-/-
Ccl17
e/e
 (n=10) mice after 4 weeks of HFD. (B) Representative images (left) and quantification 
(right) of Oil-red-O
+
 area in aortic root sections are shown. (C) Quantification of lesion size in HE-stained 
aortic arches is depicted. (D) Representative dot plots of Flow cytometric analysis of 
CD3
+
CD4
+
CD25
+
Foxp3
+
 Tregs in para-aortic LNs of Apoe
-/-
, Apoe
-/-
Ccl17
e/e
 and CCL3 treated Apoe
-/-
Ccl17
e/e
 (n=10) mice after 4 weeks of HFD; numbers in dot plots are percentage of CD4
+
 events. (E+F) 
Flow cytometric analysis of CD3
+
CD4
+
CD25
+
Foxp3
+
 Tregs (E) in Spleen and (F) para-aortic LNs. Data (B-
F) represent mean±SEM, One-way analysis of variance (ANOVA) with, Kruskal-Wallis test with Dunn 
posttest were used. P values <0.05 were considered statistically significant (n=10). *P<0.05, **P<0.01, 
***P<0.001. 
 
3.2.4. Deficiency of Ccr1 reduces atherosclerosis in Apoe-/- mice by 
restraining Tregs and thereby phenocopies Ccl17 and Ccl3 
deficiency 
Since we were able to demonstrate that Ccl3 signals via Ccr1 to restrain Tregs and to 
push differentiation of naïve T cells towards pro-inflammatory subtypes such as TH1 and 
TH17 we further wanted to investigate the role of Ccr1 during atherosclerosis. For this 
purpose, we used Apoe-/-Ccr1-/- mice and fed them a high fat diet (HFD) for 12 weeks. 
We analyzed the atherosclerotic lesion formation in the aortic root, the aortic arch and in 
the thoraco-abdominal aorta (Figure 37A). A significant reduction in atherosclerotic 
lesion formation was observed in Apoe-/-Ccr1-/- mice in comparison to Apoe-/- control 
mice, as visible after Oil-red-O staining in the aortic root and the en face prepared 
thoraco-abdominal aorta (Figure 37B and D), as well as after HE staining in the aortic 
arch (Figure 37C). No alterations were observed concerning the weight of the mice, nor 
the cholesterol or triglyceride plasma levels, nor Ccl3 plasma levels (Figure 37E-H).  
Figure 37. shown on page 77. Deficiency of Ccr1 reduces atherosclerosis. (A) Experimental scheme 
depicting the type of animals used, duration of diet feeding and endpoint analysis performed. (B-D) 
Atherosclerotic lesions were quantified in Apoe
-/-
 and Apoe
-/-
Ccr1
-/- 
mice after 12 weeks of HFD. (B) 
Representative images (left) and quantification (right) of Oil-red-O
+
 area in aortic root sections are shown. 
(C) Representative images (left) and quantification of lesion size in HE-stained aortic arches are depicted. 
(D) Representative images (left) and quantification of Oil-red-O
+
 area in en face prepared thoraco-
abdominal aortas are shown. (E-H) Bodyweight (E), plasma cholesterol levels (F), plasma triglyceride 
levels (G) and CCL3 plasma levels (H) of Apoe
-/-
 (n=10) and Apoe
-/-
Ccr1
-/-
 (n=5) mice after 12 weeks of 
HFD. Data (A-H) represent mean±SEM, Student t test with Welch correction. *P < 0.05; **P < 0.01. 
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Quantitative immunostaining revealed that the reduction in atherosclerotic lesion size 
observed in Apoe-/-Ccr1-/- mice, was accompanied by a significant decrease in the 
absolute and relative numbers of MAC2+ macrophages, when compared to Apoe-/- 
control mice (Figure 38A and B). Furthermore, the absolute content of SMA+ smooth 
muscle cells was significantly increased in lesions of Apoe-/-Ccr1-/- mice, whereas the 
relative content of SMA+ smooth muscle cells showed a tendency towards higher counts 
(Figure 38A and C). We did not observe any significant changes in DAPI+ cell counts 
when comparing Apoe-/-Ccr1-/- mice to Apoe-/- mice (Figure 38D). This data indicates a 
shift towards a more stable plaque phenotype in Apoe-/-Ccr1-/- mice. 
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Figure 38. Deficiency of Ccr1 influences plaque composition. Atherosclerotic lesion composition was 
analyzed using Immunohistochemistry. (A) Representative images of macrophage (red) and smooth 
muscle cell (green) staining, in the aortic root of Apoe
-/-
 (n=10; upper picture) and Apoe
-/-
Ccr1
-/- 
(n=5; lower 
picture) mice after 12 weeks of HFD, are shown; cell nuclei are counterstained by DAPI (blue); scale bars: 
200 μm. B-D) The relative (left) and absolute quantification (right) of MAC-2
+
 macrophages (B) and SMA
+
 
smooth muscle cells (C) and the absolute number of DAPI
+
 cells (D) per plaque area are shown. Data (B-
D) represent mean±SEM, Student t test with Welch correction. P values <0.05 were considered 
statistically significant. *P<0.05 
In order to explain the differences in plaque size and plaque composition between Apoe-
/- versus Apoe-/-Ccr1-/-, we performed flow cytometric analysis of blood, as well as of 
single cell suspensions of bone marrow, spleen and para-aortic-, axillar-, inguinal- and 
mesenteric lymph nodes. Analyzing the distribution of different CD45+ leukocyte 
populations as mentioned in chapter (see methods chapter 2.2.2.3.), we observed 
higher frequencies and an expansion of CD45+ leukocytes in general. Furthermore, we 
have seen increases in Gr1+CD115- neutrophils, Gr1+CD115+ monocytes, Gr1-CD115+ 
monocytes CD11c+MHCII+ cDCs and a reduction of CD11b+F4/80+ macrophages in the 
bone marrow of Apoe-/-Ccr1-/- when compared to Apoe-/- mice. Moreover, we observed 
an increase in CD45+Gr1+CD115+ monocytes, CD45+Gr1-CD115+ monocytes in the 
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para-aortic lymph nodes (Supplemental table 17-20). When further comparing Apoe-/-
Ccr1-/- mice to Apoe-/- control mice, we observed Tregs being significantly increased in 
spleen, para-aortic-, axillar-, inguinal- and mesenteric lymph nodes of Apoe-/-Ccr1-/- mice, 
but no alterations in circulating numbers of Treg in these mice (Figure 39A-G), being in 
line with observations made in Apoe-/-Ccl3-/- and Apoe-/-Ccl17e/e mice (Figure 35). 
 
Figure 39. Ccr1 deficiency affects regulatory T cell populations. (A) Representative dot plots of Flow 
cytometric analysis of CD3
+
CD4
+
CD25
+
Foxp3
+
 Tregs in para-aortic LNs of Apoe
-/-
 (n=10) and Apoe
-/-
Ccr1
-
/- 
(n=5) mice after 12 weeks of HFD; numbers in dot plots are percentage of CD4
+
 events. (B-G) Flow 
cytometric analysis of CD3
+
CD4
+
CD25
+
Foxp3
+
 Tregs (B) in Blood (C) Spleen (D) para-aortic LNs (E) 
axillar LNs (F) inguinal LNs and (G) mesenteric LNs of Apoe
-/-
 (n=10) and Apoe
-/-
Ccr1
-/- 
(n=5) mice after 12 
weeks of HFD employing indicated surface and intracellular markers. Data (B-G) represent mean±SEM, 
Student t test with Welch correction. P values <0.05 were considered statistically significant. *P<0.05, 
**P<0.01, ***P<0.001. 
 
3.2.5. Identifying an alternative receptor for Ccl17 
Following the discovery that Ccl3 secretion by DCs is mediated by Ccl17, we continued 
analyzing Ccl3 concentrations using ELISA in plasma obtained either from C57BL/6 
(Ctrl) ► Apoe-/- mice (n=7); Ccr4-/-►Apoe-/- mice (n=7) or Ccr8-/-►Apoe-/- mice after 12 
weeks HFD (n=11); (Figure 40). We observed that plasma Ccl3 levels were significantly 
reduced in Ccr8-/-►Apoe-/- mice after 12 weeks HFD but not in C57BL/6 (Ctrl) ► Apoe-/- 
mice or in Ccr4-/-►Apoe-/- mice after 12 weeks HFD. These results indicate that Ccr8 
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might be an alternative receptor for Ccl17 and encouraged us to perform further binding 
studies involving Ccl17 and Ccr8.  
 
Figure 40. Using Ccl3 plasma levels as a read out to identify new Ccl17 receptors. Scheme depicting 
the type of animals used (left) for Ccl3 Plasma quantification (right). CCL3 plasma levels were quantified 
in Plasma from C57BL/6 (Ctrl) ► Apoe
-/-
 mice (n=7); Ccr4
-/-
 Apoe
-/- 
mice (n=7) or Ccr8
-/-
 Apoe
-/- 
mice 
after 12 weeks HFD (n=11). Data represents mean±SEM, 1-way analysis of variance (ANOVA) with, 
Kruskal-Wallis test with Dunn posttest were used. P values <0.05 were considered statistically significant. 
*P < 0.05; **P < 0.01. 
To determine whether Ccl17 induces Gi signaling via Ccr8 we transfected Glosensor-
HEK293 cells with either Ccr4 or Ccr8. Glosensor-HEK293 cells allow determining 
cAMP levels in the cell via Luciferase assay, being cAMP a readout for activated G i 
signaling. GloSensor luciferase is circularly permuted, joining the wild-type N- and C-
termini with a polypeptide or protein domain and creating engineered termini elsewhere 
within the structure. Therefore, analyte binding induces a conformational shift in the 
biosensor that allows large increases in luminescence activity. The magnitude of the 
luminescence singnal increase is proportional to the amount of analyte activity present. 
Using this system, we stimulated Ccr4 or Ccr8 transfected Glosensor-HEK293 cells with 
PBS control, Ccl17 (100 ng/ml), Ccl1 (100 ng/ml), Ccl18 (100 ng/ml) or Ccl20 (100 
ng/ml). We observed that Ccl17-induced Gi signaling in the Ccr8 transfected cells as 
well as in the Ccr4 transfected cells indicating that Ccr8 indeed is an alternative receptor 
for Ccl17. Ccl1 as a positive control for Ccr8-induced, as expected, Gi signaling in the 
Ccr8 transfected cells, but not in the Ccr4 transfected cells. Ccl20 as a negative control 
for both Ccr4 and Ccr8 did not induce Gi signaling (Figure 41). 
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Figure 41. Ccl17 induces Gi signaling via Ccr8. Gi signaling was investigated by determining cAMP 
levels using Glosensor-HEK293 cells transfected with either (A) Ccr4 or (B) Ccr8 after stimulation with 
PBS Control, Ccl17 (100 ng/ml), Ccl1 (100 ng/ml), Ccl18 (100 ng/ml) or Ccl20 (100 ng/ml). Data represent 
mean±SEM from six independent experiments. 
 
To further validate interactions between murine Ccl17 and Ccr8 we used a proximity 
ligation assay. Adherent DCs isolated from LNs of Apoe-/- mice were incubated with 
Ccl17 or Ccl1 (100 ng/ml each). After stimulation, we used primary antibodies against 
Ccl17 or Ccl1 and either Ccr4, Ccr5 or Ccr8 to perform the proximity ligation assay 
according to the manufacturer’s instructions. Using secondary antibodies labeled with 
short PLA probes and subsequent ligation and PCR amplification we generated (in case 
the desired molecules were in close proximity) signals (red dots) (Figure 42A). Figure 42 
B and C demonstrate that when incubating DCs with Ccl17 we observe the formation of 
red dots when staining with anti-Ccr4 and anti-Ccr8, but not when staining with Ccr5, 
indicating that Ccl17 binds to Ccr8. Ccl1 on the other hand does only bind to Ccr8 and 
not Ccr4 or Ccr5. 
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Figure 42. Ccl17 binds Ccr8 but not Ccr5 on the surface of DCs. (A) Scheme of proximity ligation 
reaction. Interactions between murine Ccl17 or Ccl1 and the receptors Ccr4, Ccr5 and Ccr8 were 
analyzed on the surface of adherent DCs using a proximity ligation assay after the cells were incubated 
with Ccl17 or Ccl1 (100 ng/ml each). (B) Representative images depict the presence of interaction 
between ligands and receptors (red dots) on the DC surface. (C) Signals generated by interactions 
between ligands and receptors (red dots) on the DC surface were quantified and normalized relative to 
the unstimulated control alone (n=3). Data represent means ± SEM. *P < 0.05, **P < 0.01, as analyzed by 
One-way ANOVA. 
 
To validate CCL17-CCR8 binding, we performed kinetics analyses of their binding 
curves using surface plasmon resonance (SPR) (Figure 43). Apparent affinities were 
calculated from on-rates (ka) and off-rates (kd) obtained by fitting the curves using 
BIAevaluation with the 1:1 interaction model (Langmuir). CCL17 was biotinylated and 
immobilized onto a neutravidin-coated sensor chip C1 (BIAcore). CCR8 carrying 
liposomes were perfused at 62.5 ng/ml; 125 ng/ml; 250 ng/ml; 500 ng/ml; 1000 ng/ml 
and 2000ng/ml at 5 μl/min in running buffer (HBS-EP+, pH 7.4) and regenerated with 
100 mM NaOH, 0.05% SDS and 30% acetonitrile. KD was calculated to be 1.10-09 M 
indicating a strong binding between CCL17 and CCR8.  
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Figure 43. CCL17 binds CCR8-carrying liposomes. Binding of soluble CCR8 carrying liposomes to 
immobilized CCL17 was assessed by surface plasmon resonance (SPR). Apparent affinities were 
calculated from on-rates (ka) and off-rates (kd) obtained by fitting the curves using BIAevaluation with the 
1:1 interaction model (Langmuir). KD was calculated to be 1.10
-09 
M for CCR8.  
 
3.3. Heteromeric complexes and their effects on Leukocyte function 
Besides the possibility of Ccl17 binding by itself to an alternative receptor which enables 
its effect on Treg homeostasis, other mechanism may play a role in the diverse biologic 
functions of Ccl17. For instance, Ccl17 may engage in heterophilic interactions with 
other chemokines. These heterophilic interactions in a given microenvironment may 
amplify, inhibit, or modulate the activity of Ccl17. 
3.3.1. Ccl17 forms heteromeric complexes with Ccl5 
To address possible mechanisms for synergy of the Ccl5-Ccl17 heterodimer, we used 
an in situ proximity ligation assay able detect protein-protein interactions and therefore, 
the presence of Ccl5-Ccl17 heterodimers. On DCs, which express both Ccr4 and Ccr5, 
Ccl5-Ccl17 heterodimers formed on the cell surface when adding both chemokines. The 
increase in Ccl5-Ccl17 heterodimers was inhibited by a peptide-based inhibitor (a Ccl5-
derived peptide which forms part of the heterodimer interface with Ccl17) named CAN, 
revealing that heterodimers can be disrupted by peptides (Figure 44A and B).317 
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Figure 44. Ccl17 forms heteromeric complexes with Ccl5 on surface of DCs. Interactions between 
murine Ccl17 and Ccl5 on the surface of adherent DCs were analyzed using a proximity ligation assay 
after the cells were incubated with Ccl17 or Ccl5 or a combination of both (100 ng/ml each). DCs were 
also stimulated with Ccl17 and CCl5 in the presence of the peptide CAN (60 nM). (A) Representative 
images depict the presence of interaction Ccl17 and Ccl5 (red dots) on the DC surface. (B) signals 
generated by interactions between ligands and receptors (red dots) on the DC surface were quantified 
and normalized relative to the unstimulated control alone (n=5). Data represent means ± SEM. *P < 0.05, 
as analyzed by One-way ANOVA.
317
 
 
Furthermore we used the in situ proximity ligation assay for detecting protein interactions 
between Ccl5 and Ccl17 and subsequently formed heterodimers on activated 
endothelial cells after incubation with both chemokines (Figure 45A). Endogenous 
heterodimers could be detected in mouse lymph nodes (Figure 45B) and in the plaque 
shoulder region in aortic roots of mice fed a HFD for 12 weeks (Figure 45C).317  
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Figure 45. Ccl5-Ccl17 heterodimers are present in vivo. Interactions between murine Ccl17 and Ccl5 
were analyzed on (A) the surface of adherent SVECs, (B) murine para-aortic LN sections, (C) murine 
aortic root sections, using a proximity ligation assay. Representative images depict the presence of 
interaction Ccl17 and Ccl5 (red dots).
317
 
 
Furthermore, we analyzed which effects Ccl5-Ccl17 heterodimers might have on T cell 
biology. We performed transwell filter chemotaxis assays using CD3/CD28-activated 
primary mouse T cells and determined the chemotactic index as the ratio of chemokine-
induced versus unstimulated migration by counting the cells in the bottom chamber. We 
were able to show that migration toward Ccl5-Ccl17 heterodimers was increased when 
compared to individually stimulated controls and was inhibited by the disruptive peptide 
CAN, indicating that the increase in migration is synergistically mediated by the complex 
rather than being an addition of the effects of both single chemokines (Figure 46).317 
anti-CCR4 + anti-CCL17
A
B
C
anti-CCL5 + anti-CCL17
Results 
______________________________________________________________________ 
86 
 
Figure 46. Ccl5-Ccl17 heterodimers induce more efficient T cell migration. Transwell filter 
chemotaxis assays were performed using CD3/CD28-activated primary mouse T cells (n= 8). Chemotactic 
index was determined as the ratio of chemokine-induced versus unstimulated migration by counting the 
cells in the bottom chamber. Migration toward Ccl5 and/or Ccl17 (100 ng/mL each) in the bottom chamber 
was analyzed in the presence/absence of CAN (60 nM) peptide. Data represent means ± SEM. *P < 0.05, 
**P < 0.01 as analyzed by One-way ANOVA.
317
 
 
3.3.2. Ccl5-Ccl17 heterodimers induce more efficient T cell arrest 
To further assess the functional effects of chemokine heterodimers, we studied induced 
T cell arrest using IL-2- and CD3/C28-activated human T cells perfused over IL-1β-
stimulated human aortic endothelial cells (HAoECs). We observed that CCL5 and 
CCL17-induced T cell arrest with higher potency and efficacy than CCL5 or CCL17 
alone (Figure 47A), establishing that heterodimers are responsible for the synergistic 
effects. This synergistic effect was inhibited by the disruptive peptide CAN (Figure 
47B).317 
 
Figure 47. CCL5-CCL17 heterodimers induce more efficient T cell arrest. The firm arrest of IL-2- and 
CD3/C28-activated human T cells perfused over IL-1β-stimulated human aortic endothelial cells 
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(HAoECs) at 1.5 dyne/cm 2 was analyzed by counting high-power fields (HPF). For T-cell arrest, (A) 
CCL5 (1nM) and CCL17 (0.1nM) were immobilized on HAoECs in (B) combination with CAN or CKEY 
(both 10 nM) (A), n=5; (B) n=3). Data represent means ± SEM. *P < 0.05, **P < 0.01 as analyzed by 
Kruskal-Wallis test.
317
 
3.3.3. Ccl5-Ccl17 heterodimers provoke more efficient binding of Ccl17 to 
Ccr4 
To analyze how Ccl5-Ccl17 heterodimers induce more efficient T cell migration and 
arrest we again performed proximity ligation assays and focused on analyzing the 
interactions between either Ccl17 and the receptors Ccr4 and Ccr5, or Ccl5 and the 
receptors Ccr4 and Ccr5. When stimulating the adherent DCs with Ccl5 and Ccl17 we 
first observed more efficient binding of Ccl17 to Ccr4 (Figure 48A) as well as increased 
ligand-receptor cross-interactions, meaning that interactions between Ccl5 and Ccr4 
(Figure 48C) where detectable as well as interactions between Ccl17 and Ccr5 (Figure 
48D). We did not observe increases in interactions between Ccl5 and Ccr5 when 
stimulating the cells with a combination of Ccl5 and Ccl17 when compared to the Ccl5 
treated control (Figure 48B).317 
 
Figure 48. Ccl5-Ccl17 heterodimers bind to Ccr5 and more efficiently to Ccr4 on the surface of 
DCs. (A-D) Interactions between murine CCL5, CCL17, CCR4, and CCR5 were detected on the surface 
of adherent DCs using a proximity ligation assay after the cells were incubated with Ccl5, Ccl17, or both 
(100 ng/mL each) in the presence/absence of CAN (60 nM). Proximity ligation signals generated by 
interactions between (A) murine Ccl17 and the receptor Ccr4; (B) murine Ccl5 and the receptor Ccr5; (C) 
Ccl5 and the receptor Ccr4; (D) murine Ccl17 and the receptor Ccr5 were analyzed. (A-D) Signals 
generated by interactions between ligands and receptors (red dots) on the DC surface were quantified by 
IHC and normalized relative to the unstimulated control alone (n=3). Data represent mean±SEM from a 
number of independent experiments, as indicated. *p<0.05, **p<0.01, compared to Ccl5 and Ccl17 
combined in the absence of CAN, as analyzed by Mann-Whitney-test.
317
 
 
To further assess if CCL5-CCL17 heterodimers induce a more efficient binding of 
CCL17 to CCR4, we performed binding competition assays. We used CCL17–Alexa 
 Ccl17-Ccr4
re
la
tiv
e
 t
o
 c
o
n
tr
o
l
0
1
2
3
4  Ccl5-Ccr5
re
la
tiv
e
 t
o
 c
o
n
tr
o
l
0
1
2
3
4 C c l5 -C c r4
re
la
ti
v
e
 t
o
 c
o
n
tr
o
l
0
1
2
3
4
 Ccl17-Ccr5
re
la
tiv
e
 t
o
 c
o
n
tr
o
l
0
1
2
3
4
5
-+
+-
+
+
Ccl5
Ccl17
+
+
+- - -CAN
-+
+-
+
+
Ccl5
Ccl17
+
+
+- - -CAN
-+
+-
+
+
Ccl5
Ccl17
+
+
+- - -CAN
-+
+-
+
+
Ccl5
Ccl17
+
+
+- - -CAN
A B C D
Results 
______________________________________________________________________ 
88 
Fluor 647 bound to CCR4-expressing human embryonic kidney (HEK) 293 transfectants 
and measured the rate by which the CCL17–Alexa Fluor 647 was displaced by 
unlabeled CCL17 in the presence or absence of CCL5 (Figure 49). We observed that in 
the presence of CCL5 the CCL17–Alexa Fluor 647 was displaced much more efficient 
then when CCL5 was absent.317 
 
Figure 49. CCL5-CCL17 heterodimer binds more efficient to CCR4. Binding competition assay; 
CCL17–Alexa Fluor 647 (2.5 nM) bound to CCR4-expressing human embryonic kidney (HEK) 293 
transfectants was displaced by unlabeled CCL17 in the presence or absence of CCL5 (1 nM; n = 6).
317 
 
3.3.4. Ccl5-Ccl17 heterodimers provoke heterodimerization of the receptors 
Ccr4 and Ccr5 
To gain mechanistic insights on how the synergistic effects of the Ccl5-Ccl17 
heterodimer work, we again used the in situ proximity ligation assay reporting protein 
interactions which this time detect the presence of Ccr4-Ccr5 heterodimers. On DCs, 
which express both Ccr4 and Ccr5, Ccr4-Ccr5 heterodimers assembled on the cell 
surface when adding Ccl5 and Ccl17 in combination. The increase in Ccr4-Ccr5 
heterodimers was inhibited by the disruptive peptide CAN and by the R5-TM1/4 peptides 
(inhibiting heterodimerization of CCR4 and CCR5) that inhibit dimerization of Ccr4 and 
Ccr5 (Figure 50).317 
Figure 50. shown on page 89. Ccl5-Ccl17 heterodimers provoke heteromerization of the receptors 
Ccr4 and Ccr5. Interactions between murine Ccr4 and Ccr5, were analyzed on the surface of adherent 
DCs using a proximity ligation assay after the cells were incubated with Ccl17 or Ccl5 or a combination of 
both (100 ng/ml each). DCs were also stimulated with Ccl17 and Ccl5 in the presence of the peptide CAN 
(60 nM) or R5-TM1/4 peptides (50mg/ml). (A) Representative images depict the presence of interaction 
between Ccr4 and Ccr5 (red dots) on the DC surface. (B) Signals generated by interactions between 
ligands and receptors (red dots) on the DC surface were quantified and normalized relative to the 
unstimulated control alone (n=3). Data represent means ± SEM. *P < 0.05, **P < 0.01 as analyzed by 
Kruskal-Wallis test.
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3.3.5. Synergistic effect of Ccl5-Ccl17 heterodimers in T cell transmigration 
is dependent on Ccr4 and Ccr5 heterodimerization. 
Since we discovered that Ccl5-Ccl17 heterodimers induce stronger T cell migration and 
provoke heterodimerization of the receptors Ccr4 and Ccr5 we further studied if the 
increase in migration observed with the heterodimer is dependent on the 
heterodimerization of Ccr4 and Ccr5. We performed transwell filter chemotaxis assays 
using CD3/CD28-activated primary mouse T cells and determined the chemotactic index 
as the ratio of chemokine-induced versus unstimulated migration by counting the cells in 
the bottom chamber. We were able to show that migration toward Ccl5-Ccl17 
heterodimer was increased when compared to single stimulated controls and was 
inhibited by the peptide CAN, indicating that the increase in migration is synergistically 
mediated by the complex rather than being an addition of the effects of both single 
chemokines. Furthermore, we treated Ccl5-Ccl17 heterodimer stimulated cells with the 
disruptive R5-TM1/4 peptides that inhibits dimerization of Ccr4 and Ccr5, and could also 
observe reduction in migration of T cells comparable to that of single stimulated controls, 
indicating that the increase of migration-induced by the Ccl5-Ccl17 heterodimers is 
indeed dependent on the heterodimerization of the receptors Ccr4 and Ccr5 (Figure 
51).317 
Control
Ccl17
Ccl5
Ccl5 + Ccl17
 Ccr5-Ccr4
re
la
tiv
e
 t
o
 c
o
n
tr
o
l
0
1
2
3
4
5
**
**
Ccl5
+
+
+
Ccl17
CAN
R5-TM1/4 -
+
+
-
-
+
+
-
+
-+
+-
- -
- -
A B
Results 
______________________________________________________________________ 
90 
 
Figure 51. Ccl5-Ccl17 heterodimer induces T cell migration and blocking of Ccr4-Ccr5 
heteromerisation inhibits synergistic effect. Transwell filter chemotaxis assays were performed using 
CD3/CD28-activated primary mouse T cells (n= 8). Chemotactic index was determined as the ratio of 
chemokine-induced versus unstimulated migration by counting the cells in the bottom chamber. Migration 
toward Ccl5 and/or Ccl17 (100 ng/mL each) in the bottom chamber was analyzed in the 
presence/absence of CAN (60 nM) orTM1/4 (50mg/ml) peptides. Data represent mean±SEM from the 
indicated numbers of independent experiments. *P < 0.05, **P <0.01 as analyzed by one-way ANOVA.
317
 
 
To further validate the findings that the Ccl5-Ccl17 heterodimers induce synergistically a 
stronger migration of T cells via the heterodimerization of the receptors Ccr4 and Ccr5, 
we performed transwell filter chemotaxis assays using CD3/CD28-activated primary 
mouse T cells. We isolated the T cells either from Apoe-/- mice and treated them with or 
without the Ccr4 inhibitor C 021 dihydrochloride, or isolated them from Apoe-/-Ccr5-/- 
mice. We determined the chemotactic index as the ratio of chemokine-induced versus 
unstimulated migration by counting the cells in the bottom chamber. We were able to 
show that migration toward Ccl5-Ccl17 heterodimer was increased in T cells isolated 
from Apoe-/- mice that were not treated with C 021 dihydrochloride when compared to 
single stimulated controls. When treating the Apoe-/- T cells with C 021 dihydrochloride 
we could not observe any significant increase while using Ccl5-Ccl17 heterodimer. 
Using Apoe-/-Ccr5-/- we could also not observe any significant increases in the migration 
behavior of the T cells while stimulating with the heterodimer. These results again 
illustrate that the increase of migration-induced by the Ccl5-Ccl17 heterodimers is 
indeed dependent on the heterodimerization of the receptors Ccr4 and Ccr5 (Figure 
52).317 
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Figure 52. Ccl5-Ccl17 heterodimer induces T cell migration dependent on Ccr4-Ccr5 
heteromerisation. Transwell filter chemotaxis assays were performed using CD3/CD28-activated primary 
mouse Apoe
-/-
 T cells, Apoe
-/- 
T cells treated with Ccr4 inhibitor, or Apoe
-/-
Ccr5
-/- 
T cells. Chemotactic index 
was determined as the ratio of chemokine-induced versus unstimulated migration by counting the cells in 
the bottom chamber. Migration toward Ccl5 and/or Ccl17 (100 ng/mL each) in the bottom chamber was 
analyzed (n= 3-4). Data represent mean±SEM. *p<0.05, **p<0.01 as analyzed by two-way ANOVA.
317
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4. Discussion 
4.1. Discrepancy between Ccl17 deficiency and Ccr4 deficiency 
Ccl17 was first discovered by Imai and Yoshida in 1996 and characterized as a CC 
chemokine constitutively expressed in the thymus and highly selective for T cells.111 
Following that study the group was able to identify the chemokine receptor 4 (Ccr4) as 
receptor for Ccl17.112 Previous studies have suggested that Ccl17 is predominantly 
expressed in cutaneous DCs and by mucosal DCs and that it is up-regulated in Crohn's 
disease as well as murine experimental colitis.232-235 The CD11c+DC network found in 
atherosclerosis-prone regions of naive mice does not express Ccl17, but previous data 
obtained in our lab show increased frequencies of EGFP+CD11c+DCs in the aortic root 
of Ccl17e/+ and Ccl17e/eApoe-/- mice during lesion development and an elevated 
Ccl17expression in advanced stages.119 Furthermore, Ccl17 levels and myeloid DC 
numbers were high in advanced human plaques. In addition, Ccl17 transcripts were 
upregulated in human carotid endarterectomy specimens as compared with 
macroscopically healthy arteries.164,236,237 We show that deficiency in the chemokine 
Ccl17 reduces atherosclerotic lesion formation in Apoe-/- mice. These findings are in line 
with previous data obtained in our lab that could also show that deficiency in Ccl17 
reduces atherosclerosis.119 
Ccl17 is known to play a role in the recruitment and migration of different T cell subsets 
including TH1, TH2 and Tregs.
118 We were able to show that Ccl17 deficiency protects 
from atherogenesis through the expansion of regulatory T cells (Tregs) in lymphoid 
organs. Leading not only to smaller plaque size but also to a more stable plaque 
phenotype, characterized by higher smooth muscle cell (SMC) levels and reduced 
macrophage counts in the plaque area. Similar data were observed in previously 
performed experiments where the increase in Foxp3 expression was also observed in 
the aorta of Ccl17-deficient mice after high fat diet (HFD).119 Despite a partial function of 
Ccr4 in acute inflammatory Treg recruitment and maintenance of Tregs, Weber et al. did 
not observe a comparable reduction in lesion formation and infiltration in chimeric Ldlr-/- 
mice carrying Ccr4-/- bone marrow,119 neither did we observe a comparable reduction in 
lesion formation and infiltration in chimeric Apoe-/- mice carrying Apoe-/-Ccr4-/- bone 
marrow. On the contrary, we even observed increased plaque burden, which was 
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accompanied by increased cholesterol levels. Moreover, we could not observe any 
difference in plaque size nor in Treg numbers using Apoe-/-Ccr4-/- full KO mice. 
Furthermore, in a model of atopic dermatitis, the inflammatory burden was reduced in 
mice lacking Ccl17 but not Ccr4.120 Furthermore, and consistent with data obtained in 
our lab and by others, Heisseke et al. were able to show that Ccl17 deficiency protects 
from intestinal inflammation through a reduced inflammatory cytokine milieu of DC 
origin, which facilitates Treg expansion. Again, Ccl17 seemed to promote inflammation 
independently of Ccr4-mediated T cell recruitment, suggesting an autocrine mechanism 
where Ccl17 itself stimulates the DC (independent of Ccr4) leading to the secretion of 
other pro-inflammatory cytokines.122 In contrast, others have shown that expression of 
Ccr4 on Treg is crucial to secure Treg recruitment to sites of inflammation123,124 and 
facilitates Treg-dependent graft survival.125 Studies pointing towards Ccr8 as a receptor 
for Ccl17113,114 have been questioned115, but we now show for the first time, that Ccl17 
binds to Ccr8 and induces signaling.  
The main function of Ccl17 might be to recruit T cells to sites of inflammation. Together 
with other molecules expressed in the inflamed vessel wall,238 it is possible that Ccl17 
immobilized and presented by endothelial cells239 is involved in the recruitment of 
circulating T cells to atherosclerotic lesions. A similar mechanism is reported for the 
integrin-dependent arrest of memory T cells in chronically inflamed skin.240 Supporting 
this idea Weber et al. who observed that CD3+ T cells were reduced in lesions of 
Ccl17e/eApoe-/- mice, and adoptively transferred CD4+ T cells more efficiently homed to 
aortas of Ccl17+/+Apoe-/- mice than to those of Ccl17e/eApoe-/- mice.119 Nevertheless, the 
recruitment of CD4+ T cells was enhanced by Ccl17 in an air pouch model.119 This was 
in line with previous studies showing that Ccl17 enhances CD4+ T cell recruitment.114,241-
243 The involvement of Ccr4 in recruiting CD4+ T cells in response to Ccl17 (and Ccl22) 
has been shown by us and others also in vitro.241  
Next we were interested to know if Ccl17, besides being a potent chemoattractant, is 
able to directly interfere with the polarization of Tregs. Therefore, we performed in vitro 
polarization assays of naïve CD4+ T cells in the presence or absence of Ccl17. We were 
not able to observe any changes in Treg frequencies after adding Ccl17, indicating that 
Ccl17 does not directly affect Treg polarization. 
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As mentioned above, lack of Ccr4 did not resemble the effects of Ccl17 deficiency. No 
increase in frequencies of CD4+ T cells and Tregs in Apoe-/-Ccr4-/- mice were observed. 
Moreover, when culturing wild type (wt) T cells with either wt, Ccr4-/- or Ccl17-/- DCs we 
observed an increase in the frequency of Tregs when the DCs where lacking Ccl17 
which was not observed when they lacked Ccr4. Thus, the mechanisms by which Ccl17 
acts pro-inflammatory are not mediated by Ccr4, but rather through other alternative 
receptors that enable the complex functional profile of Ccl17. This would also explain 
why, unlike the deletion of Ccl17, a lack of Ccr4 did not confer protection against the 
formation of atherosclerotic lesions, which likely requires an attenuation of the full 
spectrum of Ccl17-mediated actions. 
4.2. Ccl3 as the missing secondary mediator 
Our results clearly demonstrate that Ccl17 does not interfere with the polarization of 
Tregs. Furthermore, Heisseke et al. described convincingly that Ccl17 deficiency lead to 
a reduced inflammatory cytokine milieu of DC origin. Therefore, we hypothesized that 
instead of acting directly upon Tregs, Ccl17 binds via an alternative receptor (not Ccr4) 
and in an autocrine fashion to (specific) DCs, thereby inducing the release of a 
secondary mediator restraining Treg homeostasis (see Figure 26). 
To test this hypothesis we isolated CD11b+CD11c+MHCII+ DCs via flow cytometry, and 
stimulated them with or without recombinant Ccl17, in the presence or absence of a 
specific Ccr4 inhibitor. After four hours of stimulation we collected the supernatant and 
performed a Multiplex Bead Array, detecting 26 different cytokines and chemokines. We 
only observed increased levels of Ccl3 (MIP-1α) and Cxcl10 (IP-10) after stimulation 
with Ccl17. Interestingly secretion of Ccl3 by DCs was independent of Ccr4, whereas 
secretion of Cxcl10 was dependent on Ccr4 signaling.  
Ccl3 belongs (as Ccl17) to the CC chemokine family. During the acute inflammatory 
state Ccl3 participates in the recruitment and activation of leukocytes via interacting with 
the receptors Ccr1, Ccr4 and Ccr5.244 Ccl3 is known as a pyrogen, inducing monophasic 
fevers similar to those induced by TNFα or IL-1α and IL-1β. In contrast to TNFα, IL-1α 
and IL-1β, Ccl3-induced fevers are not dampened by ibuprofen (a cyclooxygenase 
inhibitor).245 Its expression is known to be significantly increased during atherosclerotic 
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lesion formation in Apoe-/- mice.246 The main source of Ccl3 seems to be 
macrophages,247,248 but different studies also indicate that activated platelets, 
neutrophils, and mast cells secrete Ccl3.249-253 Here we demonstrated that the major 
source of Ccl3 after Ccl17 stimulation is the DC. 
Cxcl10 is a T-cell chemokine that was identified as an abundantly induced mRNA after 
interferon (IFN)-γ activation of monocytic U937 cells.254,255 Cxcl10 is constitutively 
expressed at low levels in thymic, splenic, and lymph node stroma. Its expression can 
be strongly induced by interferons in monocytes and macrophages, as well as in 
endothelial and smooth muscle cells.256,257 Several studies suggest that Cxcl10 may 
play a role in chronic inflammatory diseases, including coronary artery disease and 
related manifestations of atherosclerosis.258-260 Cxcl10 binds with a specific high-affinity, 
the G-protein–coupled receptor Cxcr3, which is highly expressed on activated effector T 
lymphocytes of the TH1 phenotype.
261-263 Cxcl10 induces migration of 
monocytes/macrophages, T cells, NK cells, and dendritic cells. Furthermore, Cxcl10 is 
involved in antitumor activity, and inhibition of bone marrow colony formation and 
angiogenesis.264,265 Heller et al. have demonstrated that the absence of Cxcl10 confers 
a reduction in early lesion formation in Apoe−/−Cxcl10−/− mice compared with Apoe−/− 
controls, indicating an important role during atherosclerotic lesion formation.258 These 
data, together with our results that Cxcl10 secretion by DCs is dependent of Ccl17 
signaling, allows us to speculate that part of the pro-atherogenic effects of Ccl17 are 
mediated via Cxcl10. 
Since Ccl17-dependent secretion of Cxcl10 by DCs is dependent on Ccr4 and secretion 
of Ccl3 is independent of Ccr4 we thought that Ccl3 might be the secondary mediator 
restraining Treg homeostasis, we were looking for. Therefore, we analyzed plasma Ccl3 
levels in samples obtained during several HFD studies. We observed that Ccl3 levels 
were significantly lower in Ccl17-deficient mice at steady state but also after 12 weeks 
HFD. Interestingly in a reverse BMT approach; transplanting ApoE-deficient control bone 
marrow into Apoe-/-Ccl17e/e mice we were able to restore Ccl3 levels back to control 
levels. These results indicate that Ccl3 is mainly produced by the hematopoietic system. 
As expected Ccr4 deficiency had no effect on Ccl3 plasma levels. Furthermore, we 
obtained Ccl3-deficient mice and investigated the regulatory T cell pool under steady 
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state using flow cytometry. Already under steady state conditions, we were able to 
observe significant increases in Treg frequencies in para-aortic, axillar and inguinal 
lymph nodes, whereas we did not observe any changes in Treg frequencies in 
circulation, nor in spleen or mesenteric lymph nodes. These results indicate a major role 
of Ccl3 in negatively controlling Treg homeostasis. Since it is known that several cell 
types are able to secrete Ccl3 under inflammatory conditions we were interested to 
know which cells secrete Ccl3 after Ccl17 stimulation. We found that DCs where the 
major source of Ccl3 after Ccl17 stimulation. To elucidate if Ccl3 interferes with T cell 
polarization and restrains differentiation into Tregs, we cultured naïve T cells under Treg 
polarizing conditions using TGF-β in the presence or absence of recombinant murine 
Ccl3. We found that Ccl3 inhibits differentiation of CD25+Foxp3+ Tregs. Furthermore, 
using naïve T cells deficient either for Ccr1, Ccr4 or Ccr5 we were able to show that 
restriction of Treg differentiation by Ccl3 was mediated via Ccr1. Different mechanisms 
of gene regulation are involved in T cell plasticity. It is known that direct interactions 
between transcription factors may antagonize the function of opposing transcription 
factors.266,267 Since we observe a downregulation in the anti-inflammatory transcription 
factor Foxp3, we thought to evaluate if we would observe an increase in the expression 
of the pro inflammatory transcription factors Tbet (TH1 cells) and RoryT (TH17 cells). 
Indeed, we observed an upregulation of Tbet and RoryT after Ccl3 stimulation that was 
abrogated in the absence of Ccr1. These results are in line with results obtained by 
Chen et al. where they could demonstrate that high-concentrations of Ccl3 decreased 
FOXP3 stability by promoting FOXP3’s degradation through K48-linkage ubiquitination. 
This degradation was mainly dependent on upregulation of Serine 473 phosphorylation 
of the PKBα/Akt1 isoform, and almost independent of mTORC1 (mammalian target of 
rapamycin complex 1) activity.268 These data clearly indicate that Ccl3 secreted by DCs 
after Ccl17 stimulation, acts via Ccr1 on Treg cells and drives their differentiation into 
pro inflammatory TH1 and TH17 cells and thereby establishing its role as a pro-
inflammatory and atherogenic molecule. To further validate the Ccl17-Ccl3 axis and to 
address the question if the Ccl17 producing DC is responsible for the secretion of Ccl3 
and the subsequent restrain of Tregs, we cultured naïve T cells deficient either in Apoe-/-
, Apoe-/-Ccr4-/-, or Apoe-/-Ccr1-/- for three days with DCs deficient or competent for Ccl17. 
We observed that when co-cultured with Apoe-/-Ccl17e/w DCs, Apoe-/- naïve CD4+ 
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CD62L+ T cells differentiated less into CD4+CD25+Foxp3+ Tregs then in comparison to 
Apoe-/- naïve CD4+ CD62L+ T cells co-cultured with Apoe-/-Ccl17e/e DCs.  Similar results 
were obtained when Apoe-/-Ccl17e/w DCs or Apoe-/-Ccl17e/e DCs were co-cultured with 
Apoe-/-Ccr4-/- naïve CD4+ CD62L+ T cells respectively. Only when Apoe-/-Ccr1-/- naïve 
CD4+ CD62L+ T cells where co-cultured with Apoe-/-Ccl17e/w DCs we could not observe 
changes in Treg frequencies when comparing them to the ones co-cultured with Apoe-/-
Ccl17e/e. These results indicate that Ccl17 producing DCs secrete a secondary mediator 
that restrains Tregs via the chemokine receptor Ccr1.  
Several clinical studies have suggested that Ccl3 could serve as a marker of clinical 
atherosclerosis,269 and studies confirmed it to be an independent marker of future 
ischemia.270,271 And as mentioned above, data obtained under steady state conditions in 
Ccl3-deficient mice showed significant increases in Treg frequencies in para-aortic, 
axillar and inguinal lymph nodes indicating a major role of Ccl3 in negatively controlling 
Treg homeostasis. Therefore, we hypothesized that Ccl3 deficiency would protect from 
atherosclerotic lesion development. In this study, we therefore aimed to establish the 
effect of Ccl3 deficiency on atherosclerotic lesion development. We were able to show 
that Ccl3 deficiency protects from atherogenesis through the expansion of Tregs in 
lymphoid organs, leading not only to smaller plaque size but also to a more stable 
plaque phenotype, characterized by reduced macrophage counts in the plaque area. 
These results were in line with data previously obtained in Ccl17-deficient mice. 
Furthermore, it confirmed data obtained by de Jager et al. who could show that 
leukocyte specific deficiency of Ccl3 in an Ldlr-/- mouse model of atherosclerosis was 
also atheroprotective.272 The study performed by de Jager et al. arguments that 
macrophages, and to a lesser extent neutrophils, are the primary source of Ccl3 and 
that hematopoietic Ccl3 deficiency leads to reduced neutrophil adhesion and 
accumulation in the plaque. Furthermore, they show that Ccl3 deficiency affects 
neutrophil elimination kinetics and that the half-life of Ccl3-deficient neutrophils was 
almost 2-fold decreased, and apoptosis rate and activation status were increased. 
Apoptosis of neutrophils is known to be a protective measure to dampen acute 
inflammatory responses and prevent unwanted tissue damage.273 Unfortunately, this 
study did not analyze the Treg compartment in lymphoid organs.272  
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To validate our assumption, that Ccl3 is the secondary mediator secreted after 
stimulation with Ccl17, we hypothesized that peritoneal administration of rmCcl3 could 
reverse the atheroprotective effects of Ccl17 deficiency. Therefore, we employed Apoe-/-
Ccl17e/e mice and fed a HFD for 4 weeks. We injected 20µg rmCcl3 intraperitoneally 
three times per week. We observed, as expected, a reduction in atherosclerotic lesion 
size in the Apoe-/-Ccl17e/e mice that were treated with PBS when compared with Apoe-/- 
mice. And this phenotype was reversed when treating the Apoe-/-Ccl17e/e mice with 
rmCcl3 instead of PBS. This was in line with a significant increase in the Treg population 
in the para-aortic lymph nodes of Apoe-/-Ccl17e/e mice that were treated with PBS and 
with a reduction in Tregs in Apoe-/-Ccl17e/e mice treated with rmCcl3, that were 
comparable in number to that of the Apoe-/- control mice receiving PBS. 
4.3. Ccl3-Ccr1 axis in atherosclerosis and other chronic inflammatory 
disorders 
Ccl3 can bind to Ccr4, Ccr1, and Ccr5, of which the latter two have been implicated in 
atherogenesis.133,274-277 Interestingly, and to our surprise Potteaux, et al. demonstrated 
that a hematopoietic deficiency of the Ccl3 receptor Ccr1 led to no differences in fatty 
streak size or composition after 8 weeks of HFD. But after 12 weeks of HFD diet the 
authors observed a 70% increase in atherosclerotic lesion size in the thoracic aorta of 
mice transplanted with Ccr1-/- bone marrow. They explained these results with the fact, 
that in their hands Ccr1-/- mice showed enhanced basal and concanavalin A-stimulated 
IFN-γ production by splenic T cells and enhanced plaque inflammation. In their 
conclusion they state that, blood-borne Ccr1 alters the immuno-inflammatory response 
in atherosclerosis and prevents excessive plaque growth and inflammation.274,276 In line 
with these findings Braunersreuther et al. found that lesion formation, T cell numbers, 
and IFN-γ content were increased in Apoe−/−Ccr1−/− mice after 12 weeks HFD but not 
after 4 weeks HFD. Furthermore the group was able to show that atherosclerotic lesion 
formation was reduced in Apoe−/−Ccr5−/− mice. They concluded that lesional 
macrophage content and TH1-related Tim3 expression were reduced, and SMC content 
and expression of IL-10 in plaques were elevated.133 These results are in contrast to a 
study performed by Söhnlein and Drechsler et al., in which the authors analyzed distinct 
functions of chemokine receptor axes in the atherogenic mobilization and recruitment of 
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classical monocytes. The authors were able to demonstrate that Apoe−/−Ccr1−/− mice 
developed significantly lesser atherosclerotic lesions after 4 weeks HFD, which was 
accompanied by an absolute reduction in macrophages and classical monocytes in the 
aorta of these animals when compared to the Apoe−/− control. Furthermore the study 
showed that after 8 weeks of HFD Apoe−/−Ccr1−/− mice still had reduced atherosclerotic 
plaque burden but that did not reach significance, although a significant reduction in 
aortic classical monocytes was observed.134  
Unfortunately, none of these studies looked into the regulatory T cell pool. Since we 
were able to demonstrate that Ccl3 signals via Ccr1 to restrain Tregs and to push 
differentiation of naïve T cells towards pro-inflammatory subtypes, such as TH1 and 
TH17, we hypothesized that Ccr1 deficiency would lead to an increase in the regulatory 
T cell pool and thereby reduce atherosclerotic lesion formation. Hence, we wanted to 
investigate the role of Ccr1 during the onset of atherosclerosis and analyze the 
regulatory T cell compartment. For this purpose, we used Apoe-/-Ccr1-/- mice and fed 
them a HFD for 12 weeks. We analyzed the atherosclerotic lesion formation in the aortic 
root, the aortic arch and in the thoracoabdominal and observed, contrary to the 
previously mentioned studies by Potteaux, et al. and Braunersreuther et al., a significant 
reduction in atherosclerotic lesion formation in Apoe-/-Ccr1-/- mice. No alterations were 
observed concerning the weight of the mice, nor in the cholesterol or triglyceride plasma 
levels or the Ccl3 plasma levels. These results could be explained by a reduction in the 
plaque macrophage content and an increase in SMC in the plaque. We also observed in 
line with our hypothesis increased frequencies of Tregs in lymphoid tissues.  
Another study performed in a different disease model was more in line with our results. 
The authors tested whether Ccl3, and its receptors, Ccr1 and Ccr5, can prevent 
radiation-induced lung inflammation and fibrosis. Irradiated mice lacking Ccl3 or its 
receptor, Ccr1, did not develop lung inflammation, fibrosis, and decline in lung function 
seen in irradiated wild-type mice. Interestingly, mice deficient for Ccr5 were not 
protected from radiation-induced injury and fibrosis.278 Several studies came to similar 
results. For example anti-Ccr1 treatments, reduce bleomycin-induced inflammation and 
collagen deposition.279-281 Other studies showed that Ccr1 deficiency protects from 
hepatic fibrosis282 and renal fibrosis.283 A number of small molecule antagonists of Ccr1 
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have been generated so far;284,285 a study using a specific Ccr1 antagonist (BX-471) 
showed protection against acute pancreatitis-associated lung injury by modulating 
neutrophil recruitment.286 Some of these small molecule antagonists even have entered 
into clinical trials;287 for example BX-471 for multiple sclerosis,288,289 CP-481715290 for 
rheumatoid arthritis (RA),291-293 AZD-4818294 for chronic obstructive pulmonary 
disease,295 and MLN-3897296 also for RA.297 Unfortunately, these antagonists failed to 
achieve their targeted clinical end points in phase 2 studies. Several scientists have 
discussed that failures of these mentioned studies and assumed that insufficient 
outcomes were due to inadequate blockade of the Ccr1 receptor over the course of the 
trial.298,299  
The role of Ccr1 in chronic inflammations, especially in atherosclerosis, still remains 
controversial and needs further characterization. One might argue the need of the Cre-
Lox recombination system for cell specific deletion of Ccr1. Placing the Cre recombinase 
gene after, for example the promotor of Foxp3, would allow for deletion of Ccr1 
specifically in Treg cells, and therefore allowing us to study the effect of Ccr1 deficiency 
in Tregs during atherosclerotic lesion formation. 
4.4. Ccr8 – a new receptor for Ccl17 
Following the discovery that Ccl17 mediates Ccl3 secretion by DCs, and that plasma 
Ccl3 levels are useful read outs we continued analyzing Ccl3 concentrations using 
ELISA in plasma obtained from HFD studies previously performed in our lab. The results 
indicate that Ccr8 might be an alternative receptor for Ccl17 and led us to perform 
further binding studies involving Ccl17 and Ccr8. Besides classical biochemical analysis 
using BIAcore technology, we were also able to confirm binding of Ccl17 to Ccr8 via a 
proximity ligation assay and confirmed signaling in transfected Glosensor-HEK293 cells 
via luciferase assay. In addition, other studies pointed towards Ccr8 as a receptor for 
Ccl17113,114 but till now had to be considered with caution, as they have been questioned 
by others.115,116 Islam, et al. argued in their study that chemokine receptors typically 
undergo internalization upon chemokine agonist binding. Therefore, they conducted 
internalization assays, using Ccr8-transfected cells. The authors showed that surface 
Ccr8 expression on Ccr8-transfected cells was reduced after treatment with increasing 
concentrations of Ccl18 or Ccl1 but not Ccl17 for 20 min at 37°C. These results led to 
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the assumption that Ccl17 cannot be a ligand of Ccr8. This does not necessarily be true. 
Mariani, et al. performed an interesting study where they compared Ccl17- and Ccl22-
dependent Ccr4 internalization as a mechanism of receptor availability and function on 
human Th2 cells. They demonstrated that Ccl22 is a strong inducer of Ccr4 
internalization, while Ccl17 is not. Nonetheless, Ccl17 is a strong chemotactic factor for 
Ccr4 expressing cells.300 Taken together we and others were able to convincingly 
demonstrate that Ccl17 binds to Ccr8, and indicate that Ccr8 might be involved in Ccl17-
dependent secretion of Ccl3, since deficiency in Ccl17 resulted in decreased plasma 
Ccl3 levels. Further experiments need to be conducted, confirming the Ccl17-Ccr8-Ccl3 
axis. 
Ccr8 is expressed in TH2 cells,
301 Tregs,114 DCs,302 monocytes303 and macrophages304 
and is involved in various disease conditions. So far not much is known about Ccr8 and 
its specific role in chronic inflammatory settings. Especially its involvement in 
atherosclerosis has still to be clarified. Several studies attribute Ccr8 expressed on TH2 
cells to the development of allergic inflammation.301 It was shown that Ccr8 is 
preferentially expressed on TH2 cells and Ccr4, Ccr8, and Cxcr3 ligands are increased in 
asthma,301,305,306 but also in atopic dermatitis.307 These effects are mainly mediated by 
the expression of Ccr8 on TH2 cells and do not explain the role of Ccr8 on the myeloid 
lineage. Moreover, Ccr8 expression on Tregs is implicated in sustaining their survival 
e.g. in graft versus host disease308 most likely through pronounced interaction of Ccl1 
with Ccr8 on Tregs underlining the pivotal role of Ccr8+ Treg cells in restraining immunity 
and controlling inflammation.309 In the absence of Ccl17 interaction of Ccl1-Ccr8 might 
further be strengthened adding to the protective effects observed in Ccl17-deficient 
mice. Likewise, Ccr8 expression has been reported on DCs, which migrate towards its 
major ligand Ccl1.310 To investigate the function of Ccr8 in macrophages, Oshio, et al. 
compared cytokine secretion from mouse peritoneal macrophages or bone marrow-
derived macrophages stimulated with various Toll-like receptors (TLR) ligands in Ccr8-
deficient and wild-type mice. They observed that Ccr8-/- macrophages showed 
attenuated secretion of TNF-α, IL-6, and IL-10 when stimulated with LPS. The authors 
were also able to show that Ccr8-dependent cytokine secretion was a characteristic of 
peritoneal macrophages but not of bone marrow-derived macrophages.311 Therefore, 
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antagonism of Ccr8 may be beneficial in ameliorating or preventing inflammatory events. 
First attempts to identify pharmacological antagonists of Ccr8 have been made but did 
not yet have convincing effects.312-314  
The role of Ccr8 in chronic inflammatory settings, especially in atherosclerosis, still 
needs to be elucidated. In addition, similar to Ccr1, a Cre-Lox recombination system for 
cell specific deletion of Ccr8 would be a helpful tool to dissect cell specific effects of 
Ccr8 and its involvement in chronic inflammatory disorders. 
4.5. Ccl5-Ccl17 heterodimers 
Nesmelova et al. wrote that, the apparent complexity of biology increases, as more 
biomolecular interactions that mediate function become known.315 Interactions between 
chemokines in a given microenvironment may amplify, inhibit, or modulate their activity. 
For instance, homo-oligomerization of Ccl5 is essential for its chemotactic functions. 
Baltus, et al. found that higher order Ccl5 oligomers were needed for Ccr1-mediated 
arrest but not for Ccr5-mediated spreading/transmigration in flow or transendothelial 
chemotaxis of leukocytes. They claimed that efficient leukocyte arrest in flow but not 
transmigration may require the presentation of Ccl5 oligomers to bridge surface-bound 
Ccl5 and Ccr1.316 These data demonstrate quite nicely the level of complexity emerging 
in chemokine biology, as we should keep in mind that different order chemokine homo-
oligomers bare potential to different modes of regulation. Recently it also came to our 
understanding, that chemokine heterodimerization represents an additional regulatory 
mechanism. A study performed by Nesmelova et al. was able to demonstrate that 
tetrameric platelet factor 4 (PF4/ Cxcl4) and dimeric IL-8 (Cxcl8), two members of the 
CXC chemokine family, interact. Thereby they exchange subunits and form 
heterodimers through extension of their antiparallel beta-sheet domains.315 Furthermore, 
Hundelshausen, et al. demonstrated that Cxcl4 enhanced the arrest of Ccl5-stimulated 
monocytes on activated endothelial cells under flow conditions, while binding of Cxcl4 to 
the monocyte surface was increased by Ccl5. These effects were conducted via 
heterophilic interaction of Cxcl4 with Ccl5.231 In a follow-up study the same authors were 
able to determine structural features of Ccl5-Cxcl4 heterodimers. These data led to 
designing stable peptide inhibitors that could specifically disrupt Ccl5-Cxcl4 interactions. 
The authors also showed that these peptides reduced atherosclerotic lesion formation 
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via reduced monocyte infiltration. These results clearly establish the in vivo relevance of 
chemokine heteromers and show the potential of targeting heteromer formation to 
achieve therapeutic effects.138  
Hundelshausen et al. identified, in an unbiased bidirectional immunoblot chemokine 
screening and through surface plasmon resonance, heteromeric interactions between 
pairwise combinations of all known human chemokines.317 The study found that neither 
CC chemokines that adopt unusual polymeric or unique monomer states (Ccl3, Ccl4, 
and Ccl18),137,318 nor transmembrane chemokines (CX3CL1 and Cxcl16) formed 
heteromers. With the exception of Ccr7 ligands, only some non-mucosal homeostatic 
chemokines or plasma chemokines activated by N-terminal cleavage319 engaged in 
interactions.317 One promising heterodimer pair that was discovered by Hundelshausen 
et al. was Ccl5-Ccl17. Using an in situ proximity ligation assay, we were able to detect 
these Ccl5-Ccl17 complexes on the surface of in vitro activated endothelial cells, after 
incubation with both chemokines. Ccl5-Ccl17 heterodimers were also shown to be 
present in lymph node sections of wild type mice, as well as in the plaque shoulder 
region in aortic roots of mice fed a HFD for 12 weeks. On DCs, which express both Ccr4 
and Ccr5, Ccl5-Ccl17 heterodimers were observed on the cell surface, when stimulating 
with both chemokines. Interestingly, we also observed Ccr4-Ccr5 complexes that were 
constitutively present. Using the disruptive peptide CAN, Ccl5-Ccl17 heterodimer 
formation could be inhibited, demonstrating that heterodimerization can be disrupted by 
peptides. Interestingly, we observed an increase of Ccr4-Ccr5 complexes when 
combining Ccl5 and Ccl17 but not by either alone. Moreover, when stimulating the DCs 
with Ccl5 and Ccl17 we observed increased binding of Ccl17 to Ccr4 (but not binding of 
Ccl5 to Ccr5), as well as increased ligand-receptor cross-interactions. This means that 
interactions between Ccl5 and Ccr4 where detectable as well as interactions between 
Ccl17 and Ccr5. This effect was impaired by CAN, thus being mediated by Ccl5-Ccl17 
heterodimers, and disrupted by Ccr5-derived peptides spanning transmembrane 1 and 4 
motifs as seen for Ccr5 homodimers. 
Moreover, we were able to show that migration toward Ccl5-Ccl17 heterodimer was 
synergistically increased when compared to single stimulated controls and was inhibited 
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by the peptide CAN, indicating that the increase in migration is synergistically mediated 
by the complex rather than being an addition of the effects of both single chemokines. 
In general, activation of chemokine receptors requires a two-site binding mechanism. 
Hereby the chemokine N-loop or core domain of the chemokine interacts with the 
receptor N terminus (site I). Furthermore, the chemokine N terminus interacts with the 
extracellular residues of the receptor (site II).320 It is believed that dependent on their 
quaternary state, chemokine’s are able to play different biological roles. Monomers are 
believed to be the receptor-binding unit, whereas dimers have been implicated in 
binding cell surface glycosaminoglycan’s. In a study performed by Qin, et al. the authors 
were able to model the structure for binding of the atypical CC chemokine vMIP-II to 
Cxcr4. These models suggest and support findings that CC chemokine homodimers are 
not able to neither bind nor activate receptors because the dimerization interface largely 
overlaps with an intermediate recognition site.321,322 However, this may not be true to all 
chemokine-receptor interactions because N-terminal and core structures in a CC-type 
heterodimers may be differently presented to receptors. Instead, binding may involve 
receptor complexes enabling synergy.  
The idea that CC-type heterodimers can induce the formation of corresponding receptor 
complexes, requiring Ccr5 transmembrane regions is supported by concomitant peptide-
based disruption of Ccl5-Ccl17 and Ccr4-Ccr5 formation and function.322 The fact that 
chemokine N-terminal residues are crucial elements during receptor activation320 
indicates that they may also play a role in the mechanisms of action for heterodimers. 
For example, N-terminal sequence variations may cause differences in N-terminal 
orientation and/or accessibility between Ccl17-Ccl5 heterodimers and Ccl5 homodimers 
to affect receptor binding and activation. Jin, et al. for instance were able to demonstrate 
that in a disulfide-trapped Ccl4 variant, dissociation of Ccl4 homodimers may be 
required to accomplish receptor binding and activation by a monomer.323 In this study, 
they showed that the disulfide-trapped Ccl4 variant binds to a heparin-sepharose 
column as strong as the wild type protein and stronger than monomeric variants. 
Nonetheless, the disulfide-trapped Ccl4 variant was not able to neither bind nor activate 
the Ccl4 receptor Ccr5. The group showed that the ability to activate Ccr5 was 
recovered after reduction of the intermolecular disulfide cross-link.323 This work clearly 
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demonstrated that Ccl4 dimers are not able to bind or activate its receptor and 
evidenced that the CC chemokine monomer is the sole receptor-interacting unit. This 
may also hold true for chemokine heterodimers, namely, Ccl5-Ccl17, when addressing 
respective heterodimers.323 
The rise in efficacy of Ccl5-bearing heterodimers may be explained by several aspects. 
For instance, Ccr5 antagonists inhibited both Ccl5-Cxcl4– and Ccl5-Ccl17–induced 
arrest. Therefore, CC-type heterodimers can modulate Ccr5 functionality, converting it 
into an arrest receptor such as Ccr1 (requiring Ccl5 oligomers and extracellular loop 3 
for sensing).132,316,324 Usage of a GAG binding–impaired Cxcl4 (GAG binding–impaired 
through mutation Cxcl4R>Q), which is still able to form heterodimers with CCL5, showed 
that synergy with Ccl5 depends on increased cell surface presentation. This hinders 
Ccr1 internalization and thereby sustains its signaling activity.317 Finally several studies 
support a functional role of heteromer formation in disease models. For instance, 
treatment of ApoE-deficient mice with the disruptive peptide CAN reduce atherosclerotic 
lesion formation by promoting Treg homeostasis. This shows that Ccl5-Ccl17 
heterodimers can be prevented (by disruptive peptides) and this reduces atherosclerotic 
lesion formation.317 Similar results were seen in studies using CKEY peptide (inhibiting 
formation of Ccl5-Cxcl4). In these studies CKEY limits atherosclerosis and acute lung 
injury by interfering with residues crucial for heterodimerization.138,325   
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5. Summary 
This work focused on the understanding of the pathophysiological role of the chemokine 
Ccl17 in the course of atherosclerosis and its effect on the biology of regulatory T cells 
(Treg). Atherosclerosis is a chronic inflammation of the vessel wall. The 
pathomechanism of atherosclerosis involves the inflammatory recruitment of leukocytes, 
which play a central role in the initiation and progression of atherosclerotic lesions. In 
addition to monocytes/macrophages, mainly dendritic cells (DCs) and T cells are 
detected in atherosclerotic plaques. Moreover, the DC-derived chemokine Ccl17 is also 
present in atherosclerotic plaques and in addition, Ccl17 interacts with the chemokine 
receptor Ccr4 and induces migration of T cells. 
Previous studies conducted in our group have shown that in ApoE-deficient mice, Ccl17 
deficiency leads to smaller atherosclerotic lesions. This result was accompanied by 
elevated levels of Tregs. While Ccl17 deficiency had an atheroprotective effect, studies 
in Ccr4-deficient animals showed no improved clinical picture. Therefore, we 
investigated which Ccl17 induced mechanisms are dependent on Ccr4 and which are 
independent of Ccr4. We could for example show that expression of Ccl17 by DCs leads 
to an increased migration of CD4+ T cells in vitro and in vivo and limits the expansion of 
Tregs by restricting their maintenance. While Ccl17-induced migration of T cells occurs 
via signaling through its receptor Ccr4, the Ccl17-dependent restriction of Tregs occurs 
independent of Ccr4. Furthermore, we discovered that Ccl17 itself, does not affect T cell 
polarization directly, but rather influences the phenotype of DCs through autocrine 
stimulation, leading to the secretion of pro-inflammatory mediators such as Cxcl10 and 
Ccl3. While Ccl17-dependent secretion of Cxcl10 by DCs was Ccr4-dependent, 
secretion of Ccl3 by DCs was independent of Ccr4, indicating that Ccl3 might be 
responsible for mediating restriction of Tregs. Subsequent experiments indeed 
confirmed that Ccl3 deficiency phenocopies the effects seen in Ccl17-deficient mice, 
abrogating atherosclerotic lesion development through induction of Treg.  
The pro-inflammatory chemokine Ccl3 was shown to directly restrict Tregs via signaling 
through its chemokine receptor Ccr1. Furthermore, using T cell polarization assays we 
were able to demonstrate that Ccl3 not just restricted polarization of Tregs but also 
induced the expression of the transcription factors RorγT and Tbet, therefore inducing 
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TH17 and TH1 responses respectively. Ccr1 deficiency diminished atherosclerotic lesion 
formation and enhanced Treg numbers. Moreover, this study was able to proof Ccl17 
binding to the chemokine receptor Ccr8 and subsequent Gi coupled signaling, 
introducing Ccr8 as a new alternative receptor for Ccl17.  
Furthermore this work evaluated the concept of chemokine heterodimerization and gave 
new insight into the broad mechanisms of Ccl17 biology. This study confirmed the 
formation of Ccl5-Ccl17 heterodimers and revealed that chemokine activity can be 
enhanced by CC-type heterodimers. As an example Ccl5-Ccl17 heterodimers show 
synergistic effects resulting in increased migration of T cells. In addition, Ccl5-Ccl17 
heterodimers induce more efficient T cell arrest and provoke more efficient binding of 
Ccl17 to Ccr4. Furthermore, it was demonstrated that functional synergism, seen with 
Ccl5-Ccl17 heterodimers, was achieved through heterodimerization of the receptors 
Ccr4 and Ccr5. The synergistic effects of Ccl5-Ccl17 heterodimers could be inhibited by 
a peptide-based inhibitor (a Ccl5-derived peptide which forms part of the heterodimer 
interface with Ccl17) named CAN. Thus, this study provides evidence that formation of 
specific chemokine heterodimers broadens their functional activity. 
Since atherosclerosis is being characterized as a chronic inflammatory disease of the 
vessel wall, one might reason that breaking the chronic inflammatory cycle and inducing 
resolution of inflammation would not only stop disease progression but also induce 
lesion regression. Here we depicted the manifold modes of action of DC derived 
chemokine Ccl17 on maintaining chronic inflammation. The data presented in this thesis 
point at a possible mechanism to pharmacologically induce resolution of inflammation by 
blocking either Ccl17 or Ccl3 or inhibiting either the receptor Ccr8 (Ccl17) or Ccr1 (Ccl3), 
thereby enhancing Treg numbers thus supporting control of (chronic) inflammation. 
Furthermore, targeting the formation of specific chemokine heterodimers by peptide-
based inhibitors demonstrates a new and alternative area to be exploited for therapeutic 
targeting.  
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6. Zusammenfassung 
Diese Arbeit konzentriert sich auf die Klärung der pathophysiologischen Rolle des 
Chemokins Ccl17 im Verlauf der Atherosklerose und seine Wirkung auf die Biologie 
regulatorischer T Zellen (Treg). Unter Atherosklerose, ist eine chronische Entzündung 
der Gefäßwand zu verstehen. Der Pathomechanismus der Atherosklerose beinhaltet die 
inflammatorische Rekrutierung leukozytärer Zellen, welche eine zentrale Bedeutung für 
die Initiierung und Progression atherosklerotischer Läsionen spielen. Neben 
Monozyten/Makrophagen sind es vor allem dendritische Zellen und T Zellen die in 
atherosklerotischen Läsionen detektiert werden können. Ccl17, ein Chemokin welches 
von dendritischen Zellen sekretiert wird, ist ebenfalls in atherosklerostischen Läsionen 
vorhanden. Außerdem aktiviert Ccl17 den Chemokinrezeptor Ccr4 und induziert die 
Migration von T Zellen. 
Frühere Studien, die in unserer Gruppe durchgeführt wurden haben gezeigt, dass in 
ApoE-defizienten Mäusen eine Ccl17 Defizienz zu kleineren atherosklerotischen 
Läsionen führt. Dieses Ergebnis ging einher mit erhöhten Werten an regulatorischen T 
Zellen. Während sich eine Ccl17 Defizienz atheroprotektiv auswirkt, zeigten Studien in 
Ccr4-defizienten Tieren kein verbessertes Krankheitsbild. Daher wurde in dieser Arbeit 
untersucht welche Ccl17-induzierten Mechanismen abhängig von Ccr4 ablaufen und 
welche unabhängig von Ccr4 verlaufen.  
Diese Arbeit konnte zum Beispiel zeigen, dass Ccl17, Ccr4 abhängig, die Migration von 
CD4+ T Zellen in vitro und in vivo induziert. Andererseits limitierte Ccl17, Ccr4 
unabhängig, die Expansion regulatorischer T Zellen. Dabei beeinflusste Ccl17 nicht 
selbst die Polarisierung naiver T Zellen, sondern stimulierte dendritische Zellen autokrin, 
was dazu führte, dass diese wiederum pro-inflammatorische Chemokine sekretierten, 
namentlich Cxcl10 (Ccr4 abhängig) und Ccl3 (Ccr4 unabhängig). Des Weiteren konnte 
gezeigt werden, dass eine Ccl3 Defizienz die Effekte einer Ccl17 Defizienz kopiert. 
Dabei wurde eine Reduktion atherosklerotischer Läsionen beobachtet, welche mit einer 
Erhöhung der regulatorischen T Zellzahlen einherging. Ccl3 inhibierte dabei die Treg 
Differenzierung abhängig von Ccr1. Eine Ccr1 Defizienz reduzierte außerdem die 
Bildung von atherosklerotischen Läsionen und erhöhte die Anzahl regulatorischer T 
Zellen. Weiterhin konnte belegt werden, dass Ccl17 an den Chemokinrezeptor Ccr8 
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bindet und ein Gi gekoppeltes Signal induziert. Weitere Studien müssen noch zeigen, 
dass die Ccl17 vermittelte Sekretion von Ccl3 über die Aktivierung von Ccr8 verläuft. 
Darüber hinaus beschäftigte sich diese Arbeit mit dem Konzept der Chemokin- 
heterodimerisierung und ermöglichte neue Einblicke in die komplexe Biologie des 
Chemokins Ccl17. Diese Studie bestätigte die Bildung von Ccl5-Ccl17-Heterodimeren 
und zeigte, dass die Chemokinaktivität durch Heterodimere vom CC-Typ verstärkt 
werden konnte. Zum Beispiel zeigten sich synergistische Effekte durch Induktion einer 
erhöhten Migration. Desweitern zeigten unsere Ergebnisse, dass Ccl5-Ccl17-
Heterodimere einen effizienteren T-Zell-Arrest induzieren und eine effizientere Bindung 
von Ccl17 an Ccr4 bewirken. Weiterhin konnten wir demonstrieren, dass ein 
funktioneller Synergismus mit Ccl5-Ccl17 Heterodimeren durch Heterodimerisierung der 
Rezeptoren Ccr4 und Ccr5 erreicht wird. Die synergistischen Effekte von Ccl5-Ccl17-
Heterodimeren konnten außerdem durch einen peptid-basierten Inhibitor (ein von Ccl5 
abgeleitetes Peptid, das einen Teil der Heterodimer-Schnittstelle mit Ccl17 bildet), 
genannt CAN, inhibiert werden.  
Atherosklerose ist als chronisch-entzündliche Erkrankung der Gefäßwand 
charakterisiert, daher zielen mögliche therapeutische Ansätze auf eine Reduktion der 
Entzündung und eine Regression der atherosklerotischen Läsionen ab. Diese Arbeit 
beschreibt die vielfältigen Wirkungsweisen des Chemokins Ccl17 und dessen Rolle 
beim Aufrechterhalten der chronischen Entzündung. Die in dieser Arbeit präsentierten 
Daten zeigten einen möglichen Mechanismus um pharmakologisch die Auflösung von 
Entzündungsreaktionen zu induzieren, indem entweder Ccl17 oder Ccl3 blockiert oder 
deren Rezeptoren Ccr8 (Ccl17) oder Ccr1 (Ccl3) inhibiert werden. Darüber hinaus 
konnte gezeigt werden, dass die Bildung spezifischer Chemokin-Heterodimere durch 
peptid-basierte Inhibitoren unterbunden werden kann.   
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8. Supplement 
 
Supplemental table 1: Circulating leukocyte subpopulations of Apoe
-/- 
and Apoe
-/-
Ccl17
e/e
 mice. 
Peripheral blood leukocyte subsets were measured by flow cytometry. All values are displayed as mean ± 
SEM (n=10-11). 
  
Supplemental table 2: Bone Marrow leukocyte subpopulations of Apoe
-/- 
and Apoe
-/-
Ccl17
e/e
 mice. 
Bone Marrow leukocyte subsets were measured by flow cytometry. All values are displayed as mean ± 
SEM (n=10-11). 
 
Figure 4
Blood
12 weeks HFD Apoe-/- Apoe-/-Ccl17e/e p-Value
Leukocytes/ml
2,6x1006
± 1,7x1005
2,9x1006
± 2,4x1005
0,28
Gr1+ monocytes/ml
6,5x1004
± 6,7x1003
6,1x1004
± 7,1x1003
0,68
Gr1- monocytes/ml
3,4x1004
± 4,3x1003
4,3x1004
± 7,5x1003
0,33
Neutrophils/ml
5,1x1005
± 3,6x1004
7,2x1005
± 1,3x1005
0,14
B cells/ml
1,4x1006
± 1,0x1005
1,4x1006
± 1,5x1005
0,63
CD3+ T cells/ml
1,9x1005
± 1,9x1004
1,9x1005
± 1,0x1004
0,83
CD4+ T cells/ml
1,1x1005
± 1,3x1004
1,3x1005
± 6,4x1003
0,18
CD8+ T cells/ml
4,0x1004
± 5,6x1003
4,5x1004
± 3,5x1003
0,49
Platelets/ml
2,6x1006
± 1,7x1005
2,9x1006
±2,4x1005
0,28
All values are displayed as mean ± SEM and P-value (n= 10-11).
BM
12 weeks HFD Apoe-/- Apoe-/-Ccl17e/e p-Value
Leukocytes/ml
7,09x1006
± 1,07x1006
8,31x1006
± 5,92x1005
0,367
Gr1+ monocytes/ml
4,76x1005
± 5,93x1004
6,44x1005
± 7,02x1004
0,098
Gr1- monocytes/ml
1,54x1005
± 1,27x1004
1,74x1005
± 1,60x1004
0,351
Neutrophils/ml
2,67x1006
± 4,95x1005
3,36x1006
± 3,44x1005
0,295
B cells/ml
1,25x1007
± 1,37x1006
1,61x1007
± 1,39x1006
0,094
cDCs/ml
1,63x1005
± 1,68x1004
1,48x1005
± 1,55x1004
0,530
pDCs/ml
4,53x1005
± 4,56x1004
5,10x1005
± 5,26x1004
0,440
Macrophages/ml
9,05x1004
± 1,42x1004
7,45x1004
± 5,21x1003
0,347
All values are displayed as mean ± SEM and P-value (n= 10-11).
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Supplemental table 3: Splenic leukocyte subpopulations of Apoe
-/- 
and Apoe
-/-
Ccl17
e/e
 mice. Splenic 
leukocyte subsets were measured by flow cytometry. All values are displayed as mean ± SEM (n=10-11). 
 
 Supplemental table 4: Para-aortic lymph node leukocyte subpopulations of Apoe-/- and Apoe-/-
Ccl17
e/e
 mice. Para-aortic lymph node leukocyte subsets were measured by flow cytometry. All values are 
displayed as mean ± SEM (n=10-11). 
  
Spleen
12 weeks HFD Apoe-/- Apoe-/-Ccl17e/e p-Value
Leukocytes/ml
5,12x1007
± 5,40x1006
6,62x1007
± 7,69x1006
0,120
Gr1+
monocytes/ml
6,75x1005
± 8,77x1004
1,15x1006
± 8,20x1005
0,077
Gr1-
monocytes/ml
4,84x1005
± 7,33x1004
8,20x1005
± 1,62x1005 0,067
Neutrophils/ml
1,21x1006
± 1,32x1005
2,31x1006
± 6,36x1005 0,091
B cells/ml
2,12x1007
± 2,48x1006
2,99x1007
± 3,91x1006 0,070
CD3+ T cells/ml
1,20x1007
± 1,38x1006
1,67x1007
± 2,07x1006 0,068
CD4+ T cells/ml
8,64x1006
± 9,68x1005
1,67x1007
± 1,50x1006 0,068
CD8+ T cells/ml
2,31x1006
± 2,81x1005
3,35x1006
± 4,94x1005 0,079
cDCs/ml
1,80x1006
± 2,04x1005
1,63x1006
± 3,31x1005 0,670
pDCs/ml
3,97x1005
± 1,41x1005
4,94x1005
± 7,99x1004 0,568
Macrophages/ml
1,81x1006
± 3,20x1005
2,01x1006
± 3,82x1005 0,696
All values are displayed as mean ± SEM and P-value (n= 10-11).
para-aortic Lymph Node
12 weeks HFD Apoe-/-
Apoe-/-
Ccl17e/e p-Value
Leukocytes/ml
2,13x1006
± 3,83x1005
1,67x1006
± 1,04x1006
0,385
Gr1+ monocytes/ml
6,70x1003
± 1,40x1003
4,18x1003
± 2,49x1003
0,147
Gr1- monocytes/ml
3,42x1004
± 5,22x1003
1,80x1004
± 1,27x1004
0,044
B cells/ml
6,97x1005
± 1,17x1005
5,48x1005
± 4,05x1005
0,412
CD3+ T cells/ml
8,83x1005
± 1,87x1005
7,60x1005
± 5,04x1005
0,632
CD4+ T cells/ml
6,24x1005
± 1,24x1005
5,66x1005
± 3,75x1005
0,746
CD8+ T cells/ml
2,13x1005
± 5,47x1004
1,69x1005
± 1,17x1005
0,532
cDCs/ml
1,75x1004
± 3,45x1003
1,54x1004
± 1,10x1004
0,690
pDCs/ml
5,50x1003
± 1,10x1003
4,30x1003
± 3,01x1003
0,436
All values are displayed as mean ± SEM and P-value (n= 10-11).
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Supplemental table 5: Circulating leukocyte subpopulations of Apoe
-/- 
and Apoe
-/-
Ccr4
-/-
 mice. 
Peripheral blood leukocyte subsets were measured by flow cytometry. All values are displayed as mean ± 
SEM (n=9-10). 
  
Supplemental table 6: Bone marrow leukocyte subpopulations of Apoe
-/- 
and Apoe
-/-
Ccr4
-/-
 mice. 
Bone marrow leukocyte subsets were measured by flow cytometry. All values are displayed as mean ± 
SEM (n=9-10). 
  
Blood
12 weeks HFD Apoe-/- Apoe-/-Ccr4-/- p-Value
Leukocytes/ml
4,60x1006
± 5,02x1005
3,31x1006
± 1,87x1005
0,062
Gr1+
monocytes/ml
2,40x1005
± 2,60x1004
1,87x1005
± 2,41x1004
0,155
Gr1-
monocytes/ml
2,23x1005
± 3,48x1004
1,40x1005
± 2,17x1004
0,065
Neutrophils/ml
1,12x1006
± 1,12x1005
8,43x1005
± 7,53x1004
0,073
B cells/ml
1,80x1006
± 1,91x1005
1,37x1006
± 2,019x1005
0,143
CD3+ T 
cells/ml
5,24x1005
± 7,95x1004
3,62x1005
± 3,55x1004
0,071
CD4+ T 
cells/ml
2,64x1005
± 4,07x1004
1,87x1005
± 1,70x1004
0,094
CD8+ T 
cells/ml
2,06x1005
± 3,35x1004
1,32x1005
± 1,34x1004
0,064
Platelets/ml 6,19x1005
± 1,25x1005
7,49x1005
± 4,60x1004
0,285
All values are displayed as mean ± SEM and P-value (n= 9-10).
Bone Marrow
12 weeks HFD Apoe-/- Apoe-/-Ccr4-/- p-Value
Leukocytes/ml
1,2x1007
± 6,57x1005
9,76x1006
± 9,18x1005 0,055
Gr1+
monocytes/ml
1,02x1006
± 1,06x1005
8,10x1005
± 1,41x1005 0,235
Gr1-
monocytes/ml
3,97x1005
± 4,03x1004
3,26x1005
± 4,12x1004 0,237
Neutrophils/ml
4,92x1006 3,00x1006
0,009± 2,20x1005 ± 6,28x1005
B cells/ml
2,92x1006
± 2,31x1005
2,20x1006
± 6,12x1005 0,288
cDCs/ml
7,22x1004
± 6,48x1003
9,75x1004
± 1,99x1004 0,265
pDCs/ml
2,57x1005
± 1,95x1004
1,87x1005
± 1,70x1004 0,061
Macrophages/ml
2,06x1005
± 3,35x1004
3,87x1005
± 5,33x1004 0,092
All values are displayed as mean ± SEM and P-value (n= 9-10).
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Supplemental table 7: Splenic leukocyte subpopulations of Apoe
-/- 
and Apoe
-/-
Ccr4
-/-
 mice. Splenic 
leukocyte subsets were measured by flow cytometry. All values are displayed as mean ± SEM (n=9-10). 
  
Supplemental table 8: Para-aortic lymph node leukocyte subpopulations of Apoe
-/- 
and Apoe
-/-
Ccr4
-
/-
 mice. Para-aortic lymph node leukocyte subsets were measured by flow cytometry. All values are 
displayed as mean ± SEM (n=9-10). 
  
Spleen
12 weeks HFD Apoe-/- Apoe-/-Ccr4-/- p-Value
Leukocytes/ml
1,12x1008
± 5,69x1005
1,00x1008
± 1,27x1006 0,335
Gr1+
monocytes/ml
1,54x1006
± 9,55x1004
1,14x1006
± 2,37x1005 0,116
Gr1-
monocytes/ml
8,46x1005
± 1,31x1005
4,87x1005
± 1,26x1005 0,068
Neutrophils/ml
2,02x1006
± 2,16x1005
2,20x1006
± 3,57x1005 0,674
B cells/ml
5,49x1007
± 2,66x1006
4,54x1007
± 5,20x1006 0,143
CD3+ T cells/ml
2,89x1007
± 1,36x1006
2,86x1007
± 4,77x1006 0,975
CD4+ T cells/ml
1,79x1007
± 8,02x1005
1,65x1007
± 2,24x1006 0,718
CD8+ T cells/ml
5,56x1006
± 3,02x1005
5,17x1006
± 9,77x1005 0,733
cDCs/ml
8,60x1006
± 5,95x1005
9,91x1006
± 8,03x1005 0,148
pDCs/ml
2,59x1005
± 4,05x1004
2,89x1005
± 3,37x1004 0,687
Macrophages/ml
5,63x1005
± 4,78x1004
4,55x1005
± 5,01x1004 0,207
All values are displayed as mean ± SEM and P-value (n= 9-10).
Para-aortic Lymph Node
12 weeks HFD Apoe-/- Apoe-/-Ccr4-/- p-Value
Leukocytes/ml
5,27x1006
±7,72x1005
3,22x1006
± 7,34x1005 0,072
Gr1+
monocytes/ml
5,04x1003
± 7,28x1002
2,71x1003
± 4,98x1002 0,023
Gr1-
monocytes/ml
1,23x1004
± 2,11x1003
1,03x1004
± 1,76x1003 0,467
B cells/ml
2,24x1006
± 3,97x1005
1,39x1006
± 4,03x1005 0,125
CD3+ T cells/ml
1,57x1006
± 1,57x1005
1,20x1006
± 1,86x1005 0,085
CD4+ T cells/ml
8,57x1005
± 8,41x1004
6,56x1005
± 1,05x1005 0,100
CD8+ T cells/ml
4,81x1005
± 8,41x1004
3,48x1005
± 5,31x1004 0,060
cDCs/ml
2,04x1005
± 2,00x1004
1,52x1005
± 2,46x1004 0,039
pDCs/ml
7,76x1003
± 9,06x1002
8,34x1003
± 2,52x1003 0,882
Macrophages/ml
4,97x1003
± 1,08x1003
3,00x1003
± 2,83x1002 0,022
All values are displayed as mean ± SEM and P-value (n= 9-10).
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Supplemental table 9: Circulating leukocyte subpopulations of Apoe
-/- 
► Apoe
-/- 
and Apoe
-/-
Ccr4
-/-
 
► Apoe
-/- 
mice. Peripheral blood leukocyte subsets were measured by flow cytometry. All values are 
displayed as mean ± SEM (n=9-10). 
  
Supplemental table 10: Bone marrow leukocyte subpopulations of Apoe
-/- 
► Apoe
-/- 
and Apoe
-/-
Ccr4
-/-
 ► Apoe
-/- 
mice. Bone marrow leukocyte subsets were measured by flow cytometry. All values are 
displayed as mean ± SEM (n=9-10). 
   
Blood
12 weeks HFD Apoe-/- Apoe-/-
Apoe-/-Ccr4-/-
 Apoe-/-
p-Value
Leukocytes/ml
4,02x1006
± 4,47x1005
4,30x1006
± 6,32x1005 0,779
Gr1+
monocytes/ml
1,03x1005
± 2,44x1004
2,24x1005
± 1,48x1004 0,002
Gr1-
monocytes/ml
1,06x1005
± 2,28x1004
1,41x1005
± 2,58x1004 0,554
Neutrophils/ml
3,17x1005
± 7,44x1004
5,83x1005
± 5,21x1004 0,009
B cells/ml
2,11x1006
± 2,13x1005
1,98x1006
± 3,43x1005 0,697
CD3+ T cells/ml
2,63x1005
± 2,33x1004
1,06x1005
± 1,78x1004 0,498
CD4+ T cells/ml
1,22x1005
± 1,15x1004
1,06x1005
± 1,78x1004 0,508
CD8+ T cells/ml
1,19x1005
± 1,04x1004
1,03x1005
± 1,81x1004 0,378
Platelets/ml
6,69x1005
± 6,19x1004
4,89x1005
±9,75x1004 0,138
All values are displayed as mean ± SEM and P-value (n= 9-10).
12 weeks HFD
Blood
Apoe-/- Apoe-/-
Apoe-/-Ccr4-/- 
Apoe-/-
p-Value
Bone Marrow
12 weeks HFD Apoe-/- Apoe-/-
Apoe-/-Ccr4-/- 
Apoe-/-
p-Value
Leukocytes/ml
1,13x1007
± 4,66x1005
8,99x1006
± 1,14x1006 0,072
Gr1+
monocytes/ml
5,49x1005
± 3,39x1004
6,28x1005
± 9,71x1005 0,425
Gr1- monocytes/ml
1,36x1005
± 7,56x1003
1,28x1005
± 2,17x1004 0,704
Neutrophils/ml
1,99x1006
± 3,01x1005
2,62x1006
± 4,36x1005 0,010
B cells/ml
9,09x1005
± 5,95x1004
7,05x1005
± 1,22x1005 0,169
cDCs/ml
1,50x1005
± 1,70x1004
1,92x1005
± 1,95x1004 0,060
pDCs/ml
2,77x1005
± 1,15x1004
2,58x1005
± 3,73x1004 0,676
Macrophages/ml
3,69x1005
± 4,57x1004
5,41x1005
± 5,43x1004 0,030
Apoe-/-Ccr4-/-
Apoe-/-
- l
rr
All values are displayed as mean ± SEM and P-value (n= 9-10).
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Supplemental table 11: Splenic leukocyte subpopulations of Apoe
-/- 
► Apoe
-/- 
and Apoe
-/-
Ccr4
-/-
 ► 
Apoe
-/- 
mice. Splenic leukocyte subsets were measured by flow cytometry. All values are displayed as 
mean ± SEM (n=9-10). 
 
Spleen
12 weeks HFD Apoe-/- Apoe-/-Ccl17e/e p-Value
Leukocytes/ml
9,34x1007
± 5,98x1006
7,77x1007
± 5,04x1004 0,082
Gr1+
monocytes/ml
4,10x1005
± 4,95x1004
3,52x1005
± 5,04x1004 0,355
Gr1- monocytes/ml
1,98x1006
± 1,23x1004
1,04x1006
± 3,01x1004 0,015
Neutrophils/ml
8,18x1005
± 1,25x1005
9,41x1005
± 1,12x1005 0,569
B cells/ml
3,38x1007
± 4,18x1006
2,43x1007
± 2,71x1006 0,067
CD3+ T cells/ml
1,46x1007
± 7,56x1005
9,23x1006
± 1,81x1006 0,017
CD4+ T cells/ml
9,95x1006
± 5,39x1005
6,33x1006
± 1,13x1006 0,015
CD8+ T cells/ml
3,69x1006
± 1,90x1005
1,94x1006
± 4,47x1005 0,005
cDCs/ml
8,73x1006
± 6,95x1005
8,18x1006
± 6,36x1005 0,472
pDCs/ml
1,48x1005
± 2,11x1004
1,02x1005
± 1,65x1004 0,16
Macrophages/ml
1,55x1006
± 1,23x1005
1,03x1006
± 2,93x1004 0,128
12 eeks F Apoe-/- Apoe-/-
Apoe-/-Ccr4-/- 
Apoe-/- p-Value
Spleen
All values are displayed as mean ± SEM and P-value (n= 9-10).
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Supplemental table 12: Para aortic lymph node leukocyte subpopulations of Apoe
-/- 
► Apoe
-/- 
and 
Apoe
-/-
Ccr4
-/-
 ► Apoe
-/- 
mice. Para aortic lymph node leukocyte subsets were measured by flow 
cytometry. All values are displayed as mean ± SEM (n=9-10). 
 
 
 
 
 
 
 
 
 
Para-aortic Lymph Node
12 weeks HFD Apoe-/- Apoe-/-Ccl17e/e p-Value
Leukocytes/ml
1,42x1006
± 3,28x1005
2,24x1006
± 2,97x1005 0,060
Gr1+
monocytes/ml
1,49x1003
± 4,71x1002
3,13x1003
± 1,93x1002 0,027
Gr1- monocytes/ml
9,35x1004
± 2,38x1003
1,94x1005
± 1,02x1004 0,004
B cells/ml
1,95x1005
± 1,57x1005
5,36x1005
± 4,15x1004 0,053
CD3+ T cells/ml
3,27x1005
± 6,47x1004
4,56x1005
± 8,85x1004 0,191
CD4+ T cells/ml
2,42x1005
± 4,79x1004
3,43x1005
± 6,76x1004 0,181
CD8+ T cells/ml
7,03x1004
± 1,50x1004
8,35x1004
± 1,79x1004 0,488
cDCs/ml
9,10x1004
± 4,93x1004
2,42x1005
± 2,03x1004 0,012
pDCs/ml
1,62x1003
± 6,19x1002
2,93x1003
± 4,60x1002 0,082
Macrophages/ml
2,52x1003
± 1,31x1003
5,44x1003
± 7,15x1002 0,070
12 eeks F Apoe-/- Apoe-/-
Apoe-/-Ccr4-/- 
Apoe-/- p-Value
ara-aortic Ly ph ode
All values are displayed as mean ± SEM and P-value (n= 9-10).
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Supplemental table 13: Circulating leukocyte subpopulations of Apoe
-/- 
and Apoe
-/-
Ccl3
-/-
 mice. 
Peripheral blood leukocyte subsets were measured by flow cytometry. All values are displayed as mean ± 
SEM (n=8-10). 
  
Supplemental table 14: Bone marrow leukocyte subpopulations of Apoe
-/- 
and Apoe
-/-
Ccl3
-/-
 mice. 
Bone marrow leukocyte subsets were measured by flow cytometry. All values are displayed as mean ± 
SEM (n=8-10). 
   
Blood
12 weeks HFD Apoe-/- Apoe-/-Ccl3-/- p-Value
Leukocytes/ml
1,64x1006
± 1,34x1005
1,92x1006
± 2,94x1005 0,3,64
Gr1+
monocytes/ml
9,54x1004
± 1,40x1004
1,25x1005
± 2,00x1004 0,233
Gr1- monocytes/ml
3,97x1004
±4,44x1003
5,97x1004
± 1,08x1004 0,083
Neutrophils/ml
3,96x1005
±4,98x1004
3,94x1005
± 6,27x1004 0,981
B cells/ml
6,41x1005
± 8,76x1004
8,00x1005
± 1,20x1005 0,291
CD3+ T cells/ml
1,38x1005
± 1,25x1004
1,36x1005
± 2,18x1004 0,936
CD4+ T cells/ml
7,35x1004
± 7,72x1003
7,38x1004
± 1,19x1004 0,986
CD8+ T cells/ml
4,05x1004
± 4,43x1003
3,50x1004
± 5,14x1003 0,426
Platelets/ml
9,81x1005
± 1,35x1005
9,63x1005
± 5,65x1004 0,911
All values are displayed as mean ± SEM and P-value (n= 8-10).
Bone Marrow
12 weeks HFD Apoe-/- Apoe-/-Ccl3-/- p-Value
Leukocytes/ml
5,54x1006
± 1,83x1006
8,20x1006
± 7,98x1005 0,227
Gr1+
monocytes/ml
4,76x1005
± 1,84x1005
7,26x1005
± 7,40x1004 0,267
Gr1- monocytes/ml
7,14x1004
± 8,62x1003
9,45x1004
± 6,91x1003 0,062
Neutrophils/ml
1,99x1006
± 1,05x1006
3,27x1006
± 7,36x1005 0,308
B cells/ml
8,58x1005
± 9,53x1004
7,36x1005
± 1,49x1005 0,485
cDCs/ml
2,32x1005
± 2,06x1004
2,91x1005
± 2,20x1004 0,072
pDCs/ml
2,42x1005
± 1,92x1004
2,92x1005
± 3,61x1004 0,213
Macrophages/ml
1,96x1005
± 1,51x1004
2,31x1005
± 2,34x1004 0,211
All values are displayed as mean ± SEM and P-value (n= 8-10).
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Supplemental table 15: Splenic leukocyte subpopulations of Apoe
-/- 
and Apoe
-/-
Ccl3
-/-
 mice. Splenic 
leukocyte subsets were measured by flow cytometry. All values are displayed as mean ± SEM (n=8-10). 
 
Supplemental table 16: Para-aortic lymph node leukocyte subpopulations of Apoe
-/- 
and Apoe
-/-
Ccl3
-/-
 mice. Para-aortic lymph node leukocyte subsets were measured by flow cytometry. All values are 
displayed as mean ± SEM (n=8-10). 
  
Spleen
12 weeks HFD Apoe-/- Apoe-/-Ccl3-/- p-Value
Leukocytes/ml
6,211x1007
± 4,00x1006
5,01x1007
± 3,91x1006 0,052
Gr1+
monocytes/ml
1,18x1006
± 4,16x1005
4,60x1005
± 2,63x1005 0,147
Gr1-
monocytes/ml
3,08x1005
± 6,85x1004
1,55x1005
± 1,82x1004 0,064
Neutrophils/ml
4,04x1006
± 2,22x1006
1,20x1006
± 8,55x1005 0,272
B cells/ml
2,10x1007
± 1,54x1006
1,75x1007
± 1,76x1006 0,144
CD3+ T cells/ml
1,03x1007
± 1,84x1006
7,98x1006
± 8,63x1005 0,303
CD4+ T cells/ml
8,76x1006
± 6,61x1005
6,57x1006
± 7,44x1005 0,049
CD8+ T cells/ml
2,23x1006
± 2,49x1005
1,70x1006
± 1,23x1005 0,088
cDCs/ml
6,59x1004
± 5,38x1003
7,60x1004
± 1,35x1004 0,462
pDCs/ml
6,56x1003
± 4,95x1002
8,15x1003
± 1,32x1003 0,244
Macrophages/ml
2,33x1004
± 2,12x1004
4,87x1004
± 1,48x1004 0,072
All values are displayed as mean ± SEM and P-value (n= 8-10).
para-aortic Lymph Node
12 weeks HFD Apoe-/- Apoe-/-Ccl3-/- p-Value
Leukocytes/ml
2,81x1006
± 8,78x1005
1,68x1006
± 5,31x1005 0,317
Gr1+
monocytes/ml
6,41x1003
± 2,04x1003
5,88x1003
± 2,07x1003 0,859
Gr1-
monocytes/ml
6,21x1003
± 2,37x1003
1,03x1003
± 1,51x1002 0,07
B cells/ml
1,35x1006
± 5,24x1005
6,41x1005
± 1,97x1005 0,267
CD3+ T cells/ml
5,81x1005
± 1,41x1005
4,99x1005
± 1,91x1005 0,731
CD4+ T cells/ml
4,70x1005
± 1,14x1005
3,46x1005
± 1,12x1005 0,457
CD8+ T cells/ml
3,60x1005
± 5,92x1004
2,85x1005
± 5,66x1004 0,381
cDCs/ml
4,93x1005
± 2,58x1005
2,25x1004
±4,78x1004 0,374
pDCs/ml
2,91x1004
± 2,27x1005
1,27x1005
± 3,60x1004 0,363
All values are displayed as mean ± SEM and P-value (n= 8-10).
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Supplemental table 17: Circulating leukocyte subpopulations of Apoe
-/- 
and Apoe
-/-
Ccr1
-/-
 mice. 
Peripheral blood leukocyte subsets were measured by flow cytometry. All values are displayed as mean ± 
SEM (n=5-10). 
 
Supplemental table 18: Bone marrow leukocyte subpopulations of Apoe
-/- 
and Apoe
-/-
Ccr1
-/-
 mice. 
Bone marrow leukocyte subsets were measured by flow cytometry. All values are displayed as mean ± 
SEM (n=5-10). 
  
Blood
12 weeks HFD Apoe-/- Apoe-/-Ccr1-/- p-Value
Leukocytes/ml
1,68x1006
± 1,48x1005
2,02x1006
± 5,25x1005 0,474
Gr1+
monocytes/ml
1,06x1005
± 1,16x1004
1,32x1005
± 3,09x1004 0,369
Gr1-
monocytes/ml
1,46x1006
±2,48x1005
2,02x1006
± 5,25x1005 0,208
Neutrophils/ml
4,94x1005
±1,11x1005
7,28x1005
± 1,92x1005 0,279
B cells/ml
6,15x1005
± 7,54x1004
6,86x1005
± 1,94x1005 0,698
CD3+ T cells/ml
8,36x1004
± 1,33x1004
6,65x1004
± 2,65x1004 0,534
CD4+ T cells/ml
4,79x1004
± 8,69x1003
3,91x1004
± 1,66x1004 0,614
CD8+ T cells/ml
1,83x1004
± 3,54x1003
1,70x1004
± 7,30x1003 0,858
Platelets/ml
1,16x1006
± 1,36x1005
8,90x1005
± 1,23x1005 0,295
All values are displayed as mean ± SEM and P-value (n= 5-10).
Bone Marrow
12 weeks HFD Apoe-/- Apoe-/-Ccr1-/- p-Value
Leukocytes/ml
4,91x1006
± 1,53x1006
1,13x1007
± 2,91x1006 0,002
Gr1+
monocytes/ml
4,68x1005
± 1,51x1005
1,45x1006
± 3,78x1005 0,001
Gr1-
monocytes/ml
2,58x1006
± 4,33x1004
6,56x1006
± 7,66x1004 0,001
Neutrophils/ml
2,11x1006
± 6,41x1005
3,55x1006
± 1,48x1006 0,001
B cells/ml
1,11x1006
± 3,20x1005
1,34x1006
± 1,97x1005 0,606
cDCs/ml
1,24x1005
± 3,06x1004
3,29x1005
± 3,27x1004 0,002
pDCs/ml
3,15x1005
± 6,27x1004
2,92x1005
± 3,96x1004 0,789
Macrophages/ml
7,37x1004
± 1,10x1004
1,83x1005
± 1,75x1004 0,001
All values are displayed as mean ± SEM and P-value (n= 5-10).
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Supplemental table 19: Splenic leukocyte subpopulations of Apoe
-/- 
and Apoe
-/-
Ccr1
-/-
 mice. Splenic 
leukocyte subsets were measured by flow cytometry. All values are displayed as mean ± SEM (n=5-10). 
 
Supplemental table 20: Para-aortic lymph node leukocyte subpopulations of Apoe
-/- 
and Apoe
-/-
Ccr1
-/-
 mice. Para-aortic lymph node leukocyte subsets were measured by flow cytometry. All values are 
displayed as mean ± SEM (n=5-10). 
 
Spleen
12 weeks HFD Apoe-/- Apoe-/-Ccr1-/- p-Value
Leukocytes/ml
5,26x1007
± 7,09x1006
6,81x1007
± 6,26x1006 0,161
Gr1+
monocytes/ml
1,33x1006
± 3,54x1005
1,79x1006
± 2,44x1005 0,370
Gr1-
monocytes/ml
1,41x1006
± 3,82x1005
1,19x1006
± 1,81x1005 0,672
Neutrophils/ml
3,32x1006
± 1,01x1006
4,09x1006
± 1,10x1006 0,627
B cells/ml
9,57x1006
± 1,48x1006
1,07x1007
± 1,17x1006 0,078
CD3+ T cells/ml
5,940x1006
± 1,48x1006
1,07x1007
± 1,17x1006 0,589
CD4+ T cells/ml
5,94x1006
± 8,92x1005
6,84x1006
± 8,44x1005 0,510
CD8+ T cells/ml
1,36x1006
± 1,98x1005
1,52x1006
± 1,96x1005 0,611
cDCs/ml
3,84x1006
± 9,79x1005
3,06x1006
± 5,33x1005 0,563
pDCs/ml
5,41x1005
± 9,77x1004
6,98x1005
± 1,61x1005 0,392
Macrophages/ml
1,76x1005
± 4,09x1004
1,31x1005
± 2,39x1004 0,442
All values are displayed as mean ± SEM and P-value (n= 5-10).
para-aortic Lymph Node
12 weeks HFD Apoe-/- Apoe-/-Ccr1-/- p-Value
Leukocytes/ml
1,18x1006
± 3,47x1005
3,42x1006
± 1,01x1006 0,092
Gr1+
monocytes/ml
9,95x1003
± 2,51x1003
1,97x1004
± 5,93x1003 0,019
Gr1-
monocytes/ml
2,26x1003
± 8,72x1002
4,95x1004
± 1,57x1004 0,079
B cells/ml
5,28x1005
± 1,80x1005
1,83x1006
± 5,47x1005 0,066
CD3+ T cells/ml
3,01x1005
± 6,73x1004
6,30x1005
± 2,03x1005 0,119
CD4+ T cells/ml
2,4x1005
± 4,86x1004
4,37x1005
± 1,51x1005 0,118
CD8+ T cells/ml
7,76x1004
± 1,69x1004
1,42x1005
± 4,48x1004 0,141
cDCs/ml
6,02x1004
± 1,29x1004
8,82x1004
± 2,25x1004 0,265
pDCs/ml
5,05x1003
± 1,18x1003
1,10x1004
± 3,42x1003 0,190
All values are displayed as mean ± SEM and P-value (n= 5-10).
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